,datetime,title,source,link,sentiment_class,sentiment_score
0,9/28/2016 3:10:26 PM,BRIEF-Incyte corp - Epacadostat in combination with Pembrolizumab was well-tolerated (INCY),Reuters,/news/stocks/brief-incyte-corp-epacadostat-in-combination-with-pembrolizumab-was-well-tolerated-incy-1001423495,negative,0.9346929788589478
1,10/7/2016 3:10:21 PM,BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial (INCY),Reuters,/news/stocks/brief-incyte-corp-provides-additional-phase-1-data-from-echo-202-trial-incy-1001442972,positive,0.9280445575714111
2,11/14/2016 6:56:18 PM,"BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-incyte-says-baricitinib-treatment-show-improvements-in-rheumatoid-arthritis-symptoms-in-phase-3-2016-11,negative,0.9534701108932495
3,11/14/2016 7:00:18 PM,"BRIEF-Baricitinib demonstrates early response compared to placebo (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-baricitinib-demonstrates-early-response-compared-to-placebo-2016-11,negative,0.9413467049598694
4,11/30/2016 5:10:03 PM,"BRIEF-Agenus to start the phase 1/2 clinical trial of anti-OX40 (AGEN, INCY)",Reuters,http://www.businessinsider.com/r-brief-agenus-to-start-the-phase-1/2-clinical-trial-of-anti-ox40-2016-11,positive,0.7239081263542175
5,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.8780308961868286
6,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.9314919114112854
7,12/16/2016 10:44:02 PM,"BRIEF-Incyte Corp , Eli Lilly amended license, development and commercialization agreement, entered into as of December 18, 2009 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-corp--eli-lilly-amended-license-development-and-commercialization-agreement-entered-into-as-of-december-18-2009-2016-12,positive,0.9028259515762329
8,12/30/2016 10:36:03 PM,BRIEF-Incyte announces first patient treated in clinical trial program in graft-versus-host disease (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-announces-first-patient-treated-in-clinical-trial-program-in-graft-versus-host-disease-2016-12,positive,0.6537199020385742
9,1/9/2017 2:34:05 PM,"BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-and-merck-to-advance-clinical-development-program-investigating-the-combination-of-epacadostat-with-keytruda-2017-1,negative,0.5860939621925354
10,1/23/2017 10:40:05 PM,BRIEF-Merus announces closing of global strategic research collaboration with Incyte (INCY),Reuters,http://www.businessinsider.com/r-brief-merus-announces-closing-of-global-strategic-research-collaboration-with-incyte-2017-1,positive,0.8814725875854492
11,1/30/2017 1:28:11 PM,BRIEF-Incyte and Calithera Biosciences announce global collaboration  to develop and commercialize CB-1158 (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-and-calithera-biosciences-announce-global-collaboration--to-develop-and-commercialize-cb-1158-2017-1,negative,0.8026859164237976
12,2/6/2017 2:14:08 PM,"BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies (MRK, INCY)",Reuters,http://www.businessinsider.com/r-brief-immunovaccine-says-princess-margaret-cancer-centre-to-conduct-phase-2-clinical-trial-to-evaluate-use-of-co-mercks-combination-of-immunotherapies-2017-2,negative,0.6521475911140442
13,2/13/2017 10:56:10 PM,"BRIEF-European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-once-daily-olumiant-tablets-for-treatment-of-rheumatoid-arthritis-2017-2,negative,0.7532097101211548
14,2/14/2017 1:03:28 PM,Incyte Corporation Bottom Line Falls 84% In Q4,RTTNews,/news/stocks/incyte-corporation-bottom-line-falls-84-in-q4-1001748239,neutral,0.9717422723770142
15,2/14/2017 1:26:10 PM,"BRIEF-Incyte and Agenus amend collaboration agreement (AGEN, INCY)",Reuters,http://www.businessinsider.com/r-brief-incyte-and-agenus-amend-collaboration-agreement-2017-2,positive,0.8616163730621338
16,2/14/2017 1:26:10 PM,BRIEF-Incyte reports Q4 earnings per share $0.05 (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-reports-q4-earnings-per-share-005-2017-2,positive,0.7428057789802551
17,2/16/2017 12:12:11 AM,"BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-additional-results-from-pivotal-ra-beam-study-published-in-new-england-journal-of-medicine-2017-2,positive,0.902260959148407
18,2/21/2017 2:46:12 PM,BRIEF-Incyte Corp says entered into letter agreement with certain entities affiliated with Julian Baker - SEC filing (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-corp-says-entered-into-letter-agreement-with-certain-entities-affiliated-with-julian-baker---sec-filing-2017-2,positive,0.720605194568634
19,2/23/2017 11:57:00 PM,"Incyte, CBOE Holdings, Regency Centers Set to Join S&P 500; Others to Join S&P MidCap 400",PR Newswire,/news/stocks/incyte-cboe-holdings-regency-centers-set-to-join-s-p-500-others-to-join-s-p-midcap-400-1001779406,positive,0.9278321266174316
20,2/24/2017 12:24:14 AM,"BRIEF-Incyte to replace Spectra Energy in S&P 500 (INCY, SE, CBOE, PBI)",Reuters,http://www.businessinsider.com/r-brief-incyte-to-replace-spectra-energy-in-sp-500-2017-2,positive,0.9367347955703735
21,3/3/2017 1:15:00 PM,"How These Biotech Stocks are Faring? -- Geron, Incyte, Illumina, and Bellerophon Therapeutics",PR Newswire,/news/stocks/how-these-biotech-stocks-are-faring-geron-incyte-illumina-and-bellerophon-therapeutics-1001802642,positive,0.9318112134933472
22,3/24/2017 11:33:55 AM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1001865270,positive,0.7716754078865051
23,3/31/2017 1:16:50 PM,"BRIEF-Incyte and Merck provide additional details on previously announced collaboration (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-and-merck-provide-additional-details-on-previously-announced-collaboration-2017-3,positive,0.9470655918121338
24,3/31/2017 1:41:14 PM,"Incyte, Merck Give Further Details On Epacadostat - KEYTRUDA Clinical Program ",RTTNews,/news/stocks/incyte-merck-give-further-details-on-epacadostat-keytruda-clinical-program-1001885736,positive,0.9476086497306824
25,4/3/2017 6:05:53 AM,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise ",RTTNews,/news/stocks/setback-for-acor-in-ampyra-suit-ears-put-on-notice-stdy-on-steady-rise-1001888420,negative,0.8297256827354431
26,4/13/2017 4:55:52 PM,Company Spotlight: Incyte ,RTTNews,/news/stocks/company-spotlight-incyte-1001921303,positive,0.9351479411125183
27,4/14/2017 3:00:00 PM,U.S. FDA Issues Complete Response Letter for Baricitinib,PR Newswire,/news/stocks/u-s-fda-issues-complete-response-letter-for-baricitinib-1001922584,positive,0.854012668132782
28,4/14/2017 3:10:34 PM,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib ,RTTNews,/news/stocks/eli-lilly-and-incyte-say-fda-issues-crl-for-baricitinib-1001922595,neutral,0.48892974853515625
29,4/14/2017 3:59:02 PM,"BRIEF-U.S. FDA issues CRL for baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-us-fda-issues-crl-for-baricitinib-2017-4,positive,0.8069430589675903
30,4/14/2017 6:05:04 PM,"U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant (LLY, INCY, PFE)",Reuters,http://www.businessinsider.com/r-us-fda-declines-to-approve-eli-lilly-and-incyte-arthritis-drug-olumiant-2017-4,neutral,0.7621970176696777
31,4/17/2017 6:24:50 AM,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move ",RTTNews,/news/stocks/fda-says-no-to-incy-zts-snaps-up-nvet-mdxg-on-the-move-1001923443,positive,0.8315284848213196
32,4/17/2017 1:59:03 PM,"US STOCKS-Futures dip on soft U.S. data, geopolitical risks (NFLX, UAL, INCY, LLY, PFE)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-dip-on-soft-us-data-geopolitical-risks-2017-4,neutral,0.9683301448822021
33,4/17/2017 2:50:35 PM,"The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling (INCY, LLY)",Business Insider,http://www.businessinsider.com/fda-rejects-lilly-and-incytes-baricitinib-2017-4,neutral,0.6186674237251282
34,4/17/2017 3:13:03 PM,"US STOCKS-Wall Street looks set to open slightly higher (NFLX, UAL, INCY, LLY, PFE, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-looks-set-to-open-slightly-higher-2017-4,negative,0.939262330532074
35,4/17/2017 4:55:07 PM,"US STOCKS-Wall St edges higher as tech, financials gain (NFLX, UAL, INCY, LLY, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-higher-as-tech-financials-gain-2017-4,negative,0.9337784647941589
36,4/17/2017 7:59:41 PM,Incyte Continues To Post Steep Loss After Initial Sell-Off ,RTTNews,/news/stocks/incyte-continues-to-post-steep-loss-after-initial-sell-off-1001924566,neutral,0.9680435061454773
37,4/17/2017 10:45:05 PM,"US STOCKS-Wall St rallies in low volume led by banks, tech (NFLX, AMZN, BA, INCY, LLY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-rallies-in-low-volume-led-by-banks-tech-2017-4,negative,0.4718031883239746
38,4/17/2017 10:45:05 PM,BRIEF-Incyte CEO's 2016 compensation was $11.8 mln (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-ceos-2016-compensation-was-118-mln-2017-4,neutral,0.5305004119873047
39,4/18/2017 3:27:48 AM,"Gainers & Losers Of Apr.17: CBLI, INFI, PBYI, OMED, INCY... ",RTTNews,/news/stocks/gainers-losers-of-apr-17-cbli-infi-pbyi-omed-incy-1001925025,positive,0.9136133790016174
40,4/19/2017 5:38:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-incyte-corporation-incy-579415,positive,0.7859386801719666
41,4/20/2017 4:00:00 PM,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)",PR Newswire,/news/stocks/shareholder-alert-bronstein-gewirtz-grossman-llc-announces-investigation-of-incyte-corporation-incy-1001935115,positive,0.5934057235717773
42,4/21/2017 9:51:09 PM,"EMA panel recommends nod for Sanofi, Regeneron's arthritis drug (SAN, REGN, JNJ, LLY, INCY)",Reuters,http://www.businessinsider.com/r-ema-panel-recommends-nod-for-sanofi-regenerons-arthritis-drug-2017-4,positive,0.6911615133285522
43,4/25/2017 1:11:08 PM,"UPDATE 1-Eli Lilly's profit beats on demand for newer drugs (LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-eli-lillys-profit-beats-on-demand-for-newer-drugs-2017-4,negative,0.63278728723526
44,4/29/2017 1:17:00 AM,"Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., Commvault Systems, Inc., ICU Medical, Inc., Incyte Corporation, MOCON, Inc., Ocwen Financial Corporation and ThereapeuticsMD, Inc.",PR Newswire,/news/stocks/lifshitz-miller-llp-announces-investigation-of-amyris-inc-commvault-systems-inc-icu-medical-inc-incyte-corporation-mocon-inc-ocwen-financial-corporation-and-thereapeuticsmd-inc-1001963656,positive,0.7927018404006958
45,5/4/2017 1:44:02 PM,"BRIEF-Incyte Q1 loss per share $0.96 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-q1-loss-per-share-096-2017-5,neutral,0.925426721572876
46,5/4/2017 2:55:20 PM,Incyte Posts Q1 Loss On Higher R&D Expenses; Jakafi Revenues Up 37% ,RTTNews,/news/stocks/incyte-posts-q1-loss-on-higher-r-d-expenses-jakafi-revenues-up-37-1001979778,neutral,0.5751079320907593
47,5/4/2017 3:29:17 PM,EARNINGS SUMMARY: Details of Incyte Corporation Q1 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-incyte-corporation-q1-earnings-report-1001980052,positive,0.9219691157341003
48,5/11/2017 12:10:00 PM,"Technical Reports on Biotech Stocks -- Celsion, Incyte, ImmunoGen, and Catabasis Pharma",PR Newswire,/news/stocks/technical-reports-on-biotech-stocks-celsion-incyte-immunogen-and-catabasis-pharma-1002003350,positive,0.9460892081260681
49,5/17/2017 11:16:05 PM,"Merck, Incyte immunotherapy combination effective in lung cancer study (MRK, INCY)",Reuters,http://www.businessinsider.com/r-merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-2017-5,negative,0.6480695605278015
50,5/18/2017 12:00:10 AM,"UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study (MRK, INCY)",Reuters,http://www.businessinsider.com/r-update-1-merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-2017-5,negative,0.8725243806838989
51,5/18/2017 1:50:07 PM,"US STOCKS-Futures fall as Trump tumult continues (WMT, INCY)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-fall-as-trump-tumult-continues-2017-5,neutral,0.963940441608429
52,5/18/2017 3:12:03 PM,"US STOCKS-Trump slump set to extend into second day (WMT, INCY)",Reuters,http://www.businessinsider.com/r-us-stocks-trump-slump-set-to-extend-into-second-day-2017-5,neutral,0.8917851448059082
53,5/18/2017 4:36:23 PM,A $25 billion biotech's stock is popping on its promising cancer data (INCY),Business Insider,http://www.businessinsider.com/incyte-stock-is-up-after-asco-cancer-data-2017-5,negative,0.5976569056510925
54,6/5/2017 1:14:03 PM,"BRIEF-Incyte Corp updates on Echo-202 trial of Incyte’s Epacadostat in combination with Merck’s Keytruda (INCY, MRK)",Reuters,http://www.businessinsider.com/r-brief-incyte-corp-updates-on-echo-202-trial-of-incytes-epacadostat-in-combination-with-mercks-keytruda-2017-6,positive,0.8841210603713989
55,6/5/2017 1:48:05 PM,"BRIEF-Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients (INCY, BMY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-epacadostat-bristol-myers-opdivo-combo-data-positive-in-head-and-neck-cancer-patients-2017-6,negative,0.6345509886741638
56,6/7/2017 2:52:06 PM,"UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial (AMGN, PFE, LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-abbvies-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-2017-6,negative,0.9333683848381042
57,6/14/2017 12:01:00 AM,Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017),PR Newswire,/news/stocks/lilly-to-present-new-data-on-olumiant-baricitinib-in-rheumatoid-arthritis-and-taltz-ixekizumab-in-psoriatic-arthritis-at-the-annual-european-congress-of-rheumatology-eular-2017-1002090752,positive,0.7774092555046082
58,6/16/2017 10:15:00 AM,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,PR Newswire,/news/stocks/new-safety-and-long-term-efficacy-data-from-baricitinib-clinical-trials-in-patients-with-moderate-to-severe-rheumatoid-arthritis-presented-at-eular-2017-1002098713,positive,0.768063485622406
59,7/3/2017 2:00:00 PM,"Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",PR Newswire,/news/stocks/japan-ministry-of-health-labor-and-welfare-mhlw-grants-marketing-approval-for-olumiant-baricitinib-for-the-treatment-of-rheumatoid-arthritis-1002143353,negative,0.9354477524757385
60,7/3/2017 2:06:59 PM,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-japan-marketing-approval-for-olumiant-quick-facts-1002143389,negative,0.8129168748855591
61,7/3/2017 2:16:04 PM,"BRIEF-Incyte says Japan Ministry of Health, Labor And Welfare grants marketing approval for Olumiant (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-japan-ministry-of-health-labor-and-welfare-grants-marketing-approval-for-olumiant-2017-7,negative,0.7859511971473694
62,7/20/2017 1:54:03 PM,BRIEF-Incyte says first patient treated in Phase 3 clinical trial of itacitinib (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-says-first-patient-treated-in-phase-3-clinical-trial-of-itacitinib-2017-7,positive,0.7838683724403381
63,7/21/2017 7:22:01 AM,"AEZS Gets Down To Serious Work, APVO Surges, FDA Tentative Nod For MRK ",RTTNews,/news/stocks/aezs-gets-down-to-serious-work-apvo-surges-fda-tentative-nod-for-mrk-1002193692,negative,0.8483994603157043
64,7/25/2017 12:15:00 PM,Lilly and Incyte Provide Update on Baricitinib,PR Newswire,/news/stocks/lilly-and-incyte-provide-update-on-baricitinib-1002201262,positive,0.9393396377563477
65,7/25/2017 12:28:12 PM,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib ,RTTNews,/news/stocks/eli-lilly-incyte-issue-update-on-resubmission-of-nda-for-baricitinib-1002201296,positive,0.9104512333869934
66,7/25/2017 12:36:07 PM,"BRIEF-Lilly and Incyte provide update on baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-and-incyte-provide-update-on-baricitinib-2017-7,positive,0.9436993598937988
67,7/26/2017 8:55:22 AM,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX ",RTTNews,/news/stocks/positive-data-ignites-ttph-mdco-makes-a-good-tango-wait-continues-for-egrx-1002204619,negative,0.6598851680755615
68,8/1/2017 1:15:18 PM,EARNINGS SUMMARY: Details of Incyte Corporation Q2 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-incyte-corporation-q2-earnings-report-1002221967,positive,0.9188451766967773
69,8/11/2017 12:15:00 PM,"Technical Snapshots for These Biotech Stocks -- ImmunoGen, Incyte, Infinity Pharma, and Jazz Pharma",PR Newswire,/news/stocks/technical-snapshots-for-these-biotech-stocks-immunogen-incyte-infinity-pharma-and-jazz-pharma-1002251519,positive,0.9447206258773804
70,8/30/2017 12:45:00 PM,Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018,PR Newswire,/news/stocks/lilly-to-file-baricitinib-resubmission-to-u-s-fda-before-end-of-january-2018-1002294227,positive,0.8667067289352417
71,8/30/2017 12:57:05 PM,"BRIEF-Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-to-file-baricitinib-resubmission-to-us-fda-before-end-of-january-2018-2017-8,positive,0.9152293801307678
72,8/30/2017 1:02:01 PM,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018 ,RTTNews,/news/stocks/lilly-to-resubmit-nda-for-baricitinib-to-fda-before-end-of-january-2018-1002294296,positive,0.8328335881233215
73,8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8,negative,0.9372472763061523
74,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345383,positive,0.7913914918899536
75,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345356,positive,0.7913914918899536
76,9/8/2017 3:07:04 PM,"BRIEF-Incyte announces pricing of public offering of 4,945,000 shares (INCY)",Reuters,http://www.businessinsider.com/r-brief-incyte-announces-pricing-of-public-offering-of-4945000-shares-2017-9,positive,0.9473251700401306
77,9/14/2017 3:00:00 PM,Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,PR Newswire,/news/stocks/baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-1002370452,negative,0.9003221988677979
78,9/14/2017 3:02:03 PM,"Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,positive,0.5306563377380371
79,9/14/2017 3:12:05 PM,"BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incytes-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-2017-9,negative,0.9352310299873352
80,9/14/2017 3:13:25 PM,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib ,RTTNews,/news/stocks/lilly-announces-new-safety-and-efficacy-data-from-phase-2-study-of-baricitinib-1002370600,positive,0.5726248621940613
81,9/14/2017 8:52:15 PM,"UPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,negative,0.9154360294342041
82,10/5/2017 2:54:00 PM,"MDA Completes Acquisition of DigitalGlobe, Creates Industry Leader in Satellite Systems, Earth Imagery, Geospatial Solutions and Analytics",PR Newswire,/news/stocks/mda-completes-acquisition-of-digitalglobe-creates-industry-leader-in-satellite-systems-earth-imagery-geospatial-solutions-and-analytics-1001610444,negative,0.808399498462677
83,10/14/2017 3:00:00 AM,"Indigenous groups, science community, marine industry, and government partners make progress in protecting endangered killer whale population",PR Newswire,/news/stocks/indigenous-groups-science-community-marine-industry-and-government-partners-make-progress-in-protecting-endangered-killer-whale-population-487896,negative,0.8135910630226135
84,10/19/2017 7:07:03 PM,BRIEF-Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent (INCY),Reuters,http://www.businessinsider.com/r-brief-concert-pharma-says-ptab-denies-incyte-petition-challenging-ctp-543-patent-2017-10,positive,0.689905047416687
85,10/30/2017 10:57:07 PM,BRIEF-Incyte Corp names new member to its board of directors (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-corp-names-new-member-to-its-board-of-directors-2017-10,positive,0.9369193315505981
86,10/31/2017 9:37:06 AM,"AstraZeneca plans new pivotal lung cancer trial with Incyte (AZN, INCY, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-plans-new-pivotal-lung-cancer-trial-with-incyte-2017-10,positive,0.7332110404968262
87,10/31/2017 12:22:14 PM,BRIEF-Incyte says Q3 earnings per share $0.17 (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-says-q3-earnings-per-share-017-2017-10,positive,0.7223540544509888
88,10/31/2017 12:24:43 PM,Incyte Corporation Announces 2% Retreat In Q3 Earnings,RTTNews,/news/stocks/incyte-corporation-announces-2-retreat-in-q3-earnings-1006294889,neutral,0.9715116620063782
89,11/5/2017 3:00:00 PM,ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo,PR Newswire,/news/stocks/acr-arhp-2017-new-analysis-shows-rheumatoid-arthritis-patients-treated-with-baricitinib-reported-greater-improvements-in-pain-compared-to-adalimumab-or-placebo-1006960473,negative,0.9226011633872986
90,11/6/2017 5:38:55 AM,"Lilly, Incyte: Baricitinib Shows Greater Improvements In Pain Control In RA ",RTTNews,/news/stocks/lilly-incyte-baricitinib-shows-greater-improvements-in-pain-control-in-ra-1007018255,negative,0.9568936228752136
91,11/15/2017 1:42:03 PM,BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia (INCY),Reuters,http://www.businessinsider.com/r-brief-incyte-initiates-clinical-trial-of-ruxolitinib-for-treatment-of-essential-thrombocythemia-2017-11,negative,0.49452221393585205
92,11/15/2017 1:47:32 PM,Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia ,RTTNews,/news/stocks/incyte-starts-clinical-trial-of-ruxolitinib-for-essential-thrombocythemia-1008131651,positive,0.6111664175987244
93,12/5/2017 2:12:06 PM,BRIEF-Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer (INCY),Reuters,http://www.businessinsider.com/r-brief-immunovaccine-announces-positive-clinical-data-from-its-collaborative-combination-immunotherapy-trial-in-advanced-ovarian-cancer-2017-12,negative,0.940847635269165
94,12/6/2017 9:52:03 PM,"FACBOX-Corporate alternative minimum tax threat hits pharma, tech (BA, VRTX, INCY, REGN, CDNS, CELG, ADSK)",Reuters,http://www.businessinsider.com/r-facbox-corporate-alternative-minimum-tax-threat-hits-pharma-tech-2017-12,neutral,0.796172022819519
95,1/2/2018 6:00:00 PM,Vancouver Island 2018 Property Assessment Notices in the Mail,PR Newswire,/news/stocks/vancouver-island-2018-property-assessment-notices-in-the-mail-1001658057,positive,0.8823054432868958
96,2/15/2018 1:05:32 PM,EARNINGS SUMMARY: Details of Incyte Corporation Q4 Earnings Report,RTTNews,/news/stocks/earnings-summary-details-of-incyte-corporation-q4-earnings-report-1015886075,positive,0.9202057719230652
97,3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162,positive,0.7716754078865051
98,4/6/2018 1:39:13 PM,"BRIEF-Incyte, Merck Provide Update On Phase 3 Study",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/JfjeqDAUI3o/brief-incyte-merck-provide-update-on-phase-3-study-idUSASC09V4M,positive,0.9407566785812378
99,4/6/2018 1:42:04 PM,"Incyte, Merck Stop Phase 3 Study Of Epacadostat In Combination With KEYTRUDA ",RTTNews,/news/stocks/incyte-merck-stop-phase-3-study-of-epacadostat-in-combination-with-keytruda-1020676568,positive,0.5658868551254272
100,4/6/2018 3:21:06 PM,"A cancer drugmaker just failed a key trial and its stock is crashing (INCY, MRK)",Business Insider,http://markets.businessinsider.com/news/stocks/incyte-stock-price-after-ido-cancer-drug-trial-failure-2018-4-1020683045,neutral,0.8993933796882629
101,4/19/2018 11:27:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-incyte-corporation-incy-1021615753,positive,0.7859386801719666
102,4/20/2018 4:54:00 PM,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)",PR Newswire,/news/stocks/shareholder-alert-bronstein-gewirtz-&-grossman-llc-announces-investigation-of-incyte-corporation-incy-602214,positive,0.5934057235717773
103,4/23/2018 11:01:10 PM,FDA panel votes against approving higher dose of Lilly-Incyte arthritis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/9K4QOf-ipd0/fda-panel-votes-against-approving-higher-dose-of-lilly-incyte-arthritis-drug-idUSL3N1S0688,negative,0.5371960997581482
104,4/23/2018 11:25:53 PM,UPDATE 1-FDA panel backs lower dose of Lilly-Incyte arthritis drug over higher,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/ka8_C3HTlvw/update-1-fda-panel-backs-lower-dose-of-lilly-incyte-arthritis-drug-over-higher-idUSL3N1S069D,negative,0.8619508147239685
105,4/24/2018 12:44:14 AM,UPDATE 2-FDA panel against higher dose of Lilly-Incyte arthritis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/UQXywE4nj6U/update-2-fda-panel-against-higher-dose-of-lilly-incyte-arthritis-drug-idUSL3N1S069D,negative,0.7305306792259216
106,4/24/2018 2:11:00 AM,"FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis",PR Newswire,/news/stocks/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-1022051417,negative,0.5407771468162537
107,4/24/2018 2:58:55 AM,"FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose ",RTTNews,/news/stocks/fda-panel-backs-lower-dose-of-lilly-incyte-arthritis-drug-but-not-higher-dose-1022054657,negative,0.48646464943885803
108,4/24/2018 8:46:50 AM,"PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA ",RTTNews,/news/stocks/prta-jolted-fda-strikes-down-pfe-s-herceptin-biosimilar-no-relief-yet-for-kmda-1022084035,neutral,0.8953303694725037
109,5/1/2018 1:27:33 PM,BRIEF-Incyte Reports Q1 Loss Of $0.19 Per Share,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/YlTVtrFAnjg/brief-incyte-reports-q1-loss-of-0-19-per-share-idUSASC09YIO,neutral,0.9595927000045776
110,6/1/2018 5:24:21 PM,FDA approves lower dose of Lilly-Incyte arthritis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/rKqLETg_pyM/fda-approves-lower-dose-of-lilly-incyte-arthritis-drug-idUSL3N1T34VJ,negative,0.6355651617050171
111,6/1/2018 5:55:01 PM,UPDATE 1-FDA approves lower dose of Lilly-Incyte arthritis drug,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/fG0OCgAr0AE/update-1-fda-approves-lower-dose-of-lilly-incyte-arthritis-drug-idUSL3N1T34VS,negative,0.8776506781578064
112,6/1/2018 6:04:00 PM,FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis,PR Newswire,/news/stocks/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis-1026133279,negative,0.9166295528411865
113,6/4/2018 6:46:25 AM,"FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early ",RTTNews,/news/stocks/fda-nod-for-lly-incy-ra-drug-jazz-hits-right-tones-sls-study-stopped-early-1026406603,positive,0.7329449653625488
114,6/6/2018 12:02:00 AM,"Lifshitz & Miller LLP Announces Investigation of ARMO BioSciences, Inc., Financial Engines, Inc., Globalstar, Inc., Gridsum Holding Inc., InnerWorkings, Inc., Incyte Corporation, PPG Industries, Inc.",PR Newswire,/news/stocks/lifshitz-miller-llp-announces-investigation-of-armo-biosciences-inc-financial-engines-inc-globalstar-inc-gridsum-holding-inc-innerworkings-inc-incyte-corporation-ppg-industries-inc-1026619638,positive,0.6779910922050476
115,6/11/2018 12:45:00 PM,"Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology",PR Newswire,/news/stocks/lilly-to-unveil-new-data-at-the-annual-european-congress-of-rheumatology-furthering-commitment-to-scientific-discovery-in-immunology-1026834212,negative,0.882249116897583
116,6/21/2018 2:26:02 PM,Incyte: REACH1 Pivotal Trial With Ruxolitinib Meets Primary Endpoint ,RTTNews,/news/stocks/incyte-reach1-pivotal-trial-with-ruxolitinib-meets-primary-endpoint-1027307455,negative,0.8836774826049805
117,7/30/2018 3:02:45 PM,Incyte earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/incyte-quarter-earnings-preview-q2-1027411622,positive,0.9040642380714417
118,9/7/2018 7:03:04 AM,Incyte CFO David Gryska To Retire At 2018- End; Search Underway For New CFO ,RTTNews,/news/stocks/incyte-cfo-david-gryska-to-retire-at-2018-end-search-underway-for-new-cfo-1027516016,positive,0.8485565185546875
119,9/9/2018 3:32:32 AM,"Week Ahead In Pharmaceuticals: 5 Stocks To Watch (KNSA, INCY, ANAB...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-5-stocks-to-watch-knsa-incy-anab-1027518806,positive,0.8540626168251038
120,10/21/2018 4:06:45 PM,Incyte Announces Positive Interim Data From Phase 2 Trial Of Pemigatinib ,RTTNews,/news/stocks/incyte-announces-positive-interim-data-from-phase-2-trial-of-pemigatinib-1027636188,negative,0.7638880610466003
121,10/22/2018 4:25:03 AM,Lilly And Incyte Update Safety Analysis Of OLUMIANT ,RTTNews,/news/stocks/lilly-and-incyte-update-safety-analysis-of-olumiant-1027636343,positive,0.9261642098426819
122,10/22/2018 5:43:33 AM,"FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch ",RTTNews,/news/stocks/fda-extends-date-on-bmy-s-sbla-genmab-meets-phase-3-goals-ncna-lptx-on-watch-1027636442,positive,0.8459467887878418
123,10/25/2018 2:56:23 PM,Incyte: FDA Grants Priority Review For Ruxolitinib ,RTTNews,/news/stocks/incyte-fda-grants-priority-review-for-ruxolitinib-1027655137,negative,0.5286439061164856
124,10/29/2018 3:02:58 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q3-1027666283,positive,0.9349303245544434
125,10/30/2018 12:51:55 PM,Incyte Corporation Q3 adjusted earnings Miss Estimates,RTTNews,/news/stocks/incyte-corporation-q3-adjusted-earnings-miss-estimates-1027670482,neutral,0.9315826296806335
126,12/13/2018 12:58:22 PM,Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program ,RTTNews,/news/stocks/eli-lilly-fda-grants-fast-track-designation-to-baricitinib-development-program-1027806092,negative,0.9070156812667847
127,12/17/2018 1:57:00 AM,"Innovent, Incyte In Deal For Three Clinical-stage Product Candidates In China ",RTTNews,/news/stocks/innovent-incyte-in-deal-for-three-clinical-stage-product-candidates-in-china-1027812261,negative,0.7961636781692505
128,1/3/2019 1:08:45 PM,Incyte Names Christiana Stamoulis CFO - Quick Facts ,RTTNews,/news/stocks/incyte-names-christiana-stamoulis-cfo-quick-facts-1027841373,positive,0.9485591053962708
129,1/30/2019 8:19:45 AM,Biotech Stocks Facing FDA Decision In February ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-february-1027907714,positive,0.7358179092407227
130,2/4/2019 12:52:11 PM,Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2 ,RTTNews,/news/stocks/lilly-baricitinib-meets-primary-endpoint-in-breeze-ad1-and-breeze-ad2-1027920368,negative,0.8698106408119202
131,2/13/2019 3:02:41 PM,Incyte earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/incyte-q4-earnings-preview-stock-1027949429,positive,0.9040642380714417
132,2/21/2019 11:54:23 AM,"Beware Of Fake Leukemia Drug Iclusig, Warns WHO ",RTTNews,/news/stocks/beware-of-fake-leukemia-drug-iclusig-warns-who-1027971213,neutral,0.5421308279037476
133,4/26/2019 9:15:22 AM,Biotech Stocks Facing FDA Decision In May 2019 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2019-1028141774,positive,0.8594977855682373
134,4/29/2019 3:02:37 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-q1-earnings-preview-stock-1028148533,positive,0.9349303245544434
135,4/30/2019 1:18:52 PM,Incyte Corporation Q1 adjusted earnings of $0.62 per share,RTTNews,/news/stocks/incyte-corporation-q1-adjusted-earnings-of-0-62-per-share-1028152890,positive,0.8163174390792847
136,4/30/2019 2:07:16 PM,Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib ,RTTNews,/news/stocks/incyte-to-no-longer-participate-in-co-funding-of-development-of-baricitinib-1028153188,positive,0.9280421137809753
137,6/14/2019 6:59:58 PM,7 Top-Rated Biotech Stocks to Invest In Today,InvestorPlace,/news/stocks/7-healthy-biotech-stocks-to-invest-in-1028281710,positive,0.7840100526809692
138,6/18/2019 7:03:57 PM,7 Hot Stocks to Buy for a Seemingly Sleepy Summer,InvestorPlace,/news/stocks/7-hot-stocks-to-buy-for-a-seemingly-sleepy-summer-1028289974,positive,0.796815037727356
139,6/21/2019 8:30:47 PM,Nasdaq Today: Maintaining Altitude Amid Uncertainty,InvestorPlace,/news/stocks/nasdaq-today-maintaining-altitude-amid-uncertainty-1028299511,positive,0.5723593831062317
140,6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984,neutral,0.8470374941825867
141,7/26/2019 4:04:19 PM,4 Biotech Stocks Sliding Lower,InvestorPlace,/news/stocks/4-biotech-stocks-sliding-lower-1028389963,neutral,0.9591169953346252
142,7/29/2019 3:02:47 PM,Incyte earnings: here's what to expect,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q2-1028393716,positive,0.9323586821556091
143,7/30/2019 1:31:55 PM,Incyte Corporation Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q2-adjusted-earnings-beat-estimates-1028397989,negative,0.7220250368118286
144,7/30/2019 5:50:33 PM,The 10 Best Stocks to Invest in for August,InvestorPlace,/news/stocks/the-10-best-stocks-to-invest-in-for-august-1028401236,positive,0.8345430493354797
145,8/29/2019 6:30:32 PM,10 Stocks to Buy for September,InvestorPlace,/news/stocks/10-stocks-to-buy-for-september-1028486386,positive,0.9257571697235107
146,10/7/2019 4:17:20 PM,10 Great Biotech Stocks to Buy in Q4,InvestorPlace,/news/stocks/great-biotech-stocks-to-buy-q4-1028581895,positive,0.7856953740119934
147,10/29/2019 12:54:33 PM,Incyte Q3 Profit Surges; Raises FY19 Jakafi Revenue Outlook - Quick Facts ,RTTNews,/news/stocks/incyte-q3-profit-surges-raises-fy19-jakafi-revenue-outlook-quick-facts-1028638835,negative,0.9401819705963135
148,12/2/2019 7:57:21 PM,7 Exciting Biotech Stocks to Buy Now,InvestorPlace,/news/stocks/7-exciting-biotech-companies-to-buy-1028731361,positive,0.847749650478363
149,12/14/2019 9:14:45 AM,Are These Biotech Companies Buyout Candidates? Deal Or No Deal? ,RTTNews,/news/stocks/are-these-biotech-companies-buyout-candidates-deal-or-no-deal-1028763470,positive,0.9128385186195374
150,12/19/2019 10:16:39 AM,Why Longer-Term Investors Should Buy Amarin Stock on Weakness,InvestorPlace,/news/stocks/why-longer-term-investors-should-buy-amarin-stock-on-weakness-1028775027,positive,0.9243662357330322
151,1/3/2020 3:49:58 AM,"DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz ",RTTNews,/news/stocks/drrx-plunges-on-psoriasis-trial-data-incy-fails-gravitas-301-test-agrx-abuzz-1028792377,neutral,0.9232301115989685
152,1/3/2020 8:46:36 PM,Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure,InvestorPlace,/news/stocks/incyte-news-incy-stock-tumbles-on-drug-study-fail-1028794044,neutral,0.9686580896377563
153,1/3/2020 9:26:51 PM,Stock Market Today: Is the Rally Ruined?; Tesla’s New Record,InvestorPlace,/news/stocks/stock-market-today-is-the-rally-ruined-teslas-new-record-1028794158,positive,0.5994406342506409
154,1/13/2020 7:54:23 AM,"MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S. ",RTTNews,/news/stocks/morphosys-incyte-agree-to-co-commercialize-tafasitamab-in-the-u-s-1028811317,negative,0.8561047911643982
155,1/27/2020 12:57:19 PM,Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028846153,negative,0.914971113204956
156,1/30/2020 12:47:34 PM,"Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study ",RTTNews,/news/stocks/eli-lilly-incyte-baricitinib-meets-primary-endpoint-in-breeze-ad5-study-1028859050,negative,0.9164578318595886
157,2/12/2020 3:42:23 AM,Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-s-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028895966,negative,0.8651469945907593
158,2/12/2020 3:03:08 PM,Incyte is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/incyte-q4-quarterly-earnings-preview-stock-1028898712,positive,0.9338321089744568
159,2/13/2020 12:50:11 PM,Incyte +2% premarket on Q4 beat,Seeking Alpha,https://seekingalpha.com/news/3541664-incyteplus-2-premarket-on-q4-beat?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.827430248260498
160,2/13/2020 1:24:59 PM,Incyte Corporation Q4 adjusted earnings of $0.65 per share,RTTNews,/news/stocks/incyte-corporation-q4-adjusted-earnings-of-0-65-per-share-1028902485,positive,0.7998684644699097
161,2/13/2020 1:31:30 PM,Incyte Q4 Adj. Operating Income Rises; Jakafi Revenues Up 23% - Quick Facts ,RTTNews,/news/stocks/incyte-q4-adj-operating-income-rises-jakafi-revenues-up-23-quick-facts-1028902528,negative,0.9534698724746704
162,2/19/2020 12:54:39 PM,Incyte's ruxolitinib successful in second late-stage dermatitis study,Seeking Alpha,https://seekingalpha.com/news/3543190-incytes-ruxolitinib-successful-in-second-late-stage-dermatitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7392832040786743
163,3/4/2020 3:03:44 AM,"MorphoSys, Incyte Receive Antitrust Clearance For Collaboration On Tafasitamab ",RTTNews,/news/stocks/morphosys-incyte-receive-antitrust-clearance-for-collaboration-on-tafasitamab-1028961845,negative,0.8881582021713257
164,3/16/2020 11:10:24 AM,FDA grants BTD tag to baricitinib for alopecia areata,Seeking Alpha,https://seekingalpha.com/news/3551919-fda-grants-btd-tag-to-baricitinib-for-alopecia-areata?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7808043360710144
165,4/1/2020 11:51:39 AM,Oppenheimer sees 26% downside in Intuitive Surgical in premarket action,Seeking Alpha,https://seekingalpha.com/news/3557134-oppenheimer-sees-26-downside-in-intuitive-surgical-in-premarket-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9653326869010925
166,4/3/2020 8:36:15 AM,"Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Cv4dEFP2M6M/novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-idUSL8N2BR13T,positive,0.4966251254081726
167,4/3/2020 8:39:01 AM,"RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/XItNVlVKPJw/rpt-novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-idUSL8N2BR1G8,positive,0.5399175882339478
168,4/3/2020 9:32:16 AM,"Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19",Reuters,http://feeds.reuters.com/~r/reuters/INbusinessNews/~3/3dnH_DyTX20/novartis-incyte-join-repurposing-wave-to-give-jakavi-a-trial-run-in-covid-19-idINKBN21L0SJ,positive,0.4966251254081726
169,4/3/2020 11:17:29 AM,Incyte to test Jakafi in COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3558122-incyte-to-test-jakafi-in-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7411462068557739
170,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8612488508224487
171,4/15/2020 3:13:45 PM,RemeGen candidate Fast Track'd for lupus,Seeking Alpha,https://seekingalpha.com/news/3560931-remegen-candidate-fast-trackd-for-lupus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7099936008453369
172,4/17/2020 7:56:28 PM,Incyte launches pivotal study of Jakafi for COVID-19 complication,Seeking Alpha,https://seekingalpha.com/news/3561789-incyte-launches-pivotal-study-of-jakafi-for-covidminus-19-complication?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6946926116943359
173,4/18/2020 2:40:58 PM,FDA OKs Incyte's pemigatinib for type of bile duct cancer,Seeking Alpha,https://seekingalpha.com/news/3561860-fda-oks-incytes-pemigatinib-for-type-of-bile-duct-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.543680727481842
174,4/20/2020 3:14:03 PM,FDA Approves First Targeted Treatment For Bile Duct Cancer ,RTTNews,/news/stocks/fda-approves-first-targeted-treatment-for-bile-duct-cancer-1029107579,negative,0.536994457244873
175,4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761,positive,0.8712263107299805
176,5/4/2020 3:01:31 PM,Incyte is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q1-1029160444,positive,0.9335429668426514
177,5/5/2020 12:08:57 PM,Incyte Q1 Jakafi sales up 22%; guidance affirmed,Seeking Alpha,https://seekingalpha.com/news/3569043-incyte-q1-jakafi-sales-up-22-guidance-affirmed?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9535828232765198
178,5/5/2020 1:49:57 PM,"Incyte Slips To Loss In Q1, Despite Higher Revenues - Quick Facts ",RTTNews,/news/stocks/incyte-slips-to-loss-in-q1-despite-higher-revenues-quick-facts-1029165112,neutral,0.9625600576400757
179,5/14/2020 3:47:38 PM,MorphoSys : Long-term Data From L-MIND Study Confirms Primary Analysis Results ,RTTNews,/news/stocks/morphosys-long-term-data-from-l-mind-study-confirms-primary-analysis-results-1029202670,positive,0.7211660146713257
180,5/14/2020 4:04:42 PM,Morphosys up 3% on long-term tafasitamab data in blood cancer,Seeking Alpha,https://seekingalpha.com/news/3574577-morphosys-up-3-on-long-term-tafasitamab-data-in-blood-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9491575360298157
181,5/21/2020 3:20:25 AM,MorphoSys Announce Validation Of EMA Application For Tafasitamab ,RTTNews,/news/stocks/morphosys-announce-validation-of-ema-application-for-tafasitamab-1029221981,negative,0.7067918181419373
182,6/15/2020 11:45:59 AM,Lilly launches late-stage study of baricitinib in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3582916-lilly-launches-late-stage-study-of-baricitinib-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.630946159362793
183,6/15/2020 1:00:05 PM,Lilly Starts Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients ,RTTNews,/news/stocks/lilly-starts-phase-3-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients-1029307552,negative,0.5815112590789795
184,6/29/2020 1:28:58 PM,Incyte Receives Approval For Tabrecta In Japan For Patients With Advanced NSCLC With METex14 ,RTTNews,/news/stocks/incyte-receives-approval-for-tabrecta-in-japan-for-patients-with-advanced-nsclc-with-metex14-1029349529,negative,0.921180248260498
185,7/24/2020 6:06:35 PM,5 High-Yield Drug Stocks That Are Undervalued With Great Upside,InvestorPlace,/news/stocks/high-yield-drug-stocks-undervalued-cheap-huge-upside-1029429574,negative,0.55074143409729
186,8/3/2020 3:01:57 PM,Incyte earnings preview: what to expect,Markets Insider Automation,/news/stocks/incyte-q2-earnings-preview-stock-1029461845,positive,0.8878722190856934
187,8/4/2020 1:45:55 PM,Incyte Corporation Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q2-adjusted-earnings-beat-estimates-1029466173,negative,0.7220250368118286
188,8/4/2020 1:57:23 PM,Incyte Q2 Profit Tops Estimates - Quick Facts ,RTTNews,/news/stocks/incyte-q2-profit-tops-estimates-quick-facts-1029466192,negative,0.7165793776512146
189,9/14/2020 1:19:20 PM,"Lilly, Incyte Announce Initial Data From Adaptive COVID-19 Treatment Trial - Quick Facts ",RTTNews,/news/stocks/lilly-incyte-announce-initial-data-from-adaptive-covid-19-treatment-trial-quick-facts-1029585401,positive,0.9289562702178955
190,9/18/2020 2:04:17 PM,"Lilly, Incyte: CHMP Adopts Positive Opinion For Baricitinib In Treatment Of Atopic Dermatitis ",RTTNews,/news/stocks/lilly-incyte-chmp-adopts-positive-opinion-for-baricitinib-in-treatment-of-atopic-dermatitis-1029602319,negative,0.9471803307533264
191,10/8/2020 4:20:17 PM,Lilly's baricitinib shows incremental benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3620863-lillys-baricitinib-shows-incremental-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9489912390708923
192,10/16/2020 8:03:31 PM,Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3623006-lilly-incytes-baricitinib-shows-additional-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.952124834060669
193,10/26/2020 2:02:16 PM,Health Canada accepts Incyte's pemigatinib application for bile duct cancer,Seeking Alpha,https://seekingalpha.com/news/3625781-health-canada-accepts-incytes-pemigatinib-application-for-bile-duct-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.858200192451477
194,10/29/2020 4:21:14 PM,Incyte's Atopic Dermatitis Studies Of Ruxolitinib Cream Show Clinically Meaningful Improvements ,RTTNews,/news/stocks/incyte-s-atopic-dermatitis-studies-of-ruxolitinib-cream-show-clinically-meaningful-improvements-1029742469,negative,0.9491046071052551
195,10/30/2020 12:26:12 PM,"Lilly, Incyte Report Positive New Data For Baricitinib In Adult Patients With Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-report-positive-new-data-for-baricitinib-in-adult-patients-with-alopecia-areata-1029745907,negative,0.9473748207092285
196,11/4/2020 5:09:18 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3631230-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
197,11/4/2020 6:12:11 PM,Incyte Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3631333-incyte-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6881813406944275
198,11/5/2020 3:27:24 PM,"Incyte Q3 Adj. Earnings, Revenue Miss Estimates - Quick Facts ",RTTNews,/news/stocks/incyte-q3-adj-earnings-revenue-miss-estimates-quick-facts-1029770978,neutral,0.5065063238143921
199,11/11/2020 11:11:41 PM,"Xencor, MorphoSys And Incyte Ink Collaboration Deal ",RTTNews,/news/stocks/xencor-morphosys-and-incyte-ink-collaboration-deal-1029793839,positive,0.9056556224822998
200,11/20/2020 2:57:39 AM,Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19,Seeking Alpha,https://seekingalpha.com/news/3638211-eli-lilly-arthritis-drug-gets-fda-ok-for-emergency-use-to-treat-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8861280083656311
201,11/20/2020 5:04:01 AM,FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-approval-to-lilly-s-arthritis-drug-with-remdesivir-for-covid-19-treatment-1029823536,neutral,0.5320243239402771
202,11/20/2020 7:46:37 AM,"AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B ",RTTNews,/news/stocks/azn-s-covid-jab-immunosenescence-pfe-bntx-to-seek-emergency-nod-for-vaccine-qure-aces-hope-b-1029823800,positive,0.6857633590698242
203,11/30/2020 1:53:22 PM,MacroGenics secures $25M milestone payment from Incyte,Seeking Alpha,https://seekingalpha.com/news/3639935-macrogenics-secures-25m-milestone-payment-from-incyte?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9349535703659058
204,12/2/2020 1:49:15 PM,Kinnate Biopharma increases IPO size by 25% to $213M,Seeking Alpha,https://seekingalpha.com/news/3640795-kinnate-biopharma-increases-ipo-size-25-to-213m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9479063153266907
205,12/3/2020 12:48:08 PM,IMV T cell therapy shows positive action in treatment-resistant ovarian cancer; shares up 5%,Seeking Alpha,https://seekingalpha.com/news/3641291-imv-t-cell-therapy-shows-positive-action-in-treatment-resistant-ovarian-cancer-shares-up-5?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9526138305664062
206,12/6/2020 11:14:39 PM,Eyes on Constellation Pharma after ASH conference presentation on CPI-0610 for myelofibrosis,Seeking Alpha,https://seekingalpha.com/news/3641962-eyes-on-constellation-pharma-after-ash-conference-presentation-on-cpiminus-0610-for?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8847322463989258
207,12/11/2020 7:45:03 PM,Eli Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data,Seeking Alpha,https://seekingalpha.com/news/3643811-eli-lilly-incyte-announce-peer-reviewed-publication-of-baricitinib-remdesivir-trial-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8726758360862732
208,12/14/2020 7:59:33 AM,"Novartis, Incyte: RUXCOVID Study Of Ruxolitinib In COVID-19 Patients Did Not Meet Primary Endpoint ",RTTNews,/news/stocks/novartis-incyte-ruxcovid-study-of-ruxolitinib-in-covid-19-patients-did-not-meet-primary-endpoint-1029888412,neutral,0.8652660250663757
209,12/14/2020 8:14:34 AM,Incyte/Novartis' Jakafi study in COVID-19 fails to meet endpoints,Seeking Alpha,https://seekingalpha.com/news/3643920-incyte-novartis-jakafi-study-in-covidminus-19-fails-to-meet-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9539571404457092
210,12/14/2020 6:37:56 PM,7 Biotech Stocks To Buy Beyond Covid Vaccine Plays,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-beyond-covid-vaccine-plays-1029891263,negative,0.5038461089134216
211,12/26/2020 3:15:52 PM,"The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-27-jan-2-data-releases-regulatory-filings-to-move-stocks-1029919761,positive,0.6830364465713501
212,12/29/2020 10:51:37 AM,Merus rises 4% on Incyte stake disclosure,Seeking Alpha,https://seekingalpha.com/news/3647634-merus-rises-4-on-incyte-stake-disclosure?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9261545538902283
213,12/30/2020 1:51:39 PM,Incyte & Cellenkos To Evaluate Combination Of Ruxolitinib And CK0804 - Quick Facts ,RTTNews,/news/stocks/incyte-cellenkos-to-evaluate-combination-of-ruxolitinib-and-ck0804-quick-facts-1029925112,positive,0.8158096075057983
214,12/30/2020 4:11:22 PM,Incyte and Cellenkos inks global pact for development for CK0804 in MF patients,Seeking Alpha,https://seekingalpha.com/news/3647862-incyte-and-cellenkos-inks-global-pact-for-development-for-ck0804-in-mf-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7773670554161072
215,12/30/2020 8:06:40 PM,Why These Health Care Stocks Are Moving Today,Benzinga,/news/stocks/why-these-health-care-stocks-are-moving-today-1029926005,positive,0.8750765323638916
216,1/5/2021 8:45:37 AM,MorphoSys : Swiss Regulator Accepts Marketing Authorization Application For Tafasitamab ,RTTNews,/news/stocks/morphosys-swiss-regulator-accepts-marketing-authorization-application-for-tafasitamab-1029932415,positive,0.5600547790527344
217,1/7/2021 6:10:07 PM,"Benzinga's Top Upgrades, Downgrades For January 7, 2021",Benzinga,/news/stocks/benzinga-s-top-upgrades-downgrades-for-january-7-2021-1029941508,neutral,0.5879586935043335
218,1/12/2021 9:15:06 PM,Incyte/MorphoSys' tafasitamab Canada application accepted for review,Seeking Alpha,https://seekingalpha.com/news/3650854-incyte-morphosys-tafasitamab-canada-application-accepted-for-review?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8611831068992615
219,1/13/2021 3:59:46 AM,MorphoSys And Incyte : Health Canada Accepts NDS For Anti-CD19 Antibody Tafasitamab ,RTTNews,/news/stocks/morphosys-and-incyte-health-canada-accepts-nds-for-anti-cd19-antibody-tafasitamab-1029962248,negative,0.642429769039154
220,1/13/2021 1:25:38 PM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",Benzinga,/news/stocks/the-daily-biotech-pulse-bausch-health-issues-positive-pre-announcement-acorda-streamlines-operations-1029963908,positive,0.9181804656982422
221,1/21/2021 9:37:35 PM,Incyte's retifanlimab wins FDA's Priority Review status,Seeking Alpha,https://seekingalpha.com/news/3653339-incytes-retifanlimab-wins-fdas-priority-review-status?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9290370345115662
222,1/29/2021 8:06:16 PM,Incyte's pemigatinib gets positive recommendation from CHMP,Seeking Alpha,https://seekingalpha.com/news/3656331-incytes-pemigatinib-gets-positive-recommendation-from-chmp?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9512124061584473
223,2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676,positive,0.9400112628936768
224,2/7/2021 3:01:47 PM,Here's what Wall Street expects from Incyte's earnings report,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q4-1030051647,positive,0.9164949655532837
225,2/8/2021 5:02:56 PM,Incyte Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3659533-incyte-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.71089768409729
226,2/8/2021 5:05:52 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3659536-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
227,2/9/2021 12:01:53 PM,"Incyte EPS beats by $0.16, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3659867-incyte-eps-beats-0_16-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6914128661155701
228,2/9/2021 12:54:42 PM,"Incyte Q4 topline up 36%, posts 2021 forecast",Seeking Alpha,https://seekingalpha.com/news/3659912-incyte-q4-topline-up-36-posts-2021-forecast?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.923714280128479
229,2/9/2021 1:24:01 PM,Incyte Corporation Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q4-adjusted-earnings-beat-estimates-1030059990,negative,0.8401117920875549
230,2/9/2021 1:29:07 PM,Incyte Q4 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/incyte-q4-results-top-estimates-quick-facts-1030060013,positive,0.9191045165061951
231,2/9/2021 2:10:28 PM,"The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-dynavax-poaches-gsk-vaccine-exec-kalvista-jumps-on-data-readout-corcept-issues-negative-preannouncement-1030060223,neutral,0.8829746842384338
232,2/10/2021 2:05:22 PM,Incyte is weighed down by SVB downgrade following Q4 earnings release,Seeking Alpha,https://seekingalpha.com/news/3660538-incyte-weighed-down-by-svb-downgrade-following-q4-earnings-release?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9719719886779785
233,2/10/2021 4:05:07 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-10-2021-1030067423,neutral,0.6393447518348694
234,2/19/2021 2:26:02 PM,FDA accepts Incyte's ruxolitinib NDA with Priority Review,Seeking Alpha,https://seekingalpha.com/news/3663913-fda-grants-priority-review-for-ruxolitinib-nda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6272667646408081
235,2/26/2021 9:39:21 AM,Incyte's retifanlimab application validated in Europe for anal cancer,Seeking Alpha,https://seekingalpha.com/news/3666998-incytes-retifanlimab-application-validated-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7984457015991211
236,2/26/2021 2:16:52 PM,"The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-test-awaits-j-j-s-covid-19-vaccine-lilly-to-supply-additional-antibody-therapy-doses-to-us-regulatory-setback-for-tricida-1030129439,neutral,0.9285117387771606
237,2/28/2021 2:36:40 PM,"The Past Week's Notable Insider Buys: Agree Realty, Avis Budget, Zoetis And More",Benzinga,/news/stocks/the-past-week-s-notable-insider-buys-agree-realty-avis-budget-zoetis-and-more-1030132210,positive,0.8334847688674927
238,3/1/2021 1:20:45 PM,7 Beaten Down Stocks With Significant Insider Buying,InvestorPlace,/news/stocks/7-beaten-down-stocks-with-significant-insider-buying-1030136010,neutral,0.9446586966514587
239,3/3/2021 12:04:43 PM,"Lilly, Incyte's baricitinib shows hair regrowth in late-stage alopecia areata study",Seeking Alpha,https://seekingalpha.com/news/3668631-lilly-incytes-baricitinib-successful-in-alopecia-areata-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5546414256095886
240,3/3/2021 1:04:01 PM,Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth ,RTTNews,/news/stocks/lilly-phase-3-study-on-baricitinib-meets-primary-endpoint-of-hair-regrowth-1030144664,negative,0.7628650665283203
241,3/3/2021 1:34:53 PM,"Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment- Quick Facts ",RTTNews,/news/stocks/eli-lilly-incyte-report-positive-results-for-baricitinib-in-alopecia-areata-treatment-quick-facts-1030144848,negative,0.9428061246871948
242,3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7542275786399841
243,3/18/2021 8:37:55 PM,Incyte COVID-19 candidate misses primary endpoint in late-stage study (updated),Seeking Alpha,https://seekingalpha.com/news/3674237-incyte-posts-late-stage-ruxolitinib-covid-19-study-results?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8663337826728821
244,3/23/2021 10:40:48 AM,Incyte's Pemazyre OK'd in Japan for bile duct cancer,Seeking Alpha,https://seekingalpha.com/news/3675094-incytes-pemazyre-okd-in-japan-for-bile-duct-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.81119304895401
245,3/29/2021 4:19:14 PM,Incyte's Pemazyre wins European Commission approval to treat rare form of cancer,Seeking Alpha,https://seekingalpha.com/news/3677260-incytes-pemazyre-wins-european-commission-approval-to-treat-rare-form-of-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9241110682487488
246,4/6/2021 8:39:09 PM,"FDA extends review period for Eli Lilly, Incyte's baricitinib atopic dermatitis sNDA",Seeking Alpha,https://seekingalpha.com/news/3679664-fda-extends-review-period-for-eli-lilly-incytes-baricitinib-atopic-dermatitis-snda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4313618242740631
247,4/7/2021 1:57:58 PM,"The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award",Benzinga,/news/stocks/the-daily-biotech-pulse-fibrogen-fudges-safety-data-novartis-strikes-cancer-drug-collaboration-immutep-gains-on-patent-award-1030280866,negative,0.6349209547042847
248,4/8/2021 11:23:22 AM,"Lilly, Incyte's COV-BARRIER study fails to meet primary endpoint in COVID-19",Seeking Alpha,https://seekingalpha.com/news/3680241-lilly-incytes-cov-barrier-study-fails-to-meet-primary-endpoint-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.939039409160614
249,4/8/2021 1:41:24 PM,Eli Lilly Says Late-stage Study Of Baricitinib In Hospitalized Covid Patients Didn't Meet Main Goal ,RTTNews,/news/stocks/eli-lilly-says-late-stage-study-of-baricitinib-in-hospitalized-covid-patients-didn-t-meet-main-goal-1030285100,neutral,0.7557854056358337
250,4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466,positive,0.8932459950447083
251,4/9/2021 1:11:12 PM,"Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3680680-provention-bio-downgraded-on-fda-feedback-citi-sizes-up-zuranolone-success-on-biogen?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9142313003540039
252,4/9/2021 5:30:00 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3680534-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
253,4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9712752103805542
254,4/16/2021 8:47:11 PM,Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3682728-lilly-and-incytes-baricitinib-fails-to-meet-main-goal-in-late-stage-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9349154233932495
255,4/19/2021 8:11:47 PM,Incyte and Morphosys dose first patient in late-stage lymphoma study,Seeking Alpha,https://seekingalpha.com/news/3683140-incyte-and-morphosys-dose-first-patient-in-late-stage-lymphoma-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8269583582878113
256,4/20/2021 4:36:34 AM,"Incyte, MorphoSys Say First Patient Dosed In Phase 3 InMIND Study On Follicular Lymphoma ",RTTNews,/news/stocks/incyte-morphosys-say-first-patient-dosed-in-phase-3-inmind-study-on-follicular-lymphoma-1030320025,positive,0.5653983354568481
257,4/20/2021 11:11:34 AM,"Lilly, Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients",Seeking Alpha,https://seekingalpha.com/news/3683289-lilly-incytes-second-baricitinib-study-shows-improvement-in-hair-regrowth-in-alopecia-areata-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9484562277793884
258,4/20/2021 1:51:46 PM,Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-2nd-late-stage-study-of-baricitinib-achieved-main-goal-quick-facts-1030322410,negative,0.8178072571754456
259,4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640,positive,0.7906168103218079
260,4/23/2021 3:52:51 PM,Incyte presents more data from positive late-stage studies for ruxolitinib in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3685158-incyte-presents-more-data-from-late-stage-studies-for-ruxolitinib-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5830709338188171
261,4/23/2021 4:44:02 PM,Incyte : Olumiant Shows Improvements In Severity And Extent Of Atopic Dermatitis ,RTTNews,/news/stocks/incyte-olumiant-shows-improvements-in-severity-and-extent-of-atopic-dermatitis-1030339129,negative,0.9510595798492432
262,4/29/2021 2:39:08 PM,Lilly’s Olumiant undergoes European review for hospitalized  COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3687965-lillys-olumiant-undergoes-european-review-for-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.582008957862854
263,4/29/2021 6:01:35 PM,Incyte-partnered anti-PD-1 therapy wins FDA’s orphan drug designation for liver cancer,Seeking Alpha,https://seekingalpha.com/news/3688093-incyte-partnered-anti-pd-1-therapy-wins-fdas-orphan-drug-designation-for-liver-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9005162715911865
264,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608,positive,0.8418352007865906
265,5/2/2021 3:01:32 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q1-1030374725,positive,0.9349303245544434
266,5/3/2021 5:04:25 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3689391-notable-earnings-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
267,5/4/2021 11:03:02 AM,"Incyte EPS beats by $0.03, misses on revenue; reaffirms guidance",Seeking Alpha,https://seekingalpha.com/news/3689978-incyte-eps-beats-by-003-misses-on-revenue-reaffirms-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7944973111152649
268,5/4/2021 12:07:23 PM,"Incyte posts mixed Q1 results, reaffirms guidance",Seeking Alpha,https://seekingalpha.com/news/3690068-incyte-posts-mixed-q1-results-reaffirms-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9382506012916565
269,5/4/2021 1:25:50 PM,Incyte Corporation Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q1-adjusted-earnings-beat-estimates-1030383592,negative,0.7821727395057678
270,5/4/2021 2:10:21 PM,"The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data",Benzinga,/news/stocks/the-daily-biotech-pulse-vaxart-rebounds-on-strong-vaccine-data-pfizer-s-beat-and-raise-quarter-biolinerx-data-1030383815,negative,0.5902956128120422
271,5/11/2021 8:07:41 PM,Incyte and Morphosys dose first patient in late-stage lymphoma study,Seeking Alpha,https://seekingalpha.com/news/3694803-incyte-and-morphosys-dose-first-patient-in-late-stage-lymphoma-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8269583582878113
272,5/12/2021 2:57:17 PM,"The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron",Benzinga,/news/stocks/the-daily-biotech-pulse-minerva-inflarx-report-positive-data-readouts-lucira-covid-19-test-kit-available-on-amazon-decision-day-for-heron-1030421045,positive,0.8616788387298584
273,5/17/2021 11:37:57 AM,Incyte's vitiligo treatment meets late-stage trial main goal,Seeking Alpha,https://seekingalpha.com/news/3696975-incytes-vitiligo-treatment-meets-late-stage-trial-main-goal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7842984199523926
274,5/17/2021 2:12:50 PM,Incyte Says Phase 3 TRuE-V Trial Met Primary And Key Secondary Endpoints - Quick Facts ,RTTNews,/news/stocks/incyte-says-phase-3-true-v-trial-met-primary-and-key-secondary-endpoints-quick-facts-1030436362,negative,0.9232102036476135
275,6/1/2021 11:31:09 PM,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-june-pdufa-dates-1030484849,positive,0.9476439952850342
276,6/4/2021 6:49:16 PM,Incyte and MorphoSys present new three-year data for blood cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3703435-incyte-and-morphosys-presents-new-three-year-data-for-blood-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8171363472938538
277,6/8/2021 2:13:31 PM,Incyte Says FDA Extends Review Period For Ruxolitinib SNDA - Quick Facts ,RTTNews,/news/stocks/incyte-says-fda-extends-review-period-for-ruxolitinib-snda-quick-facts-1030503209,positive,0.7131752967834473
278,6/11/2021 2:19:35 PM,Incyte : FDA Extends NDA Review Period For Ruxolitinib In Atopic Dermatitis ,RTTNews,/news/stocks/incyte-fda-extends-nda-review-period-for-ruxolitinib-in-atopic-dermatitis-1030515614,neutral,0.37381303310394287
279,6/18/2021 7:30:24 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3707786-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
280,6/20/2021 4:04:37 PM,"The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-incyte-ascendis-fda-decisions-liver-congress-presentations-and-4-ipos-1030537312,positive,0.9417259097099304
281,6/24/2021 7:42:17 AM,Biotech Stocks Facing FDA Decision In July 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2021-1030549382,positive,0.818015456199646
282,6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,positive,0.93064284324646
283,6/24/2021 7:46:21 PM,FDA panel recommends deferring Incyte's retifanlimab BLA decision,Seeking Alpha,https://seekingalpha.com/news/3709814-fda-panel-recommends-deferring-retifanlimab-bla-decision?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8436354994773865
284,6/24/2021 9:55:57 PM,FDA Panel Defers Incyte's Anal Cancer Drug ,RTTNews,/news/stocks/fda-panel-defers-incyte-s-anal-cancer-drug-1030552820,neutral,0.5845729112625122
285,6/25/2021 2:04:26 PM,"Incyte, MorphoSys Get Positive CHMP Opinion For Tafasitamab In Combination With Lenalidomide ",RTTNews,/news/stocks/incyte-morphosys-get-positive-chmp-opinion-for-tafasitamab-in-combination-with-lenalidomide-1030554676,negative,0.9395056366920471
286,6/29/2021 1:55:35 PM,"Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3710900-sensei-downgraded-price-target-cut-on-program-discontinuation-gileads-yescarta-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6577472686767578
287,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5084574222564697
288,7/1/2021 11:07:05 PM,Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-july-pdufa-dates-1030573631,positive,0.9455710649490356
289,7/9/2021 11:47:28 AM,China's NMPA accepts Innovent's pemigatinib NDA for review,Seeking Alpha,https://seekingalpha.com/news/3713926-chinas-nmpa-accepts-innovents-pemigatinib-nda-for-review?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5712438225746155
290,7/14/2021 11:30:52 AM,BriaCell/Incyte opens enrollment for Phase I/IIa combo study in breast cancer,Seeking Alpha,https://seekingalpha.com/news/3715023-briacellincyte-opens-enrollment-for-phase-iiia-combo-study-in-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5725290179252625
291,7/15/2021 2:07:56 PM,"The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-galapagos-sinks-on-data-j-j-recalls-sunscreen-products-fibrogen-awaits-adcom-verdict-3-ipos-1030610817,positive,0.6488502025604248
292,7/16/2021 2:09:18 PM,Lilly and Incyte provide update on FDA regulatory timeline for baricitinib,Seeking Alpha,https://seekingalpha.com/news/3715993-lilly-and-incyte-provide-update-on-fda-regulatory-timeline-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9406559467315674
293,7/16/2021 4:33:50 PM,Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis ,RTTNews,/news/stocks/lilly-fda-delays-review-of-baricitinib-snda-on-atopic-dermatitis-1030615528,neutral,0.9322182536125183
294,7/20/2021 4:14:09 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-20-2021-1030625981,neutral,0.552625298500061
295,7/20/2021 9:28:19 PM,Benchmark Upgrades Incyte After Stock Selloff,Benzinga,/news/stocks/benchmark-upgrades-incyte-after-stock-selloff-1030626932,neutral,0.8868646621704102
296,7/23/2021 8:36:31 PM,FDA declines to approve Incyte's squamous cell carcinoma treatment retifanlimab,Seeking Alpha,https://seekingalpha.com/news/3718775-fda-declines-to-approve-incytes-squamous-cell-carcinoma-treatment-retifanlimab?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8690073490142822
297,7/23/2021 9:40:34 PM,"NRXP, PDD, ACOR and IPA among after-hours movers",Seeking Alpha,https://seekingalpha.com/news/3718792-nrxp-pdd-acor-and-ipa-among-after-hours-movers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9269499778747559
298,7/24/2021 5:15:09 AM,Incyte : FDA Issues Complete Response Letter For Retifanlimab ,RTTNews,/news/stocks/incyte-fda-issues-complete-response-letter-for-retifanlimab-1030640314,positive,0.8594688177108765
299,7/27/2021 6:23:20 PM,7 Cheap Value Stocks to Buy for August 2021,InvestorPlace,/news/stocks/7-cheap-value-stocks-to-buy-for-august-2021-1030652138,positive,0.9190972447395325
300,7/29/2021 1:59:04 PM,"FDA broadens EUA for Lilly, Incyte's baricitinib for COVID-19",Seeking Alpha,https://seekingalpha.com/news/3721602-fda-broadens-eua-for-lilly-incytes-baricitinib-olumiant-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8792058825492859
301,7/29/2021 3:45:21 PM,Lilly : FDA Broadens Emergency Use Of Baricitinib In Patients Hospitalized With COVID-19 ,RTTNews,/news/stocks/lilly-fda-broadens-emergency-use-of-baricitinib-in-patients-hospitalized-with-covid-19-1030662943,negative,0.8980918526649475
302,8/1/2021 3:01:51 PM,Incyte earnings: here's what to expect,Markets Insider Automation,/news/stocks/incyte-q2-quarterly-earnings-preview-stock-1030671636,positive,0.9323586821556091
303,8/2/2021 2:02:49 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3722982-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
304,8/3/2021 12:10:40 AM,Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-august-pdufa-dates-1030679352,positive,0.946641743183136
305,8/3/2021 10:55:42 AM,"Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation",Seeking Alpha,https://seekingalpha.com/news/3723668-lilly-incytes-baricitinib-reduces-deaths-among-covid-19-patients-on-mechanical-ventilation?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8990769982337952
306,8/3/2021 11:07:14 AM,"Incyte EPS beats by $0.06, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3723697-incyte-eps-beats-0_06-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7815141081809998
307,8/3/2021 11:58:24 AM,Incyte tops Q1 forecast; Jakafi revenue outlook lowered,Seeking Alpha,https://seekingalpha.com/news/3723766-incyte-tops-q1-forecast-jakafi-revenue-outlook-lowered?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9384629726409912
308,8/3/2021 12:00:00 PM,Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation,PR Newswire,/news/stocks/lilly-and-incyte-s-baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invasive-mechanical-ventilation-1030681949,negative,0.9076222777366638
309,8/3/2021 12:36:53 PM,"Lilly, Incyte: Baricitinib Reduced Deaths In COVID-19 Patients Under Invasive Mechanical Ventilation ",RTTNews,/news/stocks/lilly-incyte-baricitinib-reduced-deaths-in-covid-19-patients-under-invasive-mechanical-ventilation-1030682109,negative,0.9218716621398926
310,8/3/2021 1:32:33 PM,Incyte Corporation Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q2-adjusted-earnings-beat-estimates-1030682501,negative,0.7220250368118286
311,8/10/2021 1:55:36 PM,"The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-arcturus-soars-on-covid-19-vaccine-updates-merck-s-keytruda-on-track-for-more-label-expansions-eliem-debuts-1030712978,negative,0.8045278787612915
312,8/11/2021 2:14:38 PM,"The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-rejects-fibrogen-s-anemia-drug-crinetics-gains-on-positive-readout-biocryst-withdraws-public-offering-1030718580,neutral,0.7697625756263733
313,8/12/2021 2:09:26 PM,"The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma",Benzinga,/news/stocks/the-daily-biotech-pulse-xeris-gets-ok-for-initiating-hyperthyroidism-study-merck-eisai-snag-fda-approval-for-drug-combo-decision-day-for-jazz-pharma-1030724099,negative,0.575188934803009
314,8/13/2021 1:43:02 PM,"The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-s-vaccine-produces-durable-response-against-variants-fda-approves-jazz-s-sleep-disorder-drug-dermata-ipo-1030728962,negative,0.8680629730224609
315,8/17/2021 10:44:48 AM,"Incyte, InnoCare In Collaboration And License Deal For Tafasitamab In Greater China ",RTTNews,/news/stocks/incyte-innocare-in-collaboration-and-license-deal-for-tafasitamab-in-greater-china-1030737122,positive,0.6115073561668396
316,8/17/2021 12:37:27 PM,Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China,Benzinga,/news/stocks/incyte-out-licenses-lymphoma-drug-to-innocare-in-greater-china-1030737433,positive,0.7401844263076782
317,8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023,positive,0.9126444458961487
318,8/24/2021 2:44:10 PM,Incyte Reports Conditional Approval Of Minjuvi In Canada For Patients With DLBCL ,RTTNews,/news/stocks/incyte-reports-conditional-approval-of-minjuvi-in-canada-for-patients-with-dlbcl-1030754890,negative,0.6880590319633484
319,8/27/2021 5:23:16 AM,MorphoSys : EU Conditionally Approves Minjuvi - Lenalidomide To Treat Relapsed Or Refractory DLBCL ,RTTNews,/news/stocks/morphosys-eu-conditionally-approves-minjuvi-lenalidomide-to-treat-relapsed-or-refractory-dlbcl-1030762334,negative,0.8865172266960144
320,8/27/2021 12:19:58 PM,Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval,Benzinga,/news/stocks/incyte---morphosys-s-diffuse-large-b-cell-lymphoma-drug-wins-european-approval-1030763271,negative,0.9490054845809937
321,8/27/2021 1:35:25 PM,"The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-morphosys-incyte-snag-european-nod-immutep-granted-chinese-patent-bolt-biotherapeutics-strike-oncology-collaboration-1030763431,negative,0.5113007426261902
322,8/30/2021 8:43:24 AM,Biotech Stocks Facing FDA Decision In September 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2021-1030766032,positive,0.7743737697601318
323,8/31/2021 8:00:15 PM,Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-september-pdufa-dates-1030770967,positive,0.9473286271095276
324,9/2/2021 7:42:44 PM,"FDA action dates, catalysts, and other events for pharma/biotech in September",Seeking Alpha,https://seekingalpha.com/news/3736842-fda-action-dates-catalysts-and-other-events-for-pharmabiotech-in-september?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9397355914115906
325,9/17/2021 7:00:20 PM,"Catalyst watch for next week: FedEx and Nike report, FOMC watch, IPO blitz",Seeking Alpha,https://seekingalpha.com/news/3740930-catalyst-watch-for-next-week-fedex-and-nike-report-fomc-watch-ipo-blitz?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9421775341033936
326,9/19/2021 3:46:51 PM,"The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-19-25-incyte-verrica-fda-decisions-and-conference-presentations-in-the-spotlight-1030808489,positive,0.941505491733551
327,9/21/2021 2:20:50 PM,"The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data",Benzinga,/news/stocks/the-daily-biotech-pulse-aprea-jumps-on-esmo-presentation-verrica-sinks-on-regulatory-setback-aerie-ceo-quits-j-j-touts-positive-covid-19-booster-shot-data-1030812654,neutral,0.6769793629646301
328,9/22/2021 5:31:14 AM,FDA Approves Incyte's Opzelura Cream To Treat Atopic Dermatitis ,RTTNews,/news/stocks/fda-approves-incyte-s-opzelura-cream-to-treat-atopic-dermatitis-1030814450,negative,0.8607857823371887
329,9/22/2021 12:29:59 PM,"FedEx, Incyte, Leap Therapeutics among major healthcare premarket losers' pack",Seeking Alpha,https://seekingalpha.com/news/3742189-fedex-incyte-leap-therapeutics-among-major-healthcare-premarket-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.49037450551986694
330,9/22/2021 1:45:28 PM,"The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-us-vaccine-contract-summit-slumps-on-adverse-regulatory-feedback-cerevel-cfo-departs-1030815550,neutral,0.9714490175247192
331,9/23/2021 1:53:54 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030818619,positive,0.7969076037406921
332,9/23/2021 1:56:57 PM,"The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data",Benzinga,/news/stocks/the-daily-biotech-pulse-restricted-authorization-for-pfizer-s-covid-19-booster-dose-abcellera-strikes-antibody-licensing-deal-solid-biosciences-issues-dmd-data-1030818618,positive,0.8776688575744629
333,9/23/2021 4:06:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-23-2021-1030819280,neutral,0.539220929145813
334,9/23/2021 6:41:43 PM,Expert Ratings For Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1030819790,positive,0.8165982961654663
335,9/27/2021 12:00:00 PM,Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases,PR Newswire,/news/stocks/syndax-pharmaceuticals-and-incyte-announce-global-collaboration-to-develop-and-commercialize-axatilimab-for-chronic-graft-versus-host-disease-and-other-fibrotic-diseases-1030825021,negative,0.8999716639518738
336,9/27/2021 12:19:44 PM,"Syndax Partners With Incyte To Develop, Commercialize Axatilimab - Quick Facts ",RTTNews,/news/stocks/syndax-partners-with-incyte-to-develop-commercialize-axatilimab-quick-facts-1030825080,positive,0.6026841998100281
337,9/27/2021 3:23:12 PM,"Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate",Benzinga,/news/stocks/syndax-pharma-incyte-ink-licensing-pact-for-graft-vs-host-disease-candidate-1030825740,negative,0.773047149181366
338,9/28/2021 2:18:52 PM,"The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive",Benzinga,/news/stocks/the-daily-biotech-pulse-eisai-biogen-pursue-approval-of-second-alzheimer-s-treatment-sanofi-changes-mrna-strategy-gsk-subsidiary-to-develop-long-acting-hiv-preventive-1030827880,positive,0.5831677317619324
339,9/30/2021 11:56:00 AM,OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata,PR Newswire,/news/stocks/olumiant-significantly-improved-hair-regrowth-to-at-least-80-scalp-coverage-as-early-as-24-weeks-across-first-completed-phase-3-studies-for-alopecia-areata-1030833394,negative,0.9547622799873352
340,9/30/2021 12:40:08 PM,"Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-present-detailed-results-from-olumiant-brave-aa1-brave-aa2-trials-in-alopecia-areata-1030833516,positive,0.9086092114448547
341,10/1/2021 8:17:08 PM,Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-october-pdufa-dates-1030838143,positive,0.9432098269462585
342,10/5/2021 2:01:45 PM,"The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-files-for-booster-dose-authorization-gemini-restructures-strata-skin-cfo-departs-kaleido-reports-positive-readout-1030843466,positive,0.4234638512134552
343,10/6/2021 1:33:33 PM,"The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-takeda-suspends-studies-on-safety-scare-acer-s-sleep-disorder-drug-filing-accepted-for-review-voyager-s-licensing-options-deal-1030846864,neutral,0.905750572681427
344,10/7/2021 2:23:53 PM,"The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-invests-in-africa-amgen-announces-neuroscience-r-d-collaboration-decision-day-for-chemocentryx-biophytis-to-restate-results-1030850125,positive,0.89493727684021
345,10/28/2021 11:57:36 AM,EMA validates Incyte's ruxolitinib MAA as potential treatment of non-segmental vitiligo,Seeking Alpha,https://seekingalpha.com/news/3759934-ema-validates-incytes-ruxolitinib-maa-as-potential-treatment-of-non-segmental-vitiligo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8671060800552368
346,10/31/2021 7:23:54 PM,"The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-31-nov-6-earnings-pick-up-pace-eton-awaits-seizure-drug-approval-kidney-conference-more-ipos-in-the-pipeline-1030917750,negative,0.939061164855957
347,11/1/2021 11:38:54 AM,FDA accepts to review Incyte's NDA for parsaclisib,Seeking Alpha,https://seekingalpha.com/news/3761300-fda-accepts-to-review-incytes-nda-for-parsaclisib?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8154686093330383
348,11/1/2021 3:01:13 PM,Incyte is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/incyte-q3-quarterly-earnings-preview-1030922013,positive,0.9335429668426514
349,11/1/2021 3:10:27 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3761481-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
350,11/1/2021 4:37:58 PM,Incyte Q3 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3761548-incyte-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.579345703125
351,11/2/2021 11:11:50 AM,"Incyte EPS beats by $0.43, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3762697-incyte-eps-beats-0_43-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7400316596031189
352,11/2/2021 12:27:59 PM,Incyte Corporation Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/incyte-corporation-q3-adjusted-earnings-beat-estimates-1030925666,negative,0.7319275736808777
353,11/2/2021 12:52:53 PM,"The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-solid-q3-earnings-regulatory-setback-for-legend-lilly-to-supply-additional-covid-19-antibody-cocktails-to-us-1030925781,negative,0.9155561327934265
354,11/2/2021 2:01:50 PM,Incyte shares fall despite Jakafi powered Q3 earnings beat,Seeking Alpha,https://seekingalpha.com/news/3762875-incyte-shares-fall-despite-jakafi-powered-q3-earnings-beat?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.960709273815155
355,11/4/2021 3:07:00 PM,Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies,PR Newswire,/news/stocks/cellenkos-inc-secures-15-million-series-a-financing-to-accelerate-the-development-of-transformation-cell-based-therapies-1030937913,negative,0.8769652843475342
356,11/9/2021 2:30:00 PM,"OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis",PR Newswire,/news/stocks/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-more-than-3-700-patients-with-rheumatoid-arthritis-1030953796,negative,0.8902518153190613
357,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825,neutral,0.6235842108726501
358,12/3/2021 8:00:27 PM,"Catalyst watch for next week: Rivian ratings pour in, big events for Southwest Airlines, McKesson and CVS Health",Seeking Alpha,https://seekingalpha.com/news/3777035-catalyst-watch-for-next-week-rivian-ratings-pour-in-big-events-for-southwest-airlines-mckesson-and-cvs-health?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7913451194763184
359,12/3/2021 9:43:36 PM,AbbVie updates U.S. labeling info for RINVOQ in rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3777094-abbvie-updates-us-labeling-info-for-rinvoq-in-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9334484338760376
360,12/6/2021 12:07:24 PM,"The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-6-dec-11-daré-fda-decision-adcom-tryst-for-reata-multiple-conference-presentations-and-more-1031025543,positive,0.9361634850502014
361,12/10/2021 12:51:11 PM,Oncolytics Biotech jumps 9% on positive data for breast cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3779095-oncolytics-biotech-jumps-9-on-positive-data-for-breast-cancer-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9292824864387512
362,12/10/2021 10:15:55 PM,7 CEOs That Ought to Follow Jack Dorsey Out the Door,InvestorPlace,/news/stocks/7-ceos-that-ought-to-follow-jack-dorsey-out-the-door-1031039765,positive,0.9249659776687622
363,12/11/2021 7:21:54 PM,Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab  Combination Data ,RTTNews,/news/stocks/incyte-says-saw-survival-benefit-for-patients-with-refractory-dlbcl-in-tafasitamab-combination-data-1031040032,negative,0.9499901533126831
364,12/13/2021 3:56:25 PM,New Nasdaq 100 tech stocks start week off with mild gains,Seeking Alpha,https://seekingalpha.com/news/3779559-new-nasdaq-100-tech-stocks-start-week-off-with-mild-gains?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.730998158454895
365,12/14/2021 10:01:17 PM,Incyte receives Priority Review for Opzelura to treat vitiligo,Seeking Alpha,https://seekingalpha.com/news/3780150-incyte-receives-priority-review-for-opzelura-to-treat-vitiligo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8592621684074402
366,12/19/2021 2:00:00 PM,"Alnylam, Crispr Therapeutics among Goldman's biopharma M&A targets for 2022",Seeking Alpha,https://seekingalpha.com/news/3781488-alnylam-pharma-crispr-therapeutics-among-goldmans-healthcare-targets-for-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7041938304901123
367,12/20/2021 10:04:05 AM,4 Stocks Insiders Are Buying,Benzinga,/news/stocks/4-stocks-insiders-are-buying-1031055545,positive,0.915924608707428
368,12/22/2021 1:12:06 PM,"Cramer Shares His Thoughts On Incyte, Corning And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-incyte-corning-and-more-1031061513,positive,0.9421775341033936
369,1/18/2022 4:06:20 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-18-2022-1031109488,neutral,0.5561301112174988
370,1/18/2022 7:52:56 PM,Incyte upgraded to Outperform at RBC citing near-term prospects,Seeking Alpha,https://seekingalpha.com/news/3788888-incyte-upgraded-to-outperform-at-rbc-citing-near-term-prospects?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9049692749977112
371,1/18/2022 8:27:47 PM,Where Incyte Stands With Analysts,Benzinga,/news/stocks/where-incyte-stands-with-analysts-1031110231,positive,0.9358789920806885
372,1/24/2022 8:41:25 AM,Innovent : Pemazyre Approved In Hong Kong For Treatment Of Adults With Metastatic Cholangiocarcinoma ,RTTNews,/news/stocks/innovent-pemazyre-approved-in-hong-kong-for-treatment-of-adults-with-metastatic-cholangiocarcinoma-1031121702,negative,0.5566712617874146
373,1/24/2022 12:28:20 PM,Innovent's Pemazyre for bile cancer gets approval in Hong Kong,Seeking Alpha,https://seekingalpha.com/news/3790584-innovents-pemazyre-for-bile-cancer-gets-approval-in-hong-kong?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9144761562347412
374,1/25/2022 9:51:54 PM,Incyte withdraws NDA for lymphoma treatment parsaclisib,Seeking Alpha,https://seekingalpha.com/news/3791551-incyte-withdraws-nda-for-lymphoma-treatment-parsaclisib?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6317005157470703
375,1/26/2022 1:07:45 PM,"Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus",Benzinga,/news/stocks/incyte-pulls-parsaclisib-us-application-for-lymphoma-treatment-bows-out-solid-tumor-program-with-merus-1031130287,negative,0.5480931401252747
376,1/28/2022 1:59:03 PM,Lilly to stop Olumiant lupus program; fears FDA rejection of drug in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3793046-lilly-to-stop-olumiant-lupus-program-fears-fda-rejection-for-drug-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9044762253761292
377,1/28/2022 2:00:00 PM,Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis,PR Newswire,/news/stocks/updates-on-olumiant-baricitinib-phase-3-lupus-program-and-fda-review-for-atopic-dermatitis-1031139169,positive,0.8766374588012695
378,1/28/2022 2:16:35 PM,Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts ,RTTNews,/news/stocks/lilly-to-discontinue-phase-3-development-program-for-olumiant-in-lupus-quick-facts-1031139271,positive,0.8179276585578918
379,2/7/2022 3:01:13 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-stock-q4-earnings-preview-1031167280,positive,0.9349303245544434
380,2/7/2022 3:17:26 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3796574-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
381,2/7/2022 4:39:59 PM,Incyte Q4 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3796661-incyte-q4-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5793613791465759
382,2/8/2022 12:02:06 PM,"IncyteEPS of $0.10, revenue of $862.5M beats by $49.12M",Seeking Alpha,https://seekingalpha.com/news/3797081-incyteeps-of-0_10-revenue-of-862_5m-beats-49_12m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5191600322723389
383,2/8/2022 1:10:57 PM,"Incyte Corporation Q4 Profit Increases, but misses estimates",RTTNews,/news/stocks/incyte-corporation-q4-profit-increases-but-misses-estimates-1031171281,negative,0.8886991143226624
384,2/8/2022 1:26:34 PM,Incyte beats on top line buoyed by increase in Jakafi revenues,Seeking Alpha,https://seekingalpha.com/news/3797153-incyte-beats-on-top-line-buoyed-by-increase-in-jakafi-revenues?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8849650025367737
385,2/8/2022 2:29:54 PM,"The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-amgen-shares-slip-on-earnings-editas-terminates-chief-medical-officer-biogen-licenses-preclinical-rheumatoid-arthritis-biosimilar-1031171617,neutral,0.9022089242935181
386,2/9/2022 4:02:47 PM,"Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-february-9-2022-1031177709,neutral,0.512998104095459
387,2/9/2022 6:03:12 PM,Expert Ratings For Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1031178066,positive,0.8165982961654663
388,2/9/2022 7:21:12 PM,Incyte slips despite revenue beat amid mixed outlook for newly launched product,Seeking Alpha,https://seekingalpha.com/news/3798072-incyte-slips-despite-revenue-beat-amid-mixed-outlook-for-newly-launched-product?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9704603552818298
389,2/15/2022 12:55:19 PM,Insiders Buy Around $112M Of 3 Stocks,Benzinga,/news/stocks/insiders-buy-around-112m-of-3-stocks-1031195090,positive,0.9406049847602844
390,2/18/2022 8:16:57 PM,7 Insider Stocks to Buy as Execs Snap Them Up,InvestorPlace,/news/stocks/7-insider-stocks-to-buy-as-execs-snap-them-up-1031209621,positive,0.7989582419395447
391,3/8/2022 9:07:28 PM,Why Are Company Insiders Buying These 7 S&P 500 Stocks?,Benzinga,/news/stocks/why-are-company-insiders-buying-these-7-s-p-500-stocks-1031264025,positive,0.7809075713157654
392,3/11/2022 1:21:13 PM,Insiders Buy More Than $80M Of 3 Stocks,Benzinga,/news/stocks/insiders-buy-more-than-80m-of-3-stocks-1031273662,positive,0.9349136352539062
393,3/15/2022 9:44:21 AM,Incyte's Opzelura review to treat vitiligo extended by 3 months by FDA,Seeking Alpha,https://seekingalpha.com/news/3813443-incytes-opzelura-review-to-treat-vitiligo-extended-by-3-months-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8835394382476807
394,3/22/2022 9:49:59 PM,MorphoSys rises after Swissmedic grants temporary approval to lymphoma treatment,Seeking Alpha,https://seekingalpha.com/news/3816224-morphosys-rises-after-swiss-agency-approves-lymphoma-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5984829664230347
395,3/23/2022 3:23:01 AM,MorphoSys : Swissmedic Temporarily Approves Minjuvi - Lenalidomid Combination For DLBCL Treatment ,RTTNews,/news/stocks/morphosys-swissmedic-temporarily-approves-minjuvi-lenalidomid-combination-for-dlbcl-treatment-1031299780,neutral,0.9383701682090759
396,3/23/2022 12:05:37 PM,MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland,Benzinga,/news/stocks/morphosys-incyte-partnered-minjuvi-temporarily-approved-in-switzerland-1031300899,neutral,0.5674879550933838
397,3/23/2022 12:43:16 PM,"The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-positive-ulcerative-colitis-study-data-novavax-covid-shot-authorized-for-adolescents-in-india-argenx-stock-sale-1031301077,positive,0.5290573239326477
398,3/25/2022 1:00:50 PM,"Novartis, Incyte Jakavi gets EMA panel nod for expanded use in graft-versus-host disease",Seeking Alpha,https://seekingalpha.com/news/3817449-novartis-incyte-jakavi-gets-ema-panel-nod-for-expanded-use-in-graft-versus-host-disease?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7963095903396606
399,3/26/2022 4:20:00 PM,Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies,PR Newswire,/news/stocks/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-coverage-at-52-weeks-in-lilly-s-pivotal-phase-3-studies-1031309584,negative,0.8868787884712219
400,4/6/2022 2:02:15 PM,"The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy",Benzinga,/news/stocks/the-daily-biotech-pulse-bioxcel-s-igalmi-gets-fda-nod-citius-spikes-on-positive-phase-3-data-iovance-receives-positive-regulatory-feedback-for-skin-cancer-therapy-1031336312,negative,0.939556896686554
401,4/12/2022 12:53:27 PM,AbbVie myelofibrosis candidate navitoclax shows improvement in mid-stage trial,Seeking Alpha,https://seekingalpha.com/news/3822654-abbvie-myelofibrosis-candidate-navitoclax-shows-improvement-in-mid-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.955564558506012
402,4/13/2022 2:41:56 PM,Why BriaCell Therapeutics Is Rising In Pre-market? ,RTTNews,/news/stocks/why-briacell-therapeutics-is-rising-in-pre-market-1031353422,positive,0.7829808592796326
403,4/28/2022 8:12:05 PM,"Incyte, Maruho ink deal for exclusive commercialization of ruxolitinib cream in Japan",Seeking Alpha,https://seekingalpha.com/news/3828882-incyte-maruho-ink-deal-for-exclusive-commercialization-of-ruxolitinib-cream-in-japan?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8680537939071655
404,5/1/2022 10:15:52 AM,3 Nasdaq Stocks to Buy Now for Growth,InvestorPlace,/news/stocks/3-nasdaq-stocks-to-buy-now-for-growth-1031404763,positive,0.8844853043556213
405,5/2/2022 2:26:02 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3830038-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
406,5/2/2022 2:26:53 PM,"The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-1-7-phathom-fda-decision-pfizer-vertex-pharma-lead-earnings-news-ophthalmology-conference-presentations-and-more-1031408449,positive,0.9381586909294128
407,5/2/2022 3:01:13 PM,Here's what Wall Street expects from Incyte's earnings report,Markets Insider Automation,/news/stocks/incyte-q1-quarterly-earnings-preview-stock-1031408828,positive,0.9164949655532837
408,5/2/2022 3:03:34 PM,"Incyte Q1 consensus EPS, revenue estimates up Y/Y",Seeking Alpha,https://seekingalpha.com/news/3830076-incyte-q1-consensus-eps-revenue-estimates-up-yy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9462202787399292
409,5/2/2022 3:23:12 PM,Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M,Benzinga,/news/stocks/global-cord-blood-enters-therapy-market-via-cellenkos-acquisition-for-over-600m-1031409062,positive,0.7706089615821838
410,5/3/2022 11:12:50 AM,"Incyte Non-GAAP EPS of $0.55 misses by $0.14, revenue of $733.24M misses by $20.3M; reaffirms FY22 guidance",Seeking Alpha,https://seekingalpha.com/news/3830830-incyte-non-gaap-eps-of-055-misses-by-014-revenue-of-73324m-misses-by-203m-reaffirms-fy22-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6995896697044373
411,5/3/2022 2:12:32 PM,Incyte Q1 Results Miss Estimates ,RTTNews,/news/stocks/incyte-q1-results-miss-estimates-1031413446,neutral,0.7752470374107361
412,5/3/2022 3:01:06 PM,"The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-s-adcomm-for-acadia-s-pimavanserin-review-issues-for-spero-s-tebipenem-application-cortexyme-layoffs-1031414090,neutral,0.5909820199012756
413,5/3/2022 4:31:58 PM,Incyte Q1 net income drops 17% as operating expenses soar,Seeking Alpha,https://seekingalpha.com/news/3831215-incyte-q1-net-income-drops-17-as-operating-expenses-soar?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.974837601184845
414,5/4/2022 9:21:24 PM,4 Analysts Have This to Say About Incyte,Benzinga,/news/stocks/4-analysts-have-this-to-say-about-incyte-1031421544,positive,0.9264417886734009
415,5/5/2022 2:43:28 PM,"The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-s-3-product-updates-jazz-pharma-licenses-sleeping-disorder-product-argenx-aces-bleeding-disorder-study-1031425784,positive,0.9387506246566772
416,5/11/2022 12:45:00 PM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-for-the-treatment-of-certain-hospitalized-patients-with-covid-19-1031447417,negative,0.8625271916389465
417,5/11/2022 1:04:22 PM,"Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19 ",RTTNews,/news/stocks/eli-lilly-incyte-announce-fda-approval-of-olumiant-for-hospitalized-patients-with-covid-19-1031447512,negative,0.8166871070861816
418,5/12/2022 6:40:12 PM,Concert Pharma surges as U.S. patent office upholds key patent,Seeking Alpha,https://seekingalpha.com/news/3838008-cnce-stock-surges-as-us-patent-office-upholds-key-patent?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9075652360916138
419,5/13/2022 5:55:52 PM,"Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas",Benzinga,/news/stocks/amid-slowing-sales-at-home-innovent-biologics-stumbles-overseas-1031459391,neutral,0.9719640016555786
420,5/13/2022 7:49:59 PM,Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted,Benzinga,/news/stocks/mizuho-sees-relief-for-this-small-cap-stock-after-patent-legal-overhang-lifted-1031459572,negative,0.9503768682479858
421,5/20/2022 1:56:10 PM,"Lilly, Incyte's Olumiant get EMA panel nod for hair loss disorder alopecia areata",Seeking Alpha,https://seekingalpha.com/news/3841375-lilly-incytes-olumiant-get-ema-panel-nod-for-hair-loss-disorder-alopecia-areata?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6624099612236023
422,5/20/2022 2:11:00 PM,CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA),PR Newswire,/news/stocks/chmp-recommends-approval-of-lilly-and-incyte-s-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata-aa-1031478443,negative,0.823082447052002
423,5/20/2022 2:29:07 PM,Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-for-olumiant-for-severe-alopecia-areata-treatment-1031478481,negative,0.9450750350952148
424,6/10/2022 11:13:29 AM,"AbbVie navitoclax, Jakafi combo shows promise in trial to treat rare bone marrow cancer",Seeking Alpha,https://seekingalpha.com/news/3847598-abbvie-navitoclax-jakafi-combo-shows-promise-in-trial-to-treat-rare-bone-marrow-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9031885862350464
425,6/10/2022 12:31:56 PM,CTI BioPharma slips after disclosing data for myelofibrosis therapy,Seeking Alpha,https://seekingalpha.com/news/3847640-ctic-stock-slips-on-data-for-myelofibrosis-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.9546101689338684
426,6/14/2022 3:50:00 AM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-as-first-and-only-systemic-medicine-for-adults-with-severe-alopecia-areata-1031526339,negative,0.8151333332061768
427,6/14/2022 7:47:24 AM,FDA Approves Lilly's Olumiant As First Systemic Treatment For Alopecia ,RTTNews,/news/stocks/fda-approves-lilly-s-olumiant-as-first-systemic-treatment-for-alopecia-1031526677,negative,0.7089864015579224
428,6/14/2022 9:39:14 AM,FDA Approves First Medicine Ever For Alopecia Areata ,RTTNews,/news/stocks/fda-approves-first-medicine-ever-for-alopecia-areata-1031526865,positive,0.5018296241760254
429,6/14/2022 2:37:49 PM,"Morning Brief: Top Financial Stories Dominating on Tuesday, June 14",Benzinga,/news/stocks/morning-brief-top-financial-stories-dominating-on-tuesday-june-14-1031527745,positive,0.9107048511505127
430,6/14/2022 8:09:00 PM,Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock,Benzinga,/news/stocks/approval-of-baricitinib-for-patchy-baldness-validates-clinical-patch-for-this-small-cap-stock-1031528830,negative,0.9399095177650452
431,6/15/2022 12:55:15 PM,"Pre-market Movers: REV, ASTL, VNRX, VORB, GGR… ",RTTNews,/news/stocks/pre-market-movers-rev-astl-vnrx-vorb-ggr-1031530111,positive,0.9534586071968079
432,6/27/2022 10:04:34 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/defensive-stocks-to-buy-for-a-bear-market-1031557948,positive,0.9065269827842712
433,6/27/2022 10:04:38 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-for-a-bear-market-1031552985,positive,0.9065269827842712
434,6/28/2022 9:17:30 AM,Biotech Stocks Facing FDA Decision In July 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2022-1031553516,positive,0.9208682775497437
435,7/1/2022 11:26:23 AM,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates-1031562548,positive,0.9478204250335693
436,7/7/2022 4:54:50 PM,CTI BioPharma initiated at outperform at Cowen on potential for Vonjo for myelofibrosis,Seeking Alpha,https://seekingalpha.com/news/3855085-cti-biopharma-initiated-at-outperform-at-cowen-on-potential-for-vonjo-for-myelofibrosis?utm_source=businessinsider&utm_medium=referral,negative,0.7278863191604614
437,7/12/2022 7:33:16 PM,Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?,Benzinga,/news/stocks/incyte-incy-outperforms-industry-ytd-what-lies-ahead-1031582179,positive,0.7776051163673401
438,7/18/2022 3:19:50 PM,"The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine",Benzinga,/news/stocks/the-daily-biotech-pulse-sesen-bio-stops-lead-assest-development-in-us-fda-approves-eton-pharma-s-partial-seizures-drug-bavarian-nordic-inks-multiple-supply-pact-for-monkeypox-vaccine-1031594118,negative,0.6193614602088928
439,7/19/2022 10:10:12 AM,Incyte's Opzelura for vitiligo wins FDA approval following extended review,Seeking Alpha,https://seekingalpha.com/news/3857907-incytes-opzelura-for-vitiligo-wins-fda-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9369927048683167
440,7/19/2022 3:12:33 PM,"The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-tentatively-approves-avadel-s-narcolepsy-drug-european-approval-broadens-astrazeneca-s-enhertu-in-breast-cancer-pharma-giants-earnings-1031597418,negative,0.8786939382553101
441,7/21/2022 7:03:18 PM,"New Indication Approval For Incyte ""To Usher New Growth Avenue""",Benzinga,/news/stocks/new-indication-approval-for-incyte-to-usher-new-growth-avenue-1031605581,negative,0.8550176620483398
442,7/28/2022 4:07:35 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-28-2022-1031626376,positive,0.4934685528278351
443,7/28/2022 8:27:35 PM,Expert Ratings for Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1031627079,positive,0.8165982961654663
444,7/31/2022 3:21:24 PM,Biotech Investors: August's Key PDUFA Catalysts You Must Know,Benzinga,/news/stocks/biotech-investors-august-s-key-pdufa-catalysts-you-must-know-1031631857,positive,0.8776605129241943
445,8/1/2022 2:59:27 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3863767-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
446,8/1/2022 3:01:13 PM,Here's what to expect from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-stock-price-q2-earnings-preview-1031635492,positive,0.9400319457054138
447,8/1/2022 5:04:31 PM,Incyte Q2 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3863873-incyte-q2-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,positive,0.8011259436607361
448,8/2/2022 11:02:39 AM,"Incyte Non-GAAP EPS of $1.01 beats by $0.27, revenue of $911.4M beats by $93.15M",Seeking Alpha,https://seekingalpha.com/news/3864500-incyte-non-gaap-eps-of-1_01-beats-0_27-revenue-of-911_4m-beats-93_15m?utm_source=businessinsider&utm_medium=referral,positive,0.7171259522438049
449,8/2/2022 1:25:58 PM,Incyte Q1 Results Top Estimates ,RTTNews,/news/stocks/incyte-q1-results-top-estimates-1031639268,positive,0.8880913257598877
450,8/2/2022 2:28:00 PM,"Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study",Benzinga,/news/stocks/biotech-daily-trial-setback-for-eliem-therapeutics-allarity-drops-work-on-cancer-monotherapies-axcella-aces-long-covid-study-1031639615,neutral,0.9367731809616089
451,8/2/2022 2:36:06 PM,Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%,Seeking Alpha,https://seekingalpha.com/news/3864706-incyte-q2-results-beat-on-top-and-bottom-lines-as-net-income-soars-27-shares-down-6?utm_source=businessinsider&utm_medium=referral,neutral,0.9695332050323486
452,8/3/2022 4:38:05 PM,"Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-august-3-2022-1031646200,positive,0.5270115733146667
453,8/25/2022 1:03:42 PM,"Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata",Seeking Alpha,https://seekingalpha.com/news/3876632-aclaris-lilly-ink-patent-license-deal-for-olumiant-to-treat-alopecia-areata?utm_source=businessinsider&utm_medium=referral,negative,0.818631112575531
454,8/26/2022 3:13:59 PM,Incyte wins approval of Pemazyre for rare blood cancer,Seeking Alpha,https://seekingalpha.com/news/3877104-incyte-wins-approval-of-pemazyre-for-rare-blood-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9060779213905334
455,8/26/2022 4:16:14 PM,Incyte : FDA Oks Pemazyre For Treatment Of Myeloid/lymphoid Neoplasms With FGFR1 Rearrangement ,RTTNews,/news/stocks/incyte-fda-oks-pemazyre-for-treatment-of-myeloid-lymphoid-neoplasms-with-fgfr1-rearrangement-1031708509,negative,0.7400713562965393
456,8/27/2022 1:52:44 AM,Recap Of Friday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031709013,positive,0.9370302557945251
457,9/15/2022 2:24:16 PM,Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia,Seeking Alpha,https://seekingalpha.com/news/3883116-incyte-drug-pemazyre-to-treat-rare-cancer-cholangiocarcinoma-approved-in-australia?utm_source=businessinsider&utm_medium=referral,negative,0.6406984925270081
458,9/16/2022 12:47:03 AM,"Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-15-2022---end-of-the-day-summary-1031746992,positive,0.9436883330345154
459,9/27/2022 8:15:28 AM,Mizuho Securities Reaffirms Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-reaffirms-their-hold-rating-on-incyte-incy-1031766271,positive,0.828685462474823
460,9/29/2022 3:21:55 PM,MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings,Benzinga,/news/stocks/morphosys-monjuvi-shows-long-term-durable-response-in-blood-cancer-settings-1031773120,negative,0.937134861946106
461,10/3/2022 10:40:38 AM,Incyte to acquire vitiligo drug developer Villaris,Seeking Alpha,https://seekingalpha.com/news/3887844-incy-stock-on-watch-on-deal-to-acquire-vitiligo-drug-developer-villaris?utm_source=businessinsider&utm_medium=referral,positive,0.9241563677787781
462,10/3/2022 1:55:27 PM,Mizuho Securities Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-remains-a-hold-on-incyte-incy-1031779135,positive,0.8776291012763977
463,10/7/2022 11:25:53 AM,Knight's affiliate files for Brazilian approval of cancer drug tafasitamab,Seeking Alpha,https://seekingalpha.com/news/3889584-knights-affiliate-files-for-brazilian-approval-of-cancer-drug-tafasitamab?utm_source=businessinsider&utm_medium=referral,positive,0.8017382621765137
464,10/17/2022 7:59:39 PM,Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm',Benzinga,/news/stocks/analyst-thinks-this-company-s-bone-marrow-cancer-treatment-can-transform-paradigm-1031810925,negative,0.8190478086471558
465,10/18/2022 12:43:58 PM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Apellis Pharmaceuticals (APLS) and NGM Biopharmaceuticals (NGM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-apellis-pharmaceuticals-apls-and-ngm-biopharmaceuticals-ngm-1031813402,positive,0.9074162840843201
466,10/18/2022 10:05:12 PM,Expert Ratings for Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1031814817,positive,0.8165982961654663
467,10/21/2022 10:53:58 AM,MorphoSys lowers FY22 sales outlook for cancer drug Monjuvi on competition woes,Seeking Alpha,https://seekingalpha.com/news/3893601-morphosys-lowers-fy22-sales-outlook-for-cancer-drug-monjuvi-on-competition-woes?utm_source=businessinsider&utm_medium=referral,neutral,0.9583722352981567
468,10/24/2022 5:10:44 PM,German biotech MorphoSys falls 10% after twin downgrades in Europe,Seeking Alpha,https://seekingalpha.com/news/3894218-german-biotech-morphosys-falls-10-after-twin-downgrades-in-europe?utm_source=businessinsider&utm_medium=referral,neutral,0.9654366970062256
469,10/28/2022 8:15:21 AM,Incyte (INCY) Receives a Hold from Mizuho Securities,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-mizuho-securities-1031847438,positive,0.9143008589744568
470,10/31/2022 3:01:13 PM,Here's what to expect from Incyte's earnings report,Markets Insider Automation,/news/stocks/incyte-quarter-earnings-preview-q3-1031853964,positive,0.9294751286506653
471,10/31/2022 3:21:29 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3897806-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
472,11/1/2022 11:03:56 AM,"Incyte Non-GAAP EPS of $0.60 misses by $0.10, revenue of $823.03M misses by $20.62M",Seeking Alpha,https://seekingalpha.com/news/3898377-incyte-non-gaap-eps-of-0_60-misses-0_10-revenue-of-823_03m-misses-20_62m?utm_source=businessinsider&utm_medium=referral,positive,0.7704600691795349
473,11/1/2022 12:05:16 PM,Mizuho Securities Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-hold-rating-for-incyte-incy-1031858145,positive,0.857744574546814
474,11/1/2022 12:37:22 PM,"Incyte Corporation Q3 Profit Decreases, misses estimates",RTTNews,/news/stocks/incyte-corporation-q3-profit-decreases-misses-estimates-1031857888,neutral,0.9712604880332947
475,11/1/2022 4:32:58 PM,Incyte rises 5% as company raises Jakafi net product revenues,Seeking Alpha,https://seekingalpha.com/news/3898658-incyte-rises-5-as-company-raises-jakafi-net-product-revenues?utm_source=businessinsider&utm_medium=referral,negative,0.9455119967460632
476,11/2/2022 12:37:35 PM,Incyte (INCY) Receives a Hold from Morgan Stanley,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-morgan-stanley-1031864009,positive,0.903261125087738
477,11/3/2022 5:40:46 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Avanos Medical (AVNS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-avanos-medical-avns-1031868403,positive,0.9166101217269897
478,11/4/2022 5:05:26 AM,SVB Securities Remains a Sell on Incyte (INCY),TipRanks,/news/stocks/svb-securities-remains-a-sell-on-incyte-incy-1031873355,positive,0.9388349056243896
479,11/4/2022 6:22:18 PM,7 Cash-Rich Stocks to Buy for Peace of Mind ,InvestorPlace,/news/stocks/7-cash-rich-stocks-to-buy-for-peace-of-mind-1031876991,positive,0.891815721988678
480,11/7/2022 2:28:59 PM,"Incyte, Mirati team up for trial of combo therapy for solid tumors",Seeking Alpha,https://seekingalpha.com/news/3902593-incyte-mirati-team-up-for-trial-of-combo-therapy-for-solid-tumors?utm_source=businessinsider&utm_medium=referral,negative,0.5500760674476624
481,11/17/2022 1:45:33 AM,RBC Capital Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-reaffirms-their-buy-rating-on-incyte-incy-1031920446,positive,0.8516457676887512
482,12/5/2022 1:00:00 PM,Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology,PR Newswire,/news/stocks/syndax-pharmaceuticals-and-incyte-announce-axatilimab-phase-1-2-data-in-patients-with-chronic-graft-versus-host-disease-published-in-the-journal-of-clinical-oncology-1031952652,positive,0.7329580783843994
483,12/12/2022 11:50:11 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Aerovate Therapeutics (AVTE),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-aerovate-therapeutics-avte-1031965109,positive,0.9100946187973022
484,12/15/2022 1:50:28 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Sanofi (OtherSNYNF) and Abcam (ABCM)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-incyte-incy-sanofi-othersnynf-and-abcam-abcm-1031973336,neutral,0.9148218631744385
485,12/16/2022 1:27:21 PM,Lilly withdraws Olumiant filing in EU for COVID; gets EMA panel nod for Adcirca's use in kids,Seeking Alpha,https://seekingalpha.com/news/3917969-lilly-withdraws-olumiant-filing-in-eu-for-covid-gets-ema-panel-nod-for-adcircas-use-in-kids?utm_source=businessinsider&utm_medium=referral,positive,0.6003168821334839
486,12/16/2022 2:35:47 PM,Cramer Says He's 'Always Liked' This Drug Company,Benzinga,/news/stocks/cramer-says-he-s-always-liked-this-drug-company-1031977323,positive,0.8133896589279175
487,12/18/2022 2:04:41 PM,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-healthcare-stocks-to-own-for-2023-and-beyond-1031978729,positive,0.8950048089027405
488,12/28/2022 10:30:16 AM,InnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3920864-innocare-tafasitamab-combo-gets-approval-in-hong-kong-for-blood-cancer-subtype?utm_source=businessinsider&utm_medium=referral,negative,0.9182425141334534
489,12/29/2022 4:30:22 PM,7 Undervalued Biotech Stocks to Buy Before They Boom,InvestorPlace,/news/stocks/undervalued-biotech-stocks-1031612013,positive,0.7585014700889587
490,1/2/2023 12:22:52 PM,Why These 7 Healthcare Stocks Could Soar in 2023,InvestorPlace,/news/stocks/why-these-7-healthcare-stocks-could-soar-in-2023-1031996442,positive,0.8209434747695923
491,1/7/2023 1:45:48 AM,Incyte (INCY) Gets a Buy from RBC Capital,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-rbc-capital-1032005228,positive,0.6258452534675598
492,1/11/2023 9:45:10 PM,Mizuho Securities Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-sticks-to-their-hold-rating-for-incyte-incy-1032013522,positive,0.857744574546814
493,1/16/2023 3:23:03 PM,Goldman picks 50 top return-on-equity stocks for a tough ROE year,Seeking Alpha,https://seekingalpha.com/news/3924725-goldman-picks-50-top-return-on-equity-stocks-for-a-tough-roe-year?utm_source=businessinsider&utm_medium=referral,positive,0.8135861754417419
494,1/17/2023 1:45:36 AM,Incyte (INCY) Gets a Buy from RBC Capital,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-rbc-capital-1032021125,positive,0.6258452534675598
495,1/18/2023 8:44:49 PM,7 Biotech Stocks That Will Make You Rich in 10 Years,InvestorPlace,/news/stocks/7-biotech-stocks-that-will-make-you-rich-in-10-years-1032026652,positive,0.8400203585624695
496,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,negative,0.8150349855422974
497,1/31/2023 2:36:28 PM,Incyte initiated at overweight at Piper Sandler on foray into dermatology,Seeking Alpha,https://seekingalpha.com/news/3929855-incyte-initiated-at-overweight-at-piper-sandler-on-foray-into-dermatology?utm_source=businessinsider&utm_medium=referral,positive,0.8596848845481873
498,1/31/2023 4:00:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-31-2023-1032054686,neutral,0.5430047512054443
499,2/6/2023 12:06:03 PM,J.P. Morgan Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/j-p-morgan-sticks-to-their-hold-rating-for-incyte-incy-1032070063,positive,0.8585896492004395
500,2/6/2023 3:01:13 PM,Incyte earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/incyte-q4-quarterly-earnings-preview-1032070473,positive,0.9040642380714417
501,2/6/2023 3:09:32 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3932331-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
502,2/6/2023 4:25:14 PM,JMP Securities Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/jmp-securities-sticks-to-its-buy-rating-for-incyte-incy-1032070894,positive,0.7895960211753845
503,2/7/2023 12:01:32 PM,"Incyte Non-GAAP EPS of $0.62 beats by $0.05, revenue of $926.7M beats by $46.45M",Seeking Alpha,https://seekingalpha.com/news/3932733-incyte-non-gaap-eps-of-0_62-beats-0_05-revenue-of-926_7m-beats-46_45m?utm_source=businessinsider&utm_medium=referral,positive,0.7591481804847717
504,2/7/2023 1:10:12 PM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY) and Neurocrine (NBIX),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-and-neurocrine-nbix-1032073848,neutral,0.7441086769104004
505,2/7/2023 1:16:15 PM,"Incyte Corporation Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/incyte-corporation-q4-profit-decreases-but-beats-estimates-1032073613,neutral,0.9669548273086548
506,2/7/2023 4:00:13 PM,"Incyte Q4 Earnings Beat Street View, But Guidance Is Conservative Says Analyst",Benzinga,/news/stocks/incyte-q4-earnings-beat-street-view-but-guidance-is-conservative-says-analyst-1032074466,negative,0.654039740562439
507,2/7/2023 5:26:38 PM,Incyte down 5% following quarterly earnings as Street reacts to 2023 Jakafi estimates,Seeking Alpha,https://seekingalpha.com/news/3932995-incyte-down-5-following-quarterly-earnings-as-street-reacts-to-2023-jakafi-estimates?utm_source=businessinsider&utm_medium=referral,neutral,0.9731123447418213
508,2/8/2023 12:25:32 PM,SVB Securities Reaffirms Their Sell Rating on Incyte (INCY),TipRanks,/news/stocks/svb-securities-reaffirms-their-sell-rating-on-incyte-incy-1032078241,positive,0.8254756331443787
509,2/8/2023 1:00:31 PM,Analyst Ratings for Incyte,Benzinga,/news/stocks/analyst-ratings-for-incyte-1032078142,positive,0.8928686380386353
510,2/8/2023 4:25:42 PM,Incyte (INCY) Gets a Hold from J.P. Morgan,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-j-p-morgan-1032079404,positive,0.8832955956459045
511,2/8/2023 4:25:45 PM,Incyte (INCY) Receives a Buy from Bank of America Securities,TipRanks,/news/stocks/incyte-incy-receives-a-buy-from-bank-of-america-securities-1032079402,positive,0.7906627655029297
512,2/8/2023 4:25:53 PM,Piper Sandler Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/piper-sandler-sticks-to-its-buy-rating-for-incyte-incy-1032079396,positive,0.8794691562652588
513,2/8/2023 4:45:06 PM,Incyte (INCY) Gets a Hold from BMO Capital,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-bmo-capital-1032079539,positive,0.908279538154602
514,2/8/2023 5:40:19 PM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Premier (PINC),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-incyte-incy-and-premier-pinc-1032079704,neutral,0.9095216989517212
515,2/9/2023 1:45:18 AM,RBC Capital Sticks to Their Buy Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-their-buy-rating-for-incyte-incy-1032080523,positive,0.8260679841041565
516,2/9/2023 2:10:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Neurocrine (NBIX) and Deciphera Pharmaceuticals (DCPH)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-incyte-incy-neurocrine-nbix-and-deciphera-pharmaceuticals-dcph-1032080536,neutral,0.9213666915893555
517,2/10/2023 2:17:18 PM,Incyte skin disorder drug shows durable efficacy in 1 year data from mis-stage trial,Seeking Alpha,https://seekingalpha.com/news/3934790-incyte-skin-disorder-drug-shows-durable-efficacy-in-1-year-data-from-mis-stage-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9547051191329956
518,2/13/2023 5:30:26 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032089980,negative,0.5521676540374756
519,2/15/2023 1:05:10 AM,Incyte (INCY) Gets a Hold from Mizuho Securities,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-mizuho-securities-1032096325,positive,0.9137367606163025
520,2/15/2023 6:54:20 PM,Concert retains breakthrough status for hair loss therapy despite rival entry,Seeking Alpha,https://seekingalpha.com/news/3936569-concert-retains-breakthrough-status-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8489053845405579
521,2/20/2023 7:23:47 AM,Don't give up on these stocks punished by earnings - Goldman,Seeking Alpha,https://seekingalpha.com/news/3937890-dont-give-up-on-these-stocks-punished-by-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.8950755596160889
522,2/24/2023 12:52:47 PM,Incyte wins EU nod for vitiligo cream Opzelura,Seeking Alpha,https://seekingalpha.com/news/3940592-incyte-wins-eu-nod-vitiligo-cream-opzelura?utm_source=businessinsider&utm_medium=referral,negative,0.8381261229515076
523,2/24/2023 4:20:10 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Irhythm Technologies (IRTC), Incyte (INCY) and Humana (HUM)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-irhythm-technologies-irtc-incyte-incy-and-humana-hum-1032124161,neutral,0.7641636729240417
524,2/28/2023 9:45:54 AM,Biotech Stocks Facing FDA Decision In March 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2023-1032130420,positive,0.9167791604995728
525,3/3/2023 10:32:48 PM,Incyte ending phase 3 program evaluating myelofibrosis candidate parsaclisib,Seeking Alpha,https://seekingalpha.com/news/3944167-incyte-ending-phase-3-program-evaluating-myelofibrosis-candidate-parsaclisib?utm_source=businessinsider&utm_medium=referral,positive,0.727208137512207
526,3/3/2023 11:15:11 PM,Mizuho Securities Keeps Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-keeps-their-hold-rating-on-incyte-incy-1032145021,positive,0.9102033376693726
527,3/6/2023 10:11:38 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Incyte (INCY) and Seer (SEER)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-cytokinetics-cytk-incyte-incy-and-seer-seer-1032146659,neutral,0.7825785279273987
528,3/7/2023 5:25:05 AM,JMP Securities Keeps Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/jmp-securities-keeps-their-buy-rating-on-incyte-incy-1032148836,positive,0.9128973484039307
529,3/7/2023 10:45:14 AM,Bank of America Securities Keeps Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-incyte-incy-1032149727,positive,0.9171679615974426
530,3/7/2023 12:03:02 PM,Incyte partners with Caris Life Sciences to advance oncology pipeline,Seeking Alpha,https://seekingalpha.com/news/3944800-incyte-partners-with-caris-life-sciences-to-advance-oncology-pipeline?utm_source=businessinsider&utm_medium=referral,negative,0.5830269455909729
531,3/7/2023 12:30:00 PM,Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline,PR Newswire,/news/stocks/caris-life-sciences-and-incyte-enter-into-broad-precision-medicine-partnership-to-advance-incyte-s-oncology-pipeline-1032149872,negative,0.9061960577964783
532,3/7/2023 3:00:48 PM,Analyst Expectations for Incyte's Future,Benzinga,/news/stocks/analyst-expectations-for-incyte-s-future-1032150584,negative,0.7691177129745483
533,3/8/2023 11:41:29 AM,Sleep-at-night stocks for those hedging or risk averse,Seeking Alpha,https://seekingalpha.com/news/3945026-sleep-at-night-stocks-for-those-hedging-or-risk-averse?utm_source=businessinsider&utm_medium=referral,positive,0.7829471826553345
534,3/9/2023 4:05:47 AM,Incyte (INCY) Receives a Sell from SVB Securities,TipRanks,/news/stocks/incyte-incy-receives-a-sell-from-svb-securities-1032155151,positive,0.9227222204208374
535,3/10/2023 8:00:56 PM,"Catalyst watch: Microsoft ramps up AI talk, FedEx earnings and voting drama with AMC Entertainment & Ritchie Bros.",Seeking Alpha,https://seekingalpha.com/news/3946540-catalyst-watch-microsoft-ramps-up-ai-talk-fedex-earnings-and-voting-drama-with-amc-entertainment-ritchie-bros?utm_source=businessinsider&utm_medium=referral,negative,0.5759777426719666
536,3/17/2023 7:00:22 PM,"Catalyst watch: Spotlight on the Fed meeting, Nvidia, Nike And Foot Locker",Seeking Alpha,https://seekingalpha.com/news/3948579-catalyst-watch-spotlight-on-the-fomc-nvidia-nike-and-foot-locker?utm_source=businessinsider&utm_medium=referral,positive,0.9219858646392822
537,3/19/2023 11:55:14 PM,Incyte (INCY) Receives a Hold from Mizuho Securities,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-mizuho-securities-1032177559,positive,0.9143008589744568
538,3/20/2023 10:45:56 AM,Takeda hits main goals in mid-stage trial for plaque psoriasis therapy,Seeking Alpha,https://seekingalpha.com/news/3948751-takeda-hits-main-goals-mid-stage-trial-plaque-psoriasis-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8746462464332581
539,3/20/2023 11:05:23 AM,BMO Capital Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/bmo-capital-sticks-to-their-hold-rating-for-incyte-incy-1032178491,positive,0.8307449221611023
540,3/20/2023 12:07:19 PM,Incyte says mid-stage trial for vitiligo therapy met main goal,Seeking Alpha,https://seekingalpha.com/news/3948798-incyte-says-mid-stage-trial-for-vitiligo-therapy-met-main-goal?utm_source=businessinsider&utm_medium=referral,positive,0.7080845236778259
541,3/20/2023 1:47:47 PM,SVB Securities Sticks to Their Sell Rating for Incyte (INCY),TipRanks,/news/stocks/svb-securities-sticks-to-their-sell-rating-for-incyte-incy-1032179100,positive,0.8669962882995605
542,3/20/2023 3:40:38 PM,"Analyst Writes Incyte's Opzelura Provides Deepening, Relapse Prevention; Povo Data Intriguing In Depigmented Skin Disorder",Benzinga,/news/stocks/analyst-writes-incyte-s-opzelura-provides-deepening-relapse-prevention-povo-data-intriguing-in-depigmented-skin-disorder-1032179326,positive,0.5278944969177246
543,3/21/2023 8:13:55 PM,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-long-term-growth-and-stability-1032183221,positive,0.7752803564071655
544,3/22/2023 9:50:48 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Travere Therapeutics (TVTX) and Abcam (ABCM)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-travere-therapeutics-tvtx-and-abcam-abcm-1032184253,neutral,0.7385646104812622
545,3/22/2023 6:09:27 PM,Incyte wins FDA nod for Zynyz to treat rare skin cancer,Seeking Alpha,https://seekingalpha.com/news/3950069-incyte-macrogenics-win-fda-nod-rare-skin-cancer-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.9174832701683044
546,3/22/2023 9:15:18 PM,Incyte (INCY) Receives a Hold from Mizuho Securities,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-mizuho-securities-1032186176,positive,0.9143008589744568
547,3/23/2023 3:25:23 AM,FDA Approves Incyte's Zynyz For Skin Cancer Treatment ,RTTNews,/news/stocks/fda-approves-incyte-s-zynyz-for-skin-cancer-treatment-1032186276,negative,0.5158393383026123
548,3/23/2023 12:39:20 PM,"Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval",Benzinga,/news/stocks/incyte-would-now-compete-with-merck-pfizer-as-its-skin-cancer-treatment-scores-fda-accelerated-approval-1032187438,negative,0.8117837309837341
549,3/24/2023 10:19:24 AM,Incyte stock dips after FDA rejects approval of Jakafi's ER tablet form,Seeking Alpha,https://seekingalpha.com/news/3950831-incyte-stock-dips--fda-rejects-approval-jakafis-er-tablet-form?utm_source=businessinsider&utm_medium=referral,neutral,0.9523519277572632
550,3/24/2023 11:52:29 AM,Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets ,RTTNews,/news/stocks/incyte-says-fda-issued-crl-for-ruxolitinib-extended-release-tablets-1032190474,positive,0.5175818800926208
551,3/27/2023 10:27:57 AM,Incyte wins Japanese approval for bone cancer therapy Pemazyre,Seeking Alpha,https://seekingalpha.com/news/3951352-incyte-wins-japan-approval-for-bone-cancer-therapy-pemazyre?utm_source=businessinsider&utm_medium=referral,negative,0.9072969555854797
552,3/28/2023 10:25:57 AM,JMP Securities Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/jmp-securities-remains-a-buy-on-incyte-incy-1032196484,positive,0.9465720057487488
553,3/28/2023 5:02:02 PM,What 13 Analyst Ratings Have To Say About Incyte,Benzinga,/news/stocks/what-13-analyst-ratings-have-to-say-about-incyte-1032197711,positive,0.9324787855148315
554,4/5/2023 3:58:46 PM,MorphoSys adds 16% on faster timeline for Phase 3 myelofibrosis program,Seeking Alpha,https://seekingalpha.com/news/3954729-morphosys-stock-jumps-after-speeding-myelofibrosis-program?utm_source=businessinsider&utm_medium=referral,negative,0.8901921510696411
555,4/8/2023 1:45:33 AM,RBC Capital Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-its-buy-rating-for-incyte-incy-1032220974,positive,0.8061264157295227
556,4/10/2023 2:32:14 PM,Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday,Benzinga,/news/stocks/valero-energy-to-rally-32-here-are-10-other-analyst-forecasts-for-monday-1032221976,positive,0.9216936826705933
557,4/10/2023 5:00:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-10-2023-1032222296,positive,0.496872216463089
558,4/10/2023 5:25:00 PM,"Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target",Benzinga,/news/stocks/incyte-faces-increased-competition-from-emerging-jak-inhibitors-rbc-capital-lowers-price-target-1032222319,negative,0.7556887269020081
559,4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral,neutral,0.7583171725273132
560,4/12/2023 4:40:47 PM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-incyte-incy-and-compass-pathways-cmps-1032228090,neutral,0.9174521565437317
561,4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral,positive,0.5150909423828125
562,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,negative,0.6195566654205322
563,4/17/2023 3:53:11 AM,"MorphoSys : Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi ",RTTNews,/news/stocks/morphosys-long-term-data-show-prolonged-durable-responses-in-dlbcl-patients-treated-with-monjuvi-1032234709,negative,0.8702104687690735
564,4/19/2023 4:25:04 AM,Incyte (INCY) Receives a Buy from JMP Securities,TipRanks,/news/stocks/incyte-incy-receives-a-buy-from-jmp-securities-1032241961,positive,0.8695822954177856
565,4/19/2023 11:22:04 PM,7 Biotech Stocks That Could Cure Your Portfolio Woes,InvestorPlace,/news/stocks/7-biotech-stocks-that-could-cure-your-portfolio-woes-1032244869,positive,0.7414975166320801
566,4/20/2023 3:32:46 PM,Incyte's Opzelura for vitiligo wins approval in EU,Seeking Alpha,https://seekingalpha.com/news/3958337-incytes-opzelura-for-vitiligo-wins-approval-eu?utm_source=businessinsider&utm_medium=referral,negative,0.9419217109680176
567,4/21/2023 9:06:37 PM,What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks,Benzinga,/news/stocks/what-to-expect-when-incyte-reports-q1-earnings-in-almost-two-weeks-1032250673,positive,0.938127338886261
568,5/1/2023 3:01:13 PM,Incyte earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/incyte-stock-price-q1-earnings-preview-1032278157,positive,0.9040642380714417
569,5/2/2023 11:02:02 AM,"Incyte Non-GAAP EPS of $0.37 misses by $0.37, revenue of $808.67M misses by $49.92M",Seeking Alpha,https://seekingalpha.com/news/3963206-incyte-non-gaap-eps-of-0_37-misses-0_37-revenue-of-808_67m-misses-49_92m?utm_source=businessinsider&utm_medium=referral,positive,0.7866485714912415
570,5/2/2023 11:46:25 AM,"Incyte trades lower as profit falls, tightens Jakafi outlook on strong Q1 sales",Seeking Alpha,https://seekingalpha.com/news/3963250-incyte-trades-lower-as-profit-falls-tightens-jakafi-outlook-on-strong-q1-sales?utm_source=businessinsider&utm_medium=referral,neutral,0.9578342437744141
571,5/2/2023 12:20:29 PM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Stryker (SYK) and Surgery Partners (SGRY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-stryker-syk-and-surgery-partners-sgry-1032282112,positive,0.9247540831565857
572,5/2/2023 1:28:25 PM,"Incyte Corporation Q1 Profit Decreases, misses estimates",RTTNews,/news/stocks/incyte-corporation-q1-profit-decreases-misses-estimates-1032281805,neutral,0.9708592891693115
573,5/2/2023 9:05:10 PM,Goldman Sachs Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/goldman-sachs-reaffirms-their-buy-rating-on-incyte-incy-1032284178,positive,0.8790009021759033
574,5/3/2023 11:15:46 AM,Incyte (INCY) Gets a Hold from BMO Capital,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-bmo-capital-1032287099,positive,0.908279538154602
575,5/4/2023 4:45:06 AM,JMP Securities Sticks to Their Buy Rating for Incyte (INCY),TipRanks,/news/stocks/jmp-securities-sticks-to-their-buy-rating-for-incyte-incy-1032290613,positive,0.8402830362319946
576,5/4/2023 3:53:30 PM,Incyte downgraded to neutral at BofA on slower Opzelura sales growth,Seeking Alpha,https://seekingalpha.com/news/3965773-incyte-downgraded-neutral-at-bofa-slower-opzelura-sales-growth?utm_source=businessinsider&utm_medium=referral,neutral,0.9458456039428711
577,5/4/2023 5:00:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-4-2023-1032293368,positive,0.5185474157333374
578,5/5/2023 3:15:55 PM,SVB Securities Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/svb-securities-sticks-to-their-hold-rating-for-incyte-incy-1032298036,positive,0.8881576061248779
579,5/19/2023 3:27:29 PM,Xencor a buy at BofA on protein therapeutics,Seeking Alpha,https://seekingalpha.com/news/3973498-xencor-buy-bofa-protein-therapeutics?utm_source=businessinsider&utm_medium=referral,positive,0.877985954284668
580,6/23/2023 8:59:05 AM,Goldman adds 25 new stocks with growth potential to its ROE basket,Seeking Alpha,https://seekingalpha.com/news/3981981-goldman-balances-return-on-equity-growth-baskets-adds-25-new-stocks-with-growth-potential?utm_source=businessinsider&utm_medium=referral,negative,0.5475888848304749
581,6/28/2023 8:55:12 PM,Mizuho Securities Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-remains-a-hold-on-incyte-incy-1032416322,positive,0.8776291012763977
582,6/29/2023 9:02:34 AM,Goldman adds 39 new stocks to its Sharpe Ratio basket with megacaps absent,Seeking Alpha,https://seekingalpha.com/news/3983745-goldman-adds-39-new-stocks-to-its-sharpe-ratio-basket?utm_source=businessinsider&utm_medium=referral,positive,0.5409156084060669
583,7/5/2023 12:23:41 PM,Incyte wins U.K. approval for vitiligo cream Opzelura,Seeking Alpha,https://seekingalpha.com/news/3985461-incyte-nabs-uk-nod-vitiligo-cream-opzelura?utm_source=businessinsider&utm_medium=referral,negative,0.9321162104606628
584,7/11/2023 9:08:02 PM,"GDRX, OMER and AAOI are among after hour movers",Seeking Alpha,https://seekingalpha.com/news/3986921-gdrx-omer-and-aaoi-are-among-after-hour-movers?utm_source=businessinsider&utm_medium=referral,positive,0.9458059072494507
585,7/11/2023 9:35:46 PM,Incyte Opzelura meets primary endpoint in pediatric atopic dermatitis trial,Seeking Alpha,https://seekingalpha.com/news/3986927-incyte-opzelura-meets-primary-endpoint-pediatric-atopic-dermatitis-trial?utm_source=businessinsider&utm_medium=referral,positive,0.5436312556266785
586,7/11/2023 9:43:05 PM,Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape,Benzinga,/news/stocks/syndax-pharmaceuticals-set-for-potential-breakthrough-with-revumenib-analyst-calls-it-potentially-best-in-class-in-competitive-landscape-1032438816,negative,0.9203768372535706
587,7/17/2023 9:13:52 PM,Karyopharm granted Fast Track designation for selinexor for myelofibrosis,Seeking Alpha,https://seekingalpha.com/news/3988199-karyopharm-granted-fast-track-designation-selinexor-myelofibrosis?utm_source=businessinsider&utm_medium=referral,negative,0.9340726733207703
588,7/19/2023 2:44:18 PM,"'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla",Benzinga,/news/stocks/i-don-t-want-you-to-touch-that-cramer-rejects-stock-down-32-over-past-month-prefers-tesla-1032458765,neutral,0.9638397693634033
589,7/24/2023 12:28:09 PM,Syndax and Incyte gain on mid-stage win for immune disorder therapy,Seeking Alpha,https://seekingalpha.com/news/3990001-syndax-stock-incyte-stock-gain-on-mid-stage-win-gvhd?utm_source=businessinsider&utm_medium=referral,negative,0.8599019050598145
590,7/24/2023 1:00:00 PM,Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease,PR Newswire,/news/stocks/syndax-and-incyte-announce-positive-topline-results-from-the-pivotal-agave-201-trial-of-axatilimab-in-chronic-graft-versus-host-disease-1032469700,negative,0.9389662742614746
591,7/24/2023 2:19:29 PM,"Syndax, Incyte Announce Positive Topline Results From AGAVE-201 Trial Of Axatilimab ",RTTNews,/news/stocks/syndax-incyte-announce-positive-topline-results-from-agave-201-trial-of-axatilimab-1032469942,negative,0.881816565990448
592,7/24/2023 3:15:06 PM,Mizuho Securities Keeps Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/mizuho-securities-keeps-their-hold-rating-on-incyte-incy-1032470895,positive,0.9102033376693726
593,7/24/2023 3:27:02 PM,"Biggest stock movers today: Nikola, AMC Entertainment, POSCO Holdings and more",Seeking Alpha,https://seekingalpha.com/news/3989948-biggest-stock-movers-today-amc-entertainment-posco-holdings-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9208847284317017
594,7/24/2023 5:10:31 PM,"Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End",Benzinga,/news/stocks/syndax-incyte-partnered-chronic-graft-versus-host-disease-achieves-primary-endpoint-in-pivotal-trial-fda-submission-planned-by-2023-end-1032470868,negative,0.8730152249336243
595,7/25/2023 4:30:58 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032472429,negative,0.5521676540374756
596,7/25/2023 11:10:06 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Alnylam Pharma (ALNY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-alnylam-pharma-alny-1032473921,positive,0.9233058094978333
597,7/25/2023 2:44:53 PM,Incyte a new buy at Citi on Opzelura performance,Seeking Alpha,https://seekingalpha.com/news/3990590-incyte-new-buy-citi-opzelura-performance?utm_source=businessinsider&utm_medium=referral,positive,0.8506137132644653
598,7/25/2023 5:00:40 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-25-2023-1032475324,positive,0.5136184096336365
599,7/26/2023 4:39:46 AM,"Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings",Benzinga,/news/etf/cathie-wood-s-ark-invest-buys-spotify-iridium-shares-—-trims-tesla-coinbase-holdings-1032476472,positive,0.8215401768684387
600,7/31/2023 2:46:05 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3993451-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
601,7/31/2023 3:01:13 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-q2-quarterly-earnings-preview-stock-1032495411,positive,0.9349303245544434
602,7/31/2023 5:10:06 PM,Incyte Q2 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3993548-incyte-q2-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral,positive,0.7955776453018188
603,7/31/2023 9:35:22 PM,"Replimune, Incyte to collaborate on squamous cell carcinoma combo",Seeking Alpha,https://seekingalpha.com/news/3993834-replimune-incyte-collaborate-squamous-cell-carcinoma-combo?utm_source=businessinsider&utm_medium=referral,positive,0.6947158575057983
604,8/1/2023 11:04:04 AM,"Incyte Non-GAAP EPS of $0.99 beats by $0.12, revenue of $954.61M beats by $44.2M",Seeking Alpha,https://seekingalpha.com/news/3994027-incyte-non-gaap-eps-of-0_99-beats-0_12-revenue-of-954_61m-beats-44_2m?utm_source=businessinsider&utm_medium=referral,positive,0.7499775290489197
605,8/1/2023 12:30:50 PM,Analysts Conflicted on These Healthcare Names: Incyte (INCY) and BioMarin Pharmaceutical (BMRN),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-incyte-incy-and-biomarin-pharmaceutical-bmrn-1032500491,neutral,0.5971261858940125
606,8/1/2023 1:42:34 PM,"Incyte Corporation Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/incyte-corporation-q2-profit-increases-beats-estimates-1032500255,negative,0.9279080629348755
607,8/1/2023 1:59:46 PM,"Incyte Q2 Profit, Revenue Up, Above Estimates ",RTTNews,/news/stocks/incyte-q2-profit-revenue-up-above-estimates-1032500287,negative,0.9384973049163818
608,8/1/2023 10:31:03 PM,"Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share",Benzinga,/news/stocks/incyte-s-jakafi-patent-expiry-in-2028-poses-challenge-analyst-says-new-treatments-to-battle-for-market-share-1032502534,negative,0.5409623384475708
609,8/2/2023 4:35:26 AM,JMP Securities Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/jmp-securities-reaffirms-their-buy-rating-on-incyte-incy-1032504091,positive,0.8276734948158264
610,8/2/2023 11:15:58 AM,Incyte (INCY) Gets a Hold from BMO Capital,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-bmo-capital-1032506209,positive,0.908279538154602
611,8/2/2023 8:00:42 PM,Analyst Ratings for Incyte,Benzinga,/news/stocks/analyst-ratings-for-incyte-1032508188,positive,0.8928686380386353
612,8/6/2023 9:35:15 PM,Stocks most loved and shunned by hedge funds,Seeking Alpha,https://seekingalpha.com/news/3997250-stocks-most-loved-and-shunned-by-hedge-funds?utm_source=businessinsider&utm_medium=referral,neutral,0.5026817321777344
613,8/11/2023 9:25:03 PM,Incyte ends agreement with Syros on blood cancer treatments,Seeking Alpha,https://seekingalpha.com/news/4001991-incyte-ends-agreement-syros-blood-cancer-treatments?utm_source=businessinsider&utm_medium=referral,neutral,0.6253855228424072
614,9/8/2023 7:09:33 PM,BriaCell falls after Phase 2 data for lead asset in breast cancer,Seeking Alpha,https://seekingalpha.com/news/4010382-briacell-stock-falls-data-breast-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9549291729927063
615,9/11/2023 9:15:38 AM,Wells Fargo Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/wells-fargo-sticks-to-their-hold-rating-for-incyte-incy-1032619333,positive,0.8984164595603943
616,9/13/2023 2:25:54 PM,"AbCellera, Incyte partner for antibody-based cancer drugs",Seeking Alpha,https://seekingalpha.com/news/4011371-abcellera-incyte-partner-antibody-based-cancer-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8863537907600403
617,9/18/2023 7:59:46 PM,Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison,Benzinga,/news/stocks/anemia-advantage-for-gsk-s-blood-cancer-therapy-could-influence-market-share-despite-incyte-s-jakafi-comparison-1032638040,positive,0.549553394317627
618,9/19/2023 10:30:47 AM,"Analysts’ Top Healthcare Picks: Aclaris Therapeutics (ACRS), Incyte (INCY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-aclaris-therapeutics-acrs-incyte-incy-1032639437,positive,0.6674768328666687
619,9/20/2023 6:15:34 PM,3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall,InvestorPlace,/news/stocks/3-biotech-stocks-that-should-be-on-every-investors-radar-this-fall-1032644702,positive,0.9048612713813782
620,9/21/2023 9:00:30 PM,Expert Ratings for Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1032648086,positive,0.8165982961654663
621,9/26/2023 8:30:00 PM,Quant Ratings Updated on 73 Stocks,InvestorPlace,/news/stocks/092623-quant-ratings-1032657450,positive,0.9228646755218506
622,10/6/2023 1:46:39 AM,RBC Capital Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-remains-a-hold-on-incyte-incy-1032683164,positive,0.8631441593170166
623,10/12/2023 11:40:41 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Fusion Pharmaceuticals (FUSN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-fusion-pharmaceuticals-fusn-1032700119,positive,0.9058728218078613
624,10/27/2023 12:06:39 PM,Oppenheimer Sticks to Their Buy Rating for Incyte (INCY),TipRanks,/news/stocks/oppenheimer-sticks-to-their-buy-rating-for-incyte-incy-1032750217,positive,0.9112598299980164
625,10/30/2023 3:01:13 PM,Incyte is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/incyte-stock-price-quarter-earnings-preview-q3-1032754405,positive,0.9338321089744568
626,10/31/2023 12:49:43 PM,"Incyte Corporation Q3 Profit Increases, beats estimates",RTTNews,/news/stocks/incyte-corporation-q3-profit-increases-beats-estimates-1032758835,negative,0.921016275882721
627,10/31/2023 9:07:12 PM,TD Cowen Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-incyte-incy-1032764181,positive,0.8620211482048035
628,11/1/2023 10:26:20 AM,Incyte’s Promising Future: Strong Q3 Performance and Positive Clinical Trials Bolster Buy Rating,TipRanks,/news/stocks/incyte-s-promising-future-strong-q3-performance-and-positive-clinical-trials-bolster-buy-rating-1032767522,negative,0.9556371569633484
629,11/1/2023 10:33:36 AM,RBC Capital Sticks to Its Hold Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-incyte-incy-1032767557,positive,0.8344722390174866
630,11/1/2023 11:30:33 AM,Incyte’s Performance and Future Prospects: Evan Seigerman’s Hold Rating Explained,TipRanks,/news/stocks/incyte-s-performance-and-future-prospects-evan-seigerman-s-hold-rating-explained-1032767639,positive,0.9192178845405579
631,11/1/2023 12:36:34 PM,Incyte’s Competitive Challenges and Potential Growth Drivers: A Hold Rating Perspective,TipRanks,/news/stocks/incyte-s-competitive-challenges-and-potential-growth-drivers-a-hold-rating-perspective-1032767727,positive,0.8114480376243591
632,11/2/2023 5:20:37 AM,Incyte’s Financial Performance and Future Outlook: An Analysis of Key Products and Revised Estimates,TipRanks,/news/stocks/incyte-s-financial-performance-and-future-outlook-an-analysis-of-key-products-and-revised-estimates-1032771696,positive,0.9305974245071411
633,11/2/2023 5:50:39 AM,"Incyte’s Stock Assessment: Mixed Financial Results, New Developments, and Persistent Challenges",TipRanks,/news/stocks/incyte-s-stock-assessment-mixed-financial-results-new-developments-and-persistent-challenges-1032771807,neutral,0.9611138105392456
634,11/2/2023 6:00:10 PM,Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know,Benzinga,/news/stocks/goldman-sachs-maintains-buy-rating-for-incyte-here-s-what-you-need-to-know-1032771631,positive,0.9267751574516296
635,11/2/2023 7:12:54 PM,Reni Benjamin Upholds Buy Rating on Incyte’s Stock Despite 3Q23 Financial Miss: Promising Dermatology Growth and Cash Position Drive Positive Outlook,TipRanks,/news/stocks/reni-benjamin-upholds-buy-rating-on-incyte-s-stock-despite-3q23-financial-miss-promising-dermatology-growth-and-cash-position-drive-positive-outlook-1032775109,negative,0.9526864290237427
636,11/3/2023 2:07:44 AM,Stifel Nicolaus Keeps Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-keeps-their-hold-rating-on-incyte-incy-1032776414,positive,0.9168764352798462
637,11/6/2023 11:26:36 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amarin (AMRN), Protara Therapeutics (TARA) and Incyte (INCY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-amarin-amrn-protara-therapeutics-tara-and-incyte-incy-1032784042,neutral,0.7361758947372437
638,11/9/2023 2:28:11 AM,Incyte (INCY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/incyte-incy-receives-a-buy-from-truist-financial-1032801174,positive,0.713991641998291
639,11/10/2023 3:01:38 AM,7 Underappreciated Biotech Stocks to Pick Up on the Cheap,InvestorPlace,/news/stocks/7-underappreciated-biotech-stocks-to-pick-up-on-the-cheap-1032803108,negative,0.8734825849533081
640,11/12/2023 1:18:35 PM,3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024,InvestorPlace,/news/stocks/3-biotech-stocks-that-are-poised-to-have-breakthroughs-in-2024-1032809445,negative,0.6684498190879822
641,11/14/2023 1:02:47 PM,"Analysts Are Bullish on Top Healthcare Stocks: Incyte (INCY), Royalty Pharma (RPRX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-incyte-incy-royalty-pharma-rprx-1032819857,positive,0.530550479888916
642,11/21/2023 1:00:17 PM,The Latest Analyst Ratings for Incyte,Benzinga,/news/stocks/the-latest-analyst-ratings-for-incyte-1032838795,positive,0.9273427724838257
643,11/21/2023 9:05:46 PM,"Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness",Benzinga,/news/stocks/goldman-sachs-downgrades-incyte-amid-concerns-over-jakafi-studies-competitiveness-1032840634,neutral,0.9501225352287292
644,11/30/2023 2:30:21 AM,"Analysts Offer Insights on Healthcare Companies: POINT Biopharma Global (PNT), Regeneron (REGN) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-point-biopharma-global-pnt-regeneron-regn-and-incyte-incy-1032862831,positive,0.9139043092727661
645,12/1/2023 12:17:14 PM,Incyte (INCY) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-wells-fargo-1032867832,positive,0.8940358757972717
646,12/11/2023 10:31:31 AM,"Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), Incyte (INCY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-keros-therapeutics-kros-incyte-incy-1032891099,positive,0.7205297946929932
647,12/11/2023 12:17:34 PM,Incyte’s Promising Pipeline and Approaching Challenges: A Balanced Hold Rating,TipRanks,/news/stocks/incyte-s-promising-pipeline-and-approaching-challenges-a-balanced-hold-rating-1032891209,negative,0.8432012796401978
648,12/12/2023 11:40:11 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Shattuck Labs (STTK), Incyte (INCY) and Arcellx Inc (ACLX)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-shattuck-labs-sttk-incyte-incy-and-arcellx-inc-aclx-1032895090,neutral,0.9214159846305847
649,12/12/2023 12:30:42 PM,"Analysts Offer Insights on Healthcare Companies: Inotiv (NOTV), Incyte (INCY) and Editas Medicine (EDIT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-inotiv-notv-incyte-incy-and-editas-medicine-edit-1032895176,positive,0.924882173538208
650,12/12/2023 1:02:28 PM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Pharming Group (PHAR),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-pharming-group-phar-1032895197,positive,0.9189776182174683
651,12/13/2023 5:25:30 AM,Incyte’s Growth Prospects Buoyed by Strong Pipeline and Conference Highlights: A ‘Buy’ Analysis,TipRanks,/news/stocks/incyte-s-growth-prospects-buoyed-by-strong-pipeline-and-conference-highlights-a-buy-analysis-1032898224,negative,0.7334945797920227
652,12/13/2023 4:00:24 PM,Expert Ratings for Incyte,Benzinga,/news/stocks/expert-ratings-for-incyte-1032897774,positive,0.8165982961654663
653,12/15/2023 7:30:49 PM,The 3 Most Undervalued Biotech Stocks to Buy in December,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-december-1032905899,positive,0.5335273146629333
654,12/16/2023 6:00:00 PM,AI Meets Biotech: 3 Top Stocks Transforming Medical Science,InvestorPlace,/news/stocks/ai-meets-biotech-3-top-stocks-transforming-medical-science-1032906556,positive,0.8034080266952515
655,12/19/2023 12:26:38 PM,Wells Fargo Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/wells-fargo-sticks-to-their-hold-rating-for-incyte-incy-1032914334,positive,0.8984164595603943
656,1/3/2024 12:05:44 AM,Incyte’s Growth Prospects Bolstered by Axatilimab’s Advancements and Market Potential: A Strong Buy Rating,TipRanks,/news/stocks/incyte-s-growth-prospects-bolstered-by-axatilimab-s-advancements-and-market-potential-a-strong-buy-rating-1032939737,negative,0.9403241276741028
657,1/6/2024 1:46:21 AM,RBC Capital Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-remains-a-hold-on-incyte-incy-1032947429,positive,0.8631441593170166
658,1/9/2024 11:28:42 AM,Incyte’s Strong Outlook and Strategic Initiatives Warrant a Buy Rating,TipRanks,/news/stocks/incyte-s-strong-outlook-and-strategic-initiatives-warrant-a-buy-rating-1032955258,negative,0.9109766483306885
659,1/10/2024 9:12:52 PM,"Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations",Benzinga,/news/stocks/analyst-highlights-aclaris-therapeutics-encouraging-efficacy-for-eczema-candidate-but-cautions-on-data-variations-1032958482,neutral,0.6338329315185547
660,1/11/2024 6:31:39 AM,"Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-corcept-therapeutics-cort-incyte-incy-and-nkarta-nktx-1032959797,positive,0.9118494987487793
661,1/18/2024 9:00:00 PM,3 Pharma Stocks Could Be the Pills Your Portfolio Needs,InvestorPlace,/news/stocks/?p=2625106-1032978288,positive,0.9179866313934326
662,1/26/2024 5:46:57 AM,Incyte Stock Maintains Hold Rating Amid Pipeline Risks and Patent Expiry Concerns,TipRanks,/news/stocks/incyte-stock-maintains-hold-rating-amid-pipeline-risks-and-patent-expiry-concerns-1032999678,neutral,0.963482677936554
663,1/30/2024 1:45:08 PM,"Agilent, Incyte to collaborate on companion diagnostics development",Seeking Alpha,https://seekingalpha.com/news/4060000-agilent-incyte-to-collaborate-on-companion-diagnostics-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5573042631149292
664,1/30/2024 2:46:07 PM,"Agilent, Incyte To Collaborate On CDx Development Programs - Quick Facts ",RTTNews,/news/stocks/agilent-incyte-to-collaborate-on-cdx-development-programs-quick-facts-1033010017,positive,0.5828644633293152
665,2/5/2024 6:10:24 PM,MorphoSys jumps amid report Novartis in takeover  talks;  Karyopharm surges in sympathy (update),Seeking Alpha,https://seekingalpha.com/news/4062623-morphosys-jumps-amid-report-novartis-in-advanced-talks-to-takeover?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7988959550857544
666,2/5/2024 7:39:33 PM,Why Is MorphoSys (MOR) Stock Up 50% Today?,InvestorPlace,/news/stocks/why-is-morphosys-mor-stock-up-50-today-1033031578,negative,0.589003324508667
667,2/5/2024 10:02:22 PM,Novartis enters into agreement to buy cancer drugmaker MorphoSys AG for EUR 2.7B,Seeking Alpha,https://seekingalpha.com/news/4062915-novartis-to-buy-cancer-drugmaker-morphosys-ag-for-eur-27b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7990625500679016
668,2/5/2024 10:52:08 PM,Incyte buys global rights for tafasitamab from MorphoSys,Seeking Alpha,https://seekingalpha.com/news/4062936-incyte-buys-global-rights-for-tafasitamab-from-morphosys?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8392077088356018
669,2/6/2024 1:40:09 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-cochlear-limited-othercheof-1033032169,positive,0.9120863080024719
670,2/6/2024 2:23:47 AM,MorphoSys Agrees To Be Acquired By Novartis For EUR 2.7 Bln ,RTTNews,/news/stocks/morphosys-agrees-to-be-acquired-by-novartis-for-eur-2-7-bln-1033032071,positive,0.6603121161460876
671,2/6/2024 12:47:30 PM,Incyte (INCY) Receives a Buy from Oppenheimer,TipRanks,/news/stocks/incyte-incy-receives-a-buy-from-oppenheimer-1033036040,positive,0.8205316066741943
672,2/7/2024 3:35:49 PM,Incyte’s Hold Rating Affirmed Amid MONJUVI Acquisition and Novartis Competition,TipRanks,/news/stocks/incyte-s-hold-rating-affirmed-amid-monjuvi-acquisition-and-novartis-competition-1033042545,negative,0.9152871966362
673,2/12/2024 3:01:13 PM,Incyte earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/incyte-q4-earnings-preview-stock-1033057016,positive,0.9040642380714417
674,2/12/2024 3:43:06 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4065562-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8660826683044434
675,2/12/2024 4:41:12 PM,Incyte Q4 2023 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4065619-incyte-q4-2023-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7674033045768738
676,2/13/2024 12:10:06 PM,Incyte reports mixed Q4 results; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4065957-incyte-reports-mixed-q4-results-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9493290781974792
677,2/13/2024 1:17:15 PM,"Incyte Corporation Q4 Profit Increases, but misses estimates",RTTNews,/news/stocks/incyte-corporation-q4-profit-increases-but-misses-estimates-1033060595,negative,0.8886991143226624
678,2/13/2024 1:35:09 PM,"Incyte Q4 Adj EPS Misses Estimates, But Revenues Top ",RTTNews,/news/stocks/incyte-q4-adj-eps-misses-estimates-but-revenues-top-1033060648,neutral,0.5591335296630859
679,2/13/2024 9:27:02 PM,Incyte Stock Analysis: Balancing Risks and Opportunities with a Hold Rating,TipRanks,/news/stocks/incyte-stock-analysis-balancing-risks-and-opportunities-with-a-hold-rating-1033063297,positive,0.9238563179969788
680,2/13/2024 9:31:26 PM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), SAGE Therapeutics (SAGE) and Rocket Pharmaceuticals (RCKT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-sage-therapeutics-sage-and-rocket-pharmaceuticals-rckt-1033063314,positive,0.918112576007843
681,2/13/2024 10:25:22 PM,Incyte’s Robust Market Potential and Financial Performance Prompt Buy Rating,TipRanks,/news/stocks/incyte-s-robust-market-potential-and-financial-performance-prompt-buy-rating-1033063338,negative,0.8159492611885071
682,2/14/2024 5:30:22 AM,"Analysts Are Neutral on These Healthcare Stocks: Avanos Medical (AVNS), Incyte (INCY)",TipRanks,/news/stocks/analysts-are-neutral-on-these-healthcare-stocks-avanos-medical-avns-incyte-incy-1033065257,positive,0.695349931716919
683,2/14/2024 11:30:19 AM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Edesa Biotech (EDSA) and Ocular Therapeutix (OCUL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-edesa-biotech-edsa-and-ocular-therapeutix-ocul-1033066826,positive,0.9035171866416931
684,2/14/2024 12:06:58 PM,Incite’s Strong Revenue Outlook and Pipeline Potential Justify Buy Rating Despite Price Target Adjustment,TipRanks,/news/stocks/incite-s-strong-revenue-outlook-and-pipeline-potential-justify-buy-rating-despite-price-target-adjustment-1033067277,negative,0.9006514549255371
685,2/14/2024 12:16:03 PM,RBC Capital Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-remains-a-hold-on-incyte-incy-1033067347,positive,0.8631441593170166
686,2/14/2024 12:46:42 PM,Incyte (INCY) Gets a Hold from Stifel Nicolaus,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-stifel-nicolaus-1033067486,positive,0.8935750126838684
687,2/14/2024 3:00:22 PM,The Analyst Verdict: Incyte In The Eyes Of 8 Experts,Benzinga,/news/stocks/the-analyst-verdict-incyte-in-the-eyes-of-8-experts-1033066633,positive,0.5792191624641418
688,2/14/2024 8:20:31 PM,"JMP cuts Incyte to market perform, cites need for acquisition",Seeking Alpha,https://seekingalpha.com/news/4067070-jmp-cuts-incyte-to-market-perform-cites-need-for-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8870195746421814
689,2/15/2024 6:20:41 AM,"Analysts Offer Insights on Healthcare Companies: Lantheus (LNTH), Incyte (INCY) and Fusion Pharmaceuticals (FUSN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lantheus-lnth-incyte-incy-and-fusion-pharmaceuticals-fusn-1033070617,positive,0.910377025604248
690,2/15/2024 7:55:20 AM,Incyte Corporation: A Hold Recommendation Amidst Modest Growth and Pipeline Developments,TipRanks,/news/stocks/incyte-corporation-a-hold-recommendation-amidst-modest-growth-and-pipeline-developments-1033070847,positive,0.688575029373169
691,2/16/2024 1:00:33 PM,"Analysts Conflicted on These Healthcare Names: Incyte (INCY), Gilead Sciences (GILD) and Shockwave Medical (SWAV)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-incyte-incy-gilead-sciences-gild-and-shockwave-medical-swav-1033076765,neutral,0.6240333318710327
692,2/21/2024 9:50:00 PM,Exit Now! 3 Biotech Stocks to Sell in February 2024,InvestorPlace,/news/stocks/exit-now-3-biotech-stocks-to-sell-in-february-2024-1033089894,positive,0.9039078950881958
693,2/23/2024 4:14:07 PM,Incyte a new Buy at Jefferies on prospects beyond Jakafi,Seeking Alpha,https://seekingalpha.com/news/4071170-incyte-stock-new-buy-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5978168845176697
694,2/26/2024 8:20:23 PM,7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff,InvestorPlace,/news/stocks/7-under-the-radar-biotech-stocks-gearing-up-for-liftoff-1033104299,negative,0.8890423774719238
695,2/27/2024 10:22:29 PM,FDA accepts Incyte application for graft-versus-host disease drug,Seeking Alpha,https://seekingalpha.com/news/4072754-fda-accepts-incyte-application-for-graft-versus-host-disease-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6780470609664917
696,2/28/2024 3:25:42 AM,Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment ,RTTNews,/news/stocks/incyte-s-axatilimab-receives-fda-priority-review-for-chronic-graft-versus-host-disease-treatment-1033109918,negative,0.8980493545532227
697,2/29/2024 12:59:36 PM,Knight Therapeutics launches Minjuvi in Brazil,Seeking Alpha,https://seekingalpha.com/news/4073847-knight-therapeutics-launches-minjuvi-in-brazil?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8670499920845032
698,3/5/2024 12:40:18 PM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Insmed (INSM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-insmed-insm-1033133757,positive,0.9300632476806641
699,3/7/2024 8:00:00 PM,3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise,InvestorPlace,/news/stocks/3-cancer-fighting-biotech-stocks-showing-clinical-trial-promise-1033143819,negative,0.5083664655685425
700,3/11/2024 11:08:03 AM,Incyte’s Growth Potential Weighed Against Upcoming Challenges: A Hold Rating Analysis,TipRanks,/news/stocks/incyte-s-growth-potential-weighed-against-upcoming-challenges-a-hold-rating-analysis-1033151133,negative,0.7628083229064941
701,3/11/2024 5:02:02 PM,Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead,InvestorPlace,/news/stocks/penny-stock-detox-3-stocks-to-buy-for-multibagger-returns-instead-1033152164,positive,0.9324533939361572
702,3/12/2024 9:20:08 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Fortrea Holdings Inc. (FTRE) and Abbott Labs (ABT)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-incyte-incy-fortrea-holdings-inc-ftre-and-abbott-labs-abt-1033154762,neutral,0.9153742790222168
703,3/12/2024 10:40:24 AM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and iTeos Therapeutics (ITOS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-anaptysbio-anab-and-iteos-therapeutics-itos-1033155151,positive,0.9106931686401367
704,3/12/2024 10:50:23 AM,"Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Korro Bio (KRRO) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-universal-health-uhs-korro-bio-krro-and-incyte-incy-1033155206,positive,0.9160633087158203
705,3/12/2024 12:40:21 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), AbbVie (ABBV) and ACADIA Pharmaceuticals (ACAD)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-abbvie-abbv-and-acadia-pharmaceuticals-acad-1033155948,neutral,0.7346109747886658
706,3/12/2024 5:00:56 PM,Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings),Benzinga,/news/stocks/incyte-stock-a-deep-dive-into-analyst-perspectives-8-ratings-1033156046,positive,0.8442131876945496
707,3/13/2024 4:25:16 AM,Incyte’s Hold Rating: Balancing Clinical Promise Against Financial and Market Position,TipRanks,/news/stocks/incyte-s-hold-rating-balancing-clinical-promise-against-financial-and-market-position-1033157942,negative,0.679840624332428
708,3/13/2024 10:50:11 AM,Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-gilead-sciences-gild-and-incyte-incy-1033159700,positive,0.9247164726257324
709,3/13/2024 11:40:59 AM,"Analysts Are Bullish on Top Healthcare Stocks: biote (BTMD), Incyte (INCY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-biote-btmd-incyte-incy-1033160009,positive,0.8368409872055054
710,3/25/2024 1:48:12 AM,RBC Capital Sticks to Its Hold Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-incyte-incy-1033191391,positive,0.8344722390174866
711,4/1/2024 1:35:23 PM,"Incyte and CMS collaborate for povorcitinib in Mainland China, Hong Kong, Macau, Taiwan and SEA",Seeking Alpha,https://seekingalpha.com/news/4085608-incyte-and-cms-collaborate-for-povorcitinib-in-mainland-china-hong-kong-macau-taiwan-and-sea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8482500910758972
712,4/1/2024 3:10:03 PM,"CMS To Receive License To Develop, Commercialize Povorcitinib In China And Southeast Asia ",RTTNews,/news/stocks/cms-to-receive-license-to-develop-commercialize-povorcitinib-in-china-and-southeast-asia-1033211023,negative,0.748467206954956
713,4/4/2024 3:12:55 PM,Top buy-rated stocks and sell-rated stocks within Health Care - Citi,Seeking Alpha,https://seekingalpha.com/news/4087312-top-buy-rated-stocks-and-sell-rated-stocks-within-health-care-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9045203924179077
714,4/6/2024 3:54:38 PM,Jury sides with SEC in trial over insider trading charges against former pharma executive,Seeking Alpha,https://seekingalpha.com/news/4087719-jury-sides-with-sec-in-trial-over-insider-trading-charges-against-former-pharma-executive?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.865902304649353
715,4/9/2024 2:40:06 AM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-biomarin-pharmaceutical-bmrn-and-acadia-pharmaceuticals-acad-1033231914,positive,0.9183801412582397
716,4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9173789024353027
717,4/23/2024 11:31:43 AM,Incyte to acquire immune-focused drug developer Escient,Seeking Alpha,https://seekingalpha.com/news/4092354-incyte-stock-gains-escient-buyout?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9155886173248291
718,4/23/2024 2:14:37 PM,Incyte To Buy Privately Held Escient Pharma ,RTTNews,/news/stocks/incyte-to-buy-privately-held-escient-pharma-1033275746,positive,0.9324420094490051
719,4/23/2024 7:01:14 PM,Peeling Back The Layers: Exploring Incyte Through Analyst Insights,Benzinga,/news/stocks/peeling-back-the-layers-exploring-incyte-through-analyst-insights-1033277500,positive,0.9049785137176514
720,4/23/2024 7:25:22 PM,Incyte (INCY) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-piper-sandler-1033278199,negative,0.4982808530330658
721,4/23/2024 9:03:10 PM,"Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends",Benzinga,/news/stocks/incyte-should-consider-significant-stock-buyback-and-prioritize-r-d-analyst-recommends-1033277738,positive,0.7220671772956848
722,4/23/2024 11:05:18 PM,Incyte’s Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns,TipRanks,/news/stocks/incyte-s-strategic-acquisition-a-premature-and-costly-move-amid-patent-cliff-concerns-1033278345,neutral,0.9246775507926941
723,4/24/2024 9:35:28 AM,Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation,TipRanks,/news/stocks/incyte-acquisition-strategy-and-drug-pipeline-evaluation-a-hold-recommendation-1033281662,positive,0.9276145100593567
724,4/24/2024 11:18:04 AM,Truist Financial Keeps Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-incyte-incy-1033282819,positive,0.911274790763855
725,4/24/2024 11:46:17 AM,Oppenheimer Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/oppenheimer-sticks-to-its-buy-rating-for-incyte-incy-1033282965,positive,0.8815782070159912
726,4/26/2024 6:16:16 AM,Incyte’s Strategic Acquisition and Promising Pipeline Secure Buy Rating,TipRanks,/news/stocks/incyte-s-strategic-acquisition-and-promising-pipeline-secure-buy-rating-1033293011,negative,0.8876863718032837
727,4/26/2024 8:18:41 PM,Repare Therapeutics appoints Steven Stein to its board of directors,Seeking Alpha,https://seekingalpha.com/news/4095147-repare-therapeutics-appoints-steven-stein-to-its-board-of-directors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9330792427062988
728,4/29/2024 11:53:03 AM,Truist Financial Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-incyte-incy-1033301141,positive,0.8128984570503235
729,4/29/2024 3:01:13 PM,What Wall Street expects from Incyte's earnings,Markets Insider Automation,/news/stocks/incyte-quarter-earnings-preview-q1-1033300246,positive,0.9349303245544434
730,4/29/2024 3:15:34 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4095553-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8660826683044434
731,4/29/2024 3:44:31 PM,Incyte Q1 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4095571-incyte-q1-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7512345314025879
732,4/30/2024 11:03:19 AM,"Incyte Non-GAAP EPS of $0.64 misses by $0.19, revenue of $880.89M misses by $43.75M",Seeking Alpha,https://seekingalpha.com/news/4096087-incyte-non-gaap-eps-of-0_64-misses-0_19-revenue-of-880_89m-misses-43_75m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6525466442108154
733,4/30/2024 1:22:28 PM,"Incyte Corporation Q1 Profit Increases, but misses estimates",RTTNews,/news/stocks/incyte-corporation-q1-profit-increases-but-misses-estimates-1033305484,negative,0.8968110084533691
734,4/30/2024 3:54:39 PM,"INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/incy-stock-earnings-incyte-for-q1-of-2024-1033307794,neutral,0.9534264206886292
735,5/1/2024 4:40:25 AM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-exelixis-exel-1033311766,positive,0.909485936164856
736,5/1/2024 10:39:03 AM,RBC Capital Reaffirms Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-incyte-incy-1033313601,positive,0.8489094972610474
737,5/1/2024 12:01:07 PM,"Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), TransMedics Group (TMDX) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-transmedics-group-tmdx-and-incyte-incy-1033314333,positive,0.9265267252922058
738,5/2/2024 6:16:16 AM,Incyte’s Resilient Demand and Strong Financials Justify Buy Rating Despite Q1 Sales Dip,TipRanks,/news/stocks/incyte-s-resilient-demand-and-strong-financials-justify-buy-rating-despite-q1-sales-dip-1033318462,negative,0.9319710731506348
739,5/9/2024 10:15:00 AM,The 3 Best Biotech Stocks to Buy in May 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-may-2024-1033355006,positive,0.8289586305618286
740,5/10/2024 11:30:48 AM,"Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-incyte-incy-and-ventyx-biosciences-vtyx-1033363727,positive,0.8984269499778748
741,5/13/2024 12:04:18 PM,"Incyte jumps 6%, intends to buy back $2B stock",Seeking Alpha,https://seekingalpha.com/news/4105062-incyte-jumps-6-intends-to-buy-back-2b-stock?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7418082356452942
742,5/13/2024 7:47:50 PM,"Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?",Benzinga,/news/stocks/tech-stocks-inch-higher-ahead-of-key-inflation-data-gamestop-skyrockets-tencent-fuels-china-rally-what-s-driving-markets-monday-1033372241,positive,0.5371826887130737
743,5/13/2024 10:46:49 PM,Incyte’s Strategic Financial Decisions and Market Positioning: A Hold Rating Analysis,TipRanks,/news/stocks/incyte-s-strategic-financial-decisions-and-market-positioning-a-hold-rating-analysis-1033373035,positive,0.8885018229484558
744,5/16/2024 4:26:07 AM,Incyte’s Strategic Moves Amid Share Buyback and Pipeline Expansion: A Balanced Hold Rating,TipRanks,/news/stocks/incyte-s-strategic-moves-amid-share-buyback-and-pipeline-expansion-a-balanced-hold-rating-1033391296,negative,0.8772475719451904
745,5/16/2024 8:07:29 AM,Incyte’s Share Buyback Program: A Buy Rating and Fundamental Value Increase,TipRanks,/news/stocks/incyte-s-share-buyback-program-a-buy-rating-and-fundamental-value-increase-1033392212,positive,0.8877169489860535
746,5/23/2024 11:11:00 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Incyte (INCY),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-biogen-biib-and-incyte-incy-1033416355,neutral,0.692520260810852
747,5/23/2024 2:00:56 PM,9 Analysts Have This To Say About Incyte,Benzinga,/news/stocks/9-analysts-have-this-to-say-about-incyte-1033415509,positive,0.9266036748886108
748,5/23/2024 4:43:05 PM,Incyte a new hold at Deutsche Bank as key drugs approach patent cliffs,Seeking Alpha,https://seekingalpha.com/news/4109924-incyte-new-hold-deutsche-bank-key-drugs-approach-patent-cliffs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6196371912956238
749,6/4/2024 11:35:07 AM,TD Cowen Sticks to Their Buy Rating for Incyte (INCY),TipRanks,/news/stocks/td-cowen-sticks-to-their-buy-rating-for-incyte-incy-1033450212,positive,0.8936766982078552
750,6/5/2024 12:51:42 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO) and Incyte (INCY),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bridgebio-pharma-bbio-and-incyte-incy-1033451565,neutral,0.5860179662704468
751,6/5/2024 6:55:21 PM,Incyte Corporation: A Hold Rating Amidst Clinical Data and Financial Decisions,TipRanks,/news/stocks/incyte-corporation-a-hold-rating-amidst-clinical-data-and-financial-decisions-1033455460,positive,0.9051479697227478
752,6/11/2024 1:11:12 PM,Incyte tenders ~29.8M shares at $60.00 per share,Seeking Alpha,https://seekingalpha.com/news/4114833-incyte-tenders-298m-shares-at-6000-per-share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9476693272590637
753,6/13/2024 4:01:10 PM,Analysts Conflicted on These Healthcare Names: Incyte (INCY) and Lisata Therapeutics (LSTA),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-incyte-incy-and-lisata-therapeutics-lsta-1033477676,neutral,0.6633102893829346
754,6/13/2024 4:10:29 PM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Lisata Therapeutics (LSTA),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-lisata-therapeutics-lsta-1033477674,positive,0.9128407835960388
755,6/13/2024 10:38:57 PM,"Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers",Benzinga,/news/stocks/nasdaq-100-s-p-500-close-at-record-highs-as-tech-stocks-reclaim-dominance-thursday-s-gainers-losers-1033477862,positive,0.45503565669059753
756,6/18/2024 4:01:02 PM,Analyst Expectations For Incyte's Future,Benzinga,/news/stocks/analyst-expectations-for-incyte-s-future-1033487581,negative,0.7691177129745483
757,7/1/2024 6:18:31 PM,7 Undervalued Biotech Stocks to Buy for Big-Time Returns,InvestorPlace,/news/stocks/7-undervalued-biotech-stocks-to-buy-for-big-time-returns-1033520868,negative,0.6716562509536743
758,7/2/2024 8:36:17 AM,Incite Corporation’s Sell Rating: A Critical Analysis of Financial Strategy and Pipeline Development Risks,TipRanks,/news/stocks/incite-corporation-s-sell-rating-a-critical-analysis-of-financial-strategy-and-pipeline-development-risks-1033522588,positive,0.8821532726287842
759,7/2/2024 3:35:22 PM,Incyte drops as BMO downgrades on $2B buybacks,Seeking Alpha,https://seekingalpha.com/news/4121760-incyte-stock-drops-bmo-cuts-buybacks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9626387357711792
760,7/2/2024 7:31:12 PM,Mesoblast Soars 208% YTD on Positive Regulatory Updates,Benzinga,/news/stocks/mesoblast-soars-208-ytd-on-positive-regulatory-updates-1033524166,negative,0.9194170832633972
761,7/2/2024 7:32:11 PM,"Biggest stock movers today: TSLA, PARA, RCM, STAA, and more",Seeking Alpha,https://seekingalpha.com/news/4121473-biggest-stock-movers-today-para-incy-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.911823570728302
762,7/2/2024 7:32:46 PM,This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday,Benzinga,/news/stocks/this-crowdstrike-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-tuesday-1033524168,positive,0.6733826994895935
763,7/5/2024 10:20:00 AM,3 Highly Rated Biotech Stocks for Your July Buy List,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-for-your-july-buy-list-1033531559,positive,0.9089598059654236
764,7/6/2024 6:31:00 PM,"Notable analyst calls this week: Nvidia, Spirit Airlines and PayPal among top picks",Seeking Alpha,https://seekingalpha.com/news/4122388-notable-analyst-calls-this-week-nvidia-spirit-airlines-and-paypal-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6947079300880432
765,7/9/2024 10:00:00 AM,7 Cheap Biotech Stocks With Major Upside Potential,InvestorPlace,/news/stocks/7-cheap-biotech-stocks-with-major-upside-potential-1033538625,negative,0.6298689246177673
766,7/9/2024 10:53:00 AM,The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-cathie-wood-stocks-to-buy-in-july-2024-1033538878,positive,0.7455812692642212
767,7/9/2024 7:47:11 PM,"S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?",Benzinga,/news/etf/s-p-500-hits-record-highs-eyes-6th-straight-gain-as-powell-keeps-bears-at-bay-tesla-targets-10th-consecutive-win-bank-stocks-rally-what-s-driving-markets-tuesday-1033540752,positive,0.6231928467750549
768,7/16/2024 5:01:00 PM,"Incyte, Moderna among most shorted S&P 500 healthcare stocks in June",Seeking Alpha,https://seekingalpha.com/news/4124310-incyte-moderna-among-most-shorted-sp-500-healthcare-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8085744976997375
769,7/17/2024 1:52:11 PM,Most shorted S&P 500 stocks in June,Seeking Alpha,https://seekingalpha.com/news/4125038-most-shorted-sp-500-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7860625386238098
770,7/29/2024 10:15:07 AM,Biotech Stocks Facing FDA Decision In August 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-2024-1033605090,positive,0.9172899127006531
771,7/29/2024 3:01:13 PM,Incyte earnings preview: what to expect,Markets Insider Automation,/news/stocks/incyte-stock-price-q2-earnings-preview-1033606159,positive,0.8878722190856934
772,7/29/2024 3:04:21 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4129508-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8660826683044434
773,7/29/2024 5:40:34 PM,Incyte Q2 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4129644-incyte-q2-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7679364681243896
774,7/30/2024 11:07:04 AM,"Incyte Non-GAAP EPS of -$1.82 misses by $2.93, revenue of $1.04B beats by $30M",Seeking Alpha,https://seekingalpha.com/news/4129979-incyte-non-gaap-eps-of-1_82-misses-2_93-revenue-of-1_04b-beats-30m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5174217224121094
775,7/30/2024 1:21:45 PM,Incyte Corporation Q2 Earnings Summary ,RTTNews,/news/stocks/incyte-corporation-q2-earnings-summary-1033611204,positive,0.8725875020027161
776,7/30/2024 5:13:08 PM,Incyte drops 5 clinical drug candidates following a strategic review,Seeking Alpha,https://seekingalpha.com/news/4130376-incyte-drops-5-clinical-drug-candidates-following-strategic-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9371323585510254
777,7/30/2024 9:55:54 PM,Incite’s Strong Q2 Performance and Growth Potential Affirm Buy Rating,TipRanks,/news/stocks/incite-s-strong-q2-performance-and-growth-potential-affirm-buy-rating-1033614348,negative,0.9467442035675049
778,7/31/2024 4:46:26 AM,Incyte Corporation: Hold Rating Amidst Strong Q2 Performance and Pipeline Potential,TipRanks,/news/stocks/incyte-corporation-hold-rating-amidst-strong-q2-performance-and-pipeline-potential-1033616312,negative,0.9508181214332581
779,7/31/2024 8:56:04 AM,Incyte Performance and Pipeline Analysis: Maintaining Neutral with a Revised Price Objective,TipRanks,/news/stocks/incyte-performance-and-pipeline-analysis-maintaining-neutral-with-a-revised-price-objective-1033617608,positive,0.915065348148346
780,7/31/2024 10:33:04 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Genmab (GMAB) and Penumbra (PEN)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-genmab-gmab-and-penumbra-pen-1033618565,neutral,0.7562603950500488
781,7/31/2024 10:50:17 AM,Incyte (INCY) Gets a Buy from Piper Sandler,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-piper-sandler-1033618652,negative,0.4982808530330658
782,7/31/2024 10:50:56 AM,"Analysts Are Bullish on These Healthcare Stocks: Incyte (INCY), Atricure (ATRC)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-incyte-incy-atricure-atrc-1033618648,positive,0.8011715412139893
783,7/31/2024 11:40:07 AM,Truist Financial Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-incyte-incy-1033619204,positive,0.7369586825370789
784,7/31/2024 12:09:02 PM,Oppenheimer Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-incyte-incy-1033619423,positive,0.9365195631980896
785,7/31/2024 12:10:20 PM,Incyte (INCY) Gets a Buy from Jefferies,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-jefferies-1033619413,negative,0.5261228084564209
786,7/31/2024 12:15:21 PM,"Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Day One Biopharmaceuticals (DAWN) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tilray-tlry-day-one-biopharmaceuticals-dawn-and-incyte-incy-1033619506,positive,0.924379825592041
787,7/31/2024 12:30:09 PM,Incyte (INCY) Receives a Hold from Morgan Stanley,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-morgan-stanley-1033619580,positive,0.903261125087738
788,7/31/2024 12:30:34 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1033619576,neutral,0.700346827507019
789,8/1/2024 6:07:38 AM,Incyte’s Strong Product Performance and Growth Trajectory Merit a Buy Rating,TipRanks,/news/stocks/incyte-s-strong-product-performance-and-growth-trajectory-merit-a-buy-rating-1033625020,negative,0.9353057742118835
790,8/1/2024 7:42:35 AM,Incyte Corporation: Balancing Robust Jakafi Sales Against Strategic Pipeline Shifts,TipRanks,/news/stocks/incyte-corporation-balancing-robust-jakafi-sales-against-strategic-pipeline-shifts-1033625572,negative,0.8647962808609009
791,8/1/2024 7:42:59 AM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Terns Pharmaceuticals (TERN) and Stryker (SYK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-terns-pharmaceuticals-tern-and-stryker-syk-1033625570,positive,0.9233052730560303
792,8/2/2024 2:06:46 AM,Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-sticks-to-their-hold-rating-for-incyte-incy-1033630218,positive,0.8383904695510864
793,8/7/2024 5:56:56 AM,Incyte Corporation: Revised Earnings and Cautious Hold Rating Amid Unforeseen Financial Commitment,TipRanks,/news/stocks/incyte-corporation-revised-earnings-and-cautious-hold-rating-amid-unforeseen-financial-commitment-1033651296,neutral,0.9698530435562134
794,8/12/2024 11:19:10 AM,Incyte (INCY) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/incyte-incy-gets-a-hold-from-wells-fargo-1033677800,positive,0.8940358757972717
795,8/14/2024 8:18:23 PM,FDA approves Incyte's Niktimvo for chronic graft-versus-host disease,Seeking Alpha,https://seekingalpha.com/news/4140021-fda-approves-incytes-niktimvo-for-chronic-graft-versus-host-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8234673142433167
796,8/15/2024 10:30:06 AM,RBC Capital Reaffirms Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-incyte-incy-1033695196,positive,0.8489094972610474
797,8/15/2024 11:19:34 AM,Incyte’s New Drug Approval Overcast by Market Limitations and Looming Patent Expirations,TipRanks,/news/stocks/incyte-s-new-drug-approval-overcast-by-market-limitations-and-looming-patent-expirations-1033695780,neutral,0.9016040563583374
798,8/15/2024 11:40:09 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Incyte (INCY) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-incyte-incy-and-gilead-sciences-gild-1033695853,positive,0.9215019345283508
799,8/15/2024 5:47:22 PM,Moderna was the most shorted S&P 500 healthcare stock in July,Seeking Alpha,https://seekingalpha.com/news/4139953-moderna-was-the-most-shorted-sp-500-healthcare-stock-in-july?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5078945755958557
800,8/15/2024 9:13:57 PM,Incyte's Monjuvi meets primary endpoint in follicular lymphoma phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/4140798-incyte-monjuvi-meets-primary-endpoint-follicular-lymphoma-phase-3-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8347601294517517
801,8/16/2024 8:17:30 AM,Incyte’s Niktimvo Faces Market Challenges Despite FDA Approval: Analyst Upholds Hold Rating,TipRanks,/news/stocks/incyte-s-niktimvo-faces-market-challenges-despite-fda-approval-analyst-upholds-hold-rating-1033700009,neutral,0.5999099016189575
802,8/18/2024 7:43:59 AM,"Biotech Buzz: VIRX Cuts 23% Jobs, FDA Oks New Drug For Hypoparathyroidism, SIGA Down But Not Out ",RTTNews,/news/stocks/biotech-buzz-virx-cuts-23-jobs-fda-oks-new-drug-for-hypoparathyroidism-siga-down-but-not-out-1033702057,neutral,0.8887053728103638
803,8/18/2024 3:50:23 PM,Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Cochlear Limited (OtherCHEOF),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-and-cochlear-limited-othercheof-1033702346,positive,0.9120863080024719
804,8/19/2024 4:55:13 AM,Incyte Corporation: Market Successes Counterbalanced by Valuation and Patent Expiry Concerns,TipRanks,/news/stocks/incyte-corporation-market-successes-counterbalanced-by-valuation-and-patent-expiry-concerns-1033703076,neutral,0.9479369521141052
805,9/3/2024 12:16:10 PM,RBC Capital Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-their-hold-rating-for-incyte-incy-1033744446,positive,0.8397968411445618
806,9/4/2024 11:01:23 AM,Eli Lilly inks licensing deal to expand Olumiant access in Africa,Seeking Alpha,https://seekingalpha.com/news/4146624-eli-lilly-inks-licensing-deal-to-expand-olumiant-access-in-africa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9432264566421509
807,9/6/2024 7:00:22 PM,"Catalyst Watch: Apple's iPhone event, Oracle earnings, Google antitrust trial, and the August CPI print",Seeking Alpha,https://seekingalpha.com/news/4147709-catalyst-watch-apples-iphone-event-oracle-earnings-google-antitrust-trial-and-the-august-cpi-print?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7490698099136353
808,9/9/2024 11:15:20 AM,TD Cowen Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/td-cowen-remains-a-buy-on-incyte-incy-1033757961,positive,0.9471278190612793
809,9/10/2024 9:50:23 AM,Incyte’s CDK2i: A Cautiously Optimistic Neutral Rating Amidst Early Clinical Data and Safety Concerns,TipRanks,/news/stocks/incyte-s-cdk2i-a-cautiously-optimistic-neutral-rating-amidst-early-clinical-data-and-safety-concerns-1033760323,negative,0.7147946357727051
810,9/14/2024 3:21:36 PM,Incyte Zynyz improves progression-free survival in anal cancer,Seeking Alpha,https://seekingalpha.com/news/4149791-incyte-zynyz-improves-progression-free-survival-anal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9498579502105713
811,9/16/2024 9:35:44 AM,Incyte’s Promising Clinical Data Balanced with Regulatory Uncertainty: A ‘Hold’ Recommendation,TipRanks,/news/stocks/incyte-s-promising-clinical-data-balanced-with-regulatory-uncertainty-a-hold-recommendation-1033774047,negative,0.66901034116745
812,9/16/2024 9:57:00 AM,Incyte’s Promising Clinical Developments Offset by Long Approval Timelines: Analyst Maintains Hold Rating,TipRanks,/news/stocks/incyte-s-promising-clinical-developments-offset-by-long-approval-timelines-analyst-maintains-hold-rating-1033774087,positive,0.7423968315124512
813,9/16/2024 9:58:44 AM,Incyte’s Promising Clinical Trials Underpin Buy Rating,TipRanks,/news/stocks/incyte-s-promising-clinical-trials-underpin-buy-rating-1033774189,negative,0.9047228097915649
814,9/16/2024 9:59:33 AM,Incyte’s CDK2 Inhibitor Shows Promise but Warrants Hold Rating Amid Uncertainty,TipRanks,/news/stocks/incyte-s-cdk2-inhibitor-shows-promise-but-warrants-hold-rating-amid-uncertainty-1033774186,negative,0.9330002665519714
815,9/16/2024 10:55:26 AM,Incyte Pipeline Developments: Balancing Potential and Uncertainty in Analyst Hold Rating,TipRanks,/news/stocks/incyte-pipeline-developments-balancing-potential-and-uncertainty-in-analyst-hold-rating-1033774361,positive,0.8118467330932617
816,9/16/2024 11:45:42 AM,TD Cowen Sticks to Its Buy Rating for Incyte (INCY),TipRanks,/news/stocks/td-cowen-sticks-to-its-buy-rating-for-incyte-incy-1033774839,positive,0.8631492257118225
817,9/16/2024 11:55:56 AM,Truist Financial Keeps Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-incyte-incy-1033774820,positive,0.911274790763855
818,9/16/2024 11:56:01 AM,Oppenheimer Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/oppenheimer-remains-a-buy-on-incyte-incy-1033774819,positive,0.9365195631980896
819,9/16/2024 12:06:41 PM,Stifel Nicolaus Keeps Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-keeps-their-hold-rating-on-incyte-incy-1033774890,positive,0.9168764352798462
820,9/16/2024 8:51:15 PM,"Incyte closes 5% higher bolstered by Zynyz data, Guggenheim note",Seeking Alpha,https://seekingalpha.com/news/4150128-incyte-closes-5-higher-bolstered-zynyz-data-guggenheim-note?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9357318878173828
821,9/17/2024 4:25:17 AM,Incyte’s Hold Rating: Balancing Drug Pipeline Progress and Market Dynamics,TipRanks,/news/stocks/incyte-s-hold-rating-balancing-drug-pipeline-progress-and-market-dynamics-1033776054,positive,0.7867115139961243
822,9/18/2024 4:32:58 PM,Incyte downgraded at Truist on Jakafi patent cliff,Seeking Alpha,https://seekingalpha.com/news/4150772-incyte-downgraded-truist-jakafi-patent-cliff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7093504071235657
823,9/19/2024 3:00:19 AM,Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal ,RTTNews,/news/stocks/incyte-phase-2-trial-results-of-niktimvo-in-chronic-graft-versus-host-disease-meet-primary-goal-1033781862,negative,0.5594446659088135
824,9/26/2024 2:26:55 AM,Incyte (INCY) was downgraded to a Hold Rating at Truist Financial,TipRanks,/news/stocks/incyte-incy-was-downgraded-to-a-hold-rating-at-truist-financial-1033799138,neutral,0.7074884176254272
825,10/10/2024 10:38:38 AM,Wells Fargo Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/wells-fargo-sticks-to-their-hold-rating-for-incyte-incy-1033835603,positive,0.8984164595603943
826,10/21/2024 11:45:37 AM,Incyte (INCY) Gets a Buy from TD Cowen,TipRanks,/news/stocks/incyte-incy-gets-a-buy-from-td-cowen-1033865217,positive,0.6724197268486023
827,10/23/2024 12:11:10 PM,"Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Otsuka Holdings Co (OtherOTSKF) and AngioDynamics (ANGO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-incyte-incy-otsuka-holdings-co-otherotskf-and-angiodynamics-ango-1033879677,positive,0.9126105904579163
828,10/28/2024 11:56:27 AM,Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-sticks-to-their-hold-rating-for-incyte-incy-1033902217,positive,0.8383904695510864
829,10/28/2024 6:03:17 PM,Incyte Q3 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4215092-incyte-q3-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7330562472343445
830,10/28/2024 10:00:33 PM,Here's the major earnings before the open tomorrow,Seeking Alpha,https://seekingalpha.com/news/4215158-heres-the-major-earnings-before-the-open-tomorrow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9330109357833862
831,10/29/2024 11:06:04 AM,"Incyte Non-GAAP EPS of $1.07 misses by $0.03, revenue of $1.14B beats by $60M",Seeking Alpha,https://seekingalpha.com/news/4217368-incyte-non-gaap-eps-of-1_07-misses-0_03-revenue-of-1_14b-beats-60m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5495360493659973
832,10/29/2024 11:25:33 AM,"Incyte reports Q3 EPS $1.07, consensus $1.07",TipRanks,/news/stocks/incyte-reports-q3-eps-1-07-consensus-1-07-1033909618,positive,0.619337797164917
833,10/29/2024 12:37:00 PM,"Incyte Corporation Q3 Profit Drops, Inline With Estimates ",RTTNews,/news/stocks/incyte-corporation-q3-profit-drops-inline-with-estimates-1033908348,neutral,0.9730328917503357
834,10/29/2024 1:55:13 PM,Early notable gainers among liquid option names on October 29th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-october-29th-1033910966,negative,0.9101371765136719
835,10/29/2024 2:22:01 PM,"Incyte stock jumps 8% on Q3 revenue beat, raised guidance",Seeking Alpha,https://seekingalpha.com/news/4218459-incyte-stock-jumps-on-q3-revenue-beat-raised-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9408214688301086
836,10/29/2024 5:15:31 PM,Incyte upgraded to Buy from Neutral at BofA,TipRanks,/news/stocks/incyte-upgraded-to-buy-from-neutral-at-bofa-1033911729,negative,0.7290272116661072
837,10/29/2024 6:45:18 PM,Incyte price target raised to $75 from $73 at Stifel,TipRanks,/news/stocks/incyte-price-target-raised-to-75-from-73-at-stifel-1033912161,negative,0.9414701461791992
838,10/29/2024 8:45:12 PM,Incyte’s Strong Financial Performance and Promising Pipeline Lead to Buy Rating,TipRanks,/news/stocks/incyte-s-strong-financial-performance-and-promising-pipeline-lead-to-buy-rating-1033912387,negative,0.9491371512413025
839,10/29/2024 10:16:24 PM,Incyte Stock Hold Rating: Balancing Strong Revenue Performance with Pipeline Uncertainties,TipRanks,/news/stocks/incyte-stock-hold-rating-balancing-strong-revenue-performance-with-pipeline-uncertainties-1033912601,negative,0.9465380311012268
840,10/29/2024 10:19:29 PM,Incyte (INCY) Receives a Hold from Wells Fargo,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-wells-fargo-1033912573,positive,0.880752682685852
841,10/30/2024 4:25:51 AM,Incyte’s Fair Valuation Amid Growth Prospects and Strategic Challenges,TipRanks,/news/stocks/incyte-s-fair-valuation-amid-growth-prospects-and-strategic-challenges-1033915135,negative,0.8753054738044739
842,10/30/2024 9:18:08 AM,Incyte’s Q3 2024: Strong Revenue and Clinical Progress,TipRanks,/news/stocks/incyte-s-q3-2024-strong-revenue-and-clinical-progress-1033917075,negative,0.9531965255737305
843,10/30/2024 10:11:38 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Zoetis (ZTS) and Doximity (DOCS)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-incyte-incy-zoetis-zts-and-doximity-docs-1033917458,neutral,0.7766875624656677
844,10/30/2024 10:15:35 AM,Incyte price target raised to $97 from $92 at Citi,TipRanks,/news/stocks/incyte-price-target-raised-to-97-from-92-at-citi-1033917659,negative,0.9411612749099731
845,10/30/2024 10:40:04 AM,RBC Capital Reaffirms Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-reaffirms-their-hold-rating-on-incyte-incy-1033917783,positive,0.8489094972610474
846,10/30/2024 10:55:25 AM,Incyte price target raised to $68 from $62 at Wells Fargo,TipRanks,/news/stocks/incyte-price-target-raised-to-68-from-62-at-wells-fargo-1033917901,negative,0.9430434107780457
847,10/30/2024 11:11:00 AM,Truist Financial Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/truist-financial-sticks-to-their-hold-rating-for-incyte-incy-1033918071,positive,0.8201733827590942
848,10/30/2024 11:17:54 AM,Sell Rating Assigned to Incyte: Concerns Over Jakafi’s Exclusivity Loss and Strategic Challenges,TipRanks,/news/stocks/sell-rating-assigned-to-incyte-concerns-over-jakafi-s-exclusivity-loss-and-strategic-challenges-1033918258,neutral,0.8296851515769958
849,10/30/2024 11:50:56 AM,"Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Chemed (CHE) and Incyte (INCY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-harmony-biosciences-holdings-hrmy-chemed-che-and-incyte-incy-1033918537,positive,0.9273846745491028
850,10/30/2024 12:06:21 PM,Incyte’s Strong Financial Performance and Pipeline Potential Justify Buy Rating and Increased Price Target,TipRanks,/news/stocks/incyte-s-strong-financial-performance-and-pipeline-potential-justify-buy-rating-and-increased-price-target-1033919035,negative,0.9352084994316101
851,10/30/2024 12:11:18 PM,Incyte price target raised to $82 from $81 at Oppenheimer,TipRanks,/news/stocks/incyte-price-target-raised-to-82-from-81-at-oppenheimer-1033918992,negative,0.9429997801780701
852,10/30/2024 12:51:12 PM,Incyte price target raised to $52 from $48 at BMO Capital,TipRanks,/news/stocks/incyte-price-target-raised-to-52-from-48-at-bmo-capital-1033919382,negative,0.9430131316184998
853,10/30/2024 2:35:20 PM,Incyte price target raised to $72 from $67 at RBC Capital,TipRanks,/news/stocks/incyte-price-target-raised-to-72-from-67-at-rbc-capital-1033920105,negative,0.941901445388794
854,10/31/2024 3:05:21 PM,Biotech Alert: Searches spiking for these stocks today,TipRanks,/news/stocks/biotech-alert-searches-spiking-for-these-stocks-today-1033930863,positive,0.7777097821235657
855,10/31/2024 6:12:39 PM,Karyopharm gains after changes to late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4230816-karyopharm-stock-gains-late-stage-trial-changes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9128901958465576
856,11/1/2024 3:20:17 PM,Biotech Alert: Searches spiking for these stocks today,TipRanks,/news/stocks/biotech-alert-searches-spiking-for-these-stocks-today-1033938530,positive,0.7777097821235657
857,11/4/2024 10:22:57 PM,"Syndax, Royalty Pharma enter into $350M royalty funding deal",Seeking Alpha,https://seekingalpha.com/news/4245734-syndax-royalty-pharma-enter-into-350m-royalty-funding-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6089798808097839
858,11/5/2024 11:02:23 AM,Bank of America Turns Bullish on These 2 Lesser-Known Stocks,TipRanks,/news/stocks/bank-of-america-turns-bullish-on-these-2-lesser-known-stocks-1033951959,negative,0.7039065957069397
859,11/14/2024 11:47:35 AM,RBC Capital Sticks to Its Hold Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-incyte-incy-1034018194,positive,0.8344722390174866
860,11/14/2024 2:30:28 PM,Incyte price target raised to $80 from $72 at RBC Capital,TipRanks,/news/stocks/incyte-price-target-raised-to-80-from-72-at-rbc-capital-1034019889,negative,0.9411879777908325
861,11/18/2024 9:36:16 PM,"Incyte to pause MRGPRX2 program in CSU, suspend MRGPRX4 in CP",TipRanks,/news/stocks/incyte-to-pause-mrgprx2-program-in-csu-suspend-mrgprx4-in-cp-1034033174,positive,0.5318742394447327
862,11/18/2024 9:45:11 PM,"Incyte down 9% at $70 after update on MRGPRX2, MRGPRX4 programs",TipRanks,/news/stocks/incyte-down-9-at-70-after-update-on-mrgprx2-mrgprx4-programs-1034033237,neutral,0.9696760177612305
863,11/18/2024 9:45:24 PM,Incyte drops 9% after pausing enrollment in study for urticaria asset,Seeking Alpha,https://seekingalpha.com/news/4304367-incyte-drops-9-after-pausing-enrollment-study-urticaria-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.966690182685852
864,11/18/2024 11:35:10 PM,Closing Bell Movers: Super Micro up 28% on compliance update,TipRanks,/news/stocks/closing-bell-movers-super-micro-up-28-on-compliance-update-1034033438,negative,0.9416390061378479
865,11/19/2024 1:48:21 AM,Incyte Faces Pipeline Setbacks: Hold Rating Amid Uncertainties,TipRanks,/news/stocks/incyte-faces-pipeline-setbacks-hold-rating-amid-uncertainties-1034033641,neutral,0.9571859240531921
866,11/19/2024 5:35:20 AM,Incyte’s Trials and Challenges: Hold Recommendation Amid Clinical and Financial Uncertainties,TipRanks,/news/stocks/incyte-s-trials-and-challenges-hold-recommendation-amid-clinical-and-financial-uncertainties-1034034602,neutral,0.7781727313995361
867,11/19/2024 11:36:38 AM,RBC Capital Remains a Hold on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-remains-a-hold-on-incyte-incy-1034036747,positive,0.8631441593170166
868,11/19/2024 11:45:25 AM,Incyte’s Strategic Growth Potential and Rich Pipeline Underpin Buy Rating at $86 Target,TipRanks,/news/stocks/incyte-s-strategic-growth-potential-and-rich-pipeline-underpin-buy-rating-at-86-target-1034036892,negative,0.7971234917640686
869,11/19/2024 12:06:26 PM,"Incyte Faces Pipeline Setbacks and Growth Challenges, Justifying Sell Rating",TipRanks,/news/stocks/incyte-faces-pipeline-setbacks-and-growth-challenges-justifying-sell-rating-1034037328,positive,0.5978947877883911
870,11/19/2024 12:26:13 PM,TD Cowen Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/td-cowen-remains-a-buy-on-incyte-incy-1034037389,positive,0.9471278190612793
871,11/19/2024 1:35:26 PM,Stifel Nicolaus Sticks to Its Hold Rating for Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-sticks-to-its-hold-rating-for-incyte-incy-1034037908,positive,0.824431836605072
872,11/19/2024 1:46:09 PM,Incyte price target lowered to $74 from $80 at RBC Capital,TipRanks,/news/stocks/incyte-price-target-lowered-to-74-from-80-at-rbc-capital-1034038006,neutral,0.6792088150978088
873,11/19/2024 2:25:08 PM,Incyte price target lowered to $86 from $90 at BofA,TipRanks,/news/stocks/incyte-price-target-lowered-to-86-from-90-at-bofa-1034038167,neutral,0.5899609923362732
874,11/19/2024 3:42:44 PM,"Biggest stock movers Tuesday: WMT, SMCI, INCY, and more",Seeking Alpha,https://seekingalpha.com/news/4305499-biggest-stock-movers-tuesday-smci-incy-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9200936555862427
875,11/19/2024 5:05:39 PM,"Walmart higher, Lowe’s lower after earnings: Morning Buzz",TipRanks,/news/stocks/walmart-higher-lowe-s-lower-after-earnings-morning-buzz-1034038609,neutral,0.8574807643890381
876,11/19/2024 6:40:19 PM,"Incyte trading halted, volatility trading pause",TipRanks,/news/stocks/incyte-trading-halted-volatility-trading-pause-1034038871,neutral,0.7168107032775879
877,11/19/2024 6:44:27 PM,Incyte seesaws on report of potential Merck takeover interest,Seeking Alpha,https://seekingalpha.com/news/4308468-incyte-pares-some-losses-on-report-of-potential-merck-takeover-interest?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8714175820350647
878,11/19/2024 6:45:13 PM,"Merck ‘linked’ to takeover bid for Incyte, Sky News says",TipRanks,/news/stocks/merck-linked-to-takeover-bid-for-incyte-sky-news-says-1034038905,positive,0.8126486539840698
879,11/19/2024 6:45:21 PM,Incyte trading resumes,TipRanks,/news/stocks/incyte-trading-resumes-1034038903,positive,0.9179429411888123
880,11/21/2024 4:05:27 PM,Biotech Alert: Searches spiking for these stocks today,TipRanks,/news/stocks/biotech-alert-searches-spiking-for-these-stocks-today-1034051009,positive,0.7777097821235657
881,11/22/2024 3:55:19 PM,Biotech Alert: Searches spiking for these stocks today,TipRanks,/news/stocks/biotech-alert-searches-spiking-for-these-stocks-today-1034056477,positive,0.7777097821235657
882,11/25/2024 12:47:16 PM,TD Cowen Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/td-cowen-remains-a-buy-on-incyte-incy-1034061485,positive,0.9471278190612793
883,11/28/2024 1:47:52 AM,RBC Capital Sticks to Its Hold Rating for Incyte (INCY),TipRanks,/news/stocks/rbc-capital-sticks-to-its-hold-rating-for-incyte-incy-1034073995,positive,0.8344722390174866
884,12/4/2024 2:11:17 PM,Incyte gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4362559-incyte-gains-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7908908128738403
885,12/5/2024 11:50:21 AM,Incyte gets FDA orphan designation for treatment of nodal marginal zone lymphoma,TipRanks,/news/stocks/incyte-gets-fda-orphan-designation-for-treatment-of-nodal-marginal-zone-lymphoma-1034102156,negative,0.917522668838501
886,12/5/2024 4:02:24 PM,"Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Incyte (INCY) and Prenetics Group (PRE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-keros-therapeutics-kros-incyte-incy-and-prenetics-group-pre-1034103945,positive,0.9261476993560791
887,12/8/2024 11:55:04 AM,Incyte announces results from Phase 3 trial evaluating retifanlimab in NSCLC,TipRanks,/news/stocks/incyte-announces-results-from-phase-3-trial-evaluating-retifanlimab-in-nsclc-1034110943,positive,0.554604172706604
888,12/9/2024 8:20:39 PM,Incyte reports positive Phase 3 data for Zynyz for lung cancer,Seeking Alpha,https://seekingalpha.com/news/4379589-incyte-reports-positive-phase-3-data-for-zynyz-for-lung-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9503493309020996
889,12/10/2024 11:55:12 AM,Incyte’s BET Inhibitor Program Holds Promise Amid Safety Concerns and Strategic Uncertainty,TipRanks,/news/stocks/incyte-s-bet-inhibitor-program-holds-promise-amid-safety-concerns-and-strategic-uncertainty-1034119255,negative,0.9473729133605957
890,12/10/2024 12:46:08 PM,Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY),TipRanks,/news/stocks/stifel-nicolaus-sticks-to-their-hold-rating-for-incyte-incy-1034120028,positive,0.8383904695510864
891,12/10/2024 3:40:08 PM,Incyte says Phase 3 inMIND trial met primary endpoint of PFS,TipRanks,/news/stocks/incyte-says-phase-3-inmind-trial-met-primary-endpoint-of-pfs-1034120914,positive,0.5354846715927124
892,12/13/2024 12:06:04 PM,Incyte’s Growth Prospects Hampered by Pipeline Setbacks and Market Challenges,TipRanks,/news/stocks/incyte-s-growth-prospects-hampered-by-pipeline-setbacks-and-market-challenges-1034135669,neutral,0.9622327089309692
893,12/13/2024 12:26:17 PM,TD Cowen Reaffirms Their Buy Rating on Incyte (INCY),TipRanks,/news/stocks/td-cowen-reaffirms-their-buy-rating-on-incyte-incy-1034135721,positive,0.8620211482048035
894,12/17/2024 5:25:26 AM,Incyte’s Mixed Clinical Results and Financial Challenges Lead to Hold Rating,TipRanks,/news/stocks/incyte-s-mixed-clinical-results-and-financial-challenges-lead-to-hold-rating-1034144221,neutral,0.9624553918838501
895,12/17/2024 2:31:00 PM,Incyte initiated with a Neutral at UBS,TipRanks,/news/stocks/incyte-initiated-with-a-neutral-at-ubs-1034147471,positive,0.9075819849967957
896,12/18/2024 5:40:45 AM,"Analysts Offer Insights on Healthcare Companies: Century Therapeutics (IPSC), Incyte (INCY) and Bicycle Therapeutics (BCYC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-century-therapeutics-ipsc-incyte-incy-and-bicycle-therapeutics-bcyc-1034149437,positive,0.9228442311286926
897,12/19/2024 12:20:39 PM,Incyte price target raised to $70 from $68 at Wells Fargo,TipRanks,/news/stocks/incyte-price-target-raised-to-70-from-68-at-wells-fargo-1034156881,negative,0.9417206048965454
898,12/31/2024 2:55:11 PM,Early notable gainers among liquid option names on December 31st,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-december-31st-1034183449,negative,0.9046414494514465
899,1/7/2025 1:36:03 PM,Incyte price target raised to $75 from $74 at RBC Capital,TipRanks,/news/stocks/incyte-price-target-raised-to-75-from-74-at-rbc-capital-1034201305,negative,0.9399332404136658
900,1/7/2025 1:55:20 PM,Incyte’s Strategic Balancing Act: Promising Drug Prospects Amid Competitive and Intellectual Property Challenges,TipRanks,/news/stocks/incyte-s-strategic-balancing-act-promising-drug-prospects-amid-competitive-and-intellectual-property-challenges-1034201405,negative,0.9235405325889587
901,1/7/2025 2:55:25 PM,Early notable gainers among liquid option names on January 7th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-january-7th-1034201789,negative,0.9003757238388062
902,1/8/2025 7:15:50 AM,Incyte (INCY) Receives a Hold from Truist Financial,TipRanks,/news/stocks/incyte-incy-receives-a-hold-from-truist-financial-1034204134,positive,0.904508113861084
903,1/10/2025 1:35:15 PM,Incyte Announces Retirement of Executive VP Barry Flannelly,TipRanks,/news/stocks/incyte-announces-retirement-of-executive-vp-barry-flannelly-1034215601,neutral,0.687580406665802
904,1/14/2025 5:25:32 AM,Incyte Stock: Hold Rating Amid Patent Cliff Concerns and Awaited Clinical Milestones,TipRanks,/news/stocks/incyte-stock-hold-rating-amid-patent-cliff-concerns-and-awaited-clinical-milestones-1034223984,neutral,0.942805290222168
905,1/14/2025 12:46:53 PM,Incyte’s Strategic Challenges: Navigating Post-Jakafi Growth Gap and Limited Business Development Capacity,TipRanks,/news/stocks/incyte-s-strategic-challenges-navigating-post-jakafi-growth-gap-and-limited-business-development-capacity-1034226384,positive,0.5872161984443665
906,1/15/2025 1:17:17 PM,Jefferies Remains a Buy on Incyte (INCY),TipRanks,/news/stocks/jefferies-remains-a-buy-on-incyte-incy-1034231546,positive,0.9458020925521851
907,1/15/2025 10:45:29 PM,"Incyte, Syndax announce FDA approval for Niktimvo vial sizes",TipRanks,/news/stocks/incyte-syndax-announce-fda-approval-for-niktimvo-vial-sizes-1034232778,positive,0.49919450283050537
908,1/15/2025 10:58:19 PM,"Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials",Seeking Alpha,https://seekingalpha.com/news/4395484-incyte-syndax-get-fda-okay-for-9-mg-22-mg-niktimvo-vials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5540341734886169
909,1/16/2025 1:57:28 AM,Incyte And Syndax : FDA Approves Niktimvo 9 Mg And 22 Mg Vial Sizes ,RTTNews,/news/stocks/incyte-and-syndax-fda-approves-niktimvo-9-mg-and-22-mg-vial-sizes-1034232726,positive,0.7109992504119873
910,1/23/2025 1:57:25 AM,RBC Capital Keeps Their Hold Rating on Incyte (INCY),TipRanks,/news/stocks/rbc-capital-keeps-their-hold-rating-on-incyte-incy-1034257339,positive,0.9162288308143616
911,2/7/2025 5:09:01 PM,Incyte Q4 2024 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/4405211-incyte-q4-2024-earnings-preview?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7483543753623962
